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Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is 
the third leading cause of cancer related deaths worldwide. Surgical treatments provide a 5 year 
survival of approximately 60%-70% in carefully selected patients. However tumour recurrence 
to the liver continues to be a significant issue. Disseminated tumour cells (DTC) have been 
associated with tumour recurrence and poor prognosis in several epithelial cancers. The 
biological properties of DTC in HCC and their association with adverse clinical outcomes have 
not been critically investigated. 
 
Methods: DTC were cultured from peripheral blood samples using a protocol that was 
developed in house. Their molecular and biological properties were studied using 
immunocytochemistry, molecular assays and a SCID mouse cell transplantation model.  
 
Results: Venous blood was collected from 44 patients with HCC, 50 with liver cirrhosis and 20 
healthy volunteers. Following 2 weeks of in vitro culture, cell colonies were observed in 6 
patients with HCC and 3 patients with cirrhosis. No cell growth was noted in blood cultured 
from healthy volunteers. Immunocytochemical analysis of cultured cells showed that they 
express characteristic markers of human hepatocytes. Further they also expressed phenotypic 
markers compatible with bone marrow or cancer stem cells.  Cells cultured from patients with 
HCC exhibited increased expression of glypican-3 and survivin and decreased expression of 
LYVE1. They also demonstrated 18- and 43-gene expression signatures associated with poor 
prognosis in HCC and non-HCC solid tumours. DTC from HCC patients persisted in SCID mice 
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and showed histological features of neoplasia. Survival analysis showed that HCC patients with 
DTC had reduced median survival compared to those with no DTC (13 months vs. 49 months). 
 
Conclusion: DTC are present in a sub-group of patients with aggressive tumour phenotype. An 
in depth knowledge of these cells is essential to develop novel cell targeted therapies to eradicate 
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1.1 Hepatocellular carcinoma (HCC) is the most common primary liver tumour, the sixth 
most common malignancy worldwide and the third most common cause of cancer related 
deaths (Parkin 2005). There is an uneven distribution in its incidence and marked variation in 
the underlying risk factors according to the region. The majority of HCC cases (80%) occur in 
sub-Saharan Africa or Eastern Asia. The incidence of HCC in the UK is approximately 
2.2/100,000 patients. While hepatitis B virus (HBV) infection is the main risk factor in Asia 
and Africa, hepatitis C virus (HCV) is a significant problem in Western countries and Japan. 
The exception to this observation is immigrant population to the West in whom HBV infection 
is still the predominant aetiology for HCC. Other reported risk factors include exposure to 
Aflatoxin, a mycotoxin produced by the Aspergillus fungus, heavy alcohol intake (more than 
50–70 g/day) for prolonged periods, hereditary haemochromatosis, metabolic syndrome and 
insulin resistance. In recent years there has been increasing evidence to support an association 
between obesity and HCC. Obesity is associated with diabetes mellitus and non-alcoholic 
steatohepatitis (NASH), conditions that are now believed to increase the risk of HCC (Starley 
2010). NASH is estimated to be the third most common liver disorder in North America and 
the most common in Australia and New Zealand. It is estimated that NASH will progress to 
liver cirrhosis in nearly 25% of patients. There has been a significant increase in the incidence 
of HCC in the West due to an increase in hepatitis C infection and alcohol intake. HCC is 
currently the leading cause of death among patients with cirrhosis (Sangiovanni 2004). The 
pathophysiology of hepatocarcinogenesis is linked to the evolution of cirrhosis which develops 
after long latencies of chronic liver disease. The cirrhotic liver is a preneoplastic condition and 
is the strongest predisposing factor for developing HCC, however, in 10% of cases HCC occurs 
in a normal liver.  
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The molecular pathogenesis of HCC is complex, the progression of chronic inflammation to 
cirrhosis and HCC may last 10-30 years (Buendia 2000, Thorgeirsson 2002). Several 
mechanisms are involved in the pathogenesis of HCC depending on the underlying aetiology. 
The whole process can be broadly summarised into the following steps; 1) Cirrhosis associated 
with hepatic regeneration and scarring after chronic tissue injury 2) mutations in a single or 
multiple oncogenes or tumour suppressor genes stimulating cellular proliferation (El-Serag 
2007). 
  
Hepatitis viruses: HBV and HCV induce liver injury, hepatocyte death and promote 
hepatocarcinogenesis but the mechanisms are different. HCV infection results in up regulation 
of pro-inflammatory, pro-apoptotic and pro-proliferative genes. HCV may act as a Wnt ligand, 
and it has also been implicated in RAS transactivation and p53 inactivation (Llovet 2009). The 
role of HBV in HCC carcinogenesis has been well established. HBV DNA integrates into the 
host genome and promotes expression of cellular genes that are important for cell growth and 
differentiation. HBV also induces genomic instability, genetic aberrations, inactivation of 
tumour suppressor genes and assists the production of oncoproteins.  Some of these gene 
products especially HBV X protein (HBx) has been strongly implicated in liver carcinogenesis 
(Peng 2005). 
 
Chemical injury and Genetic predispositions: Aflatoxin B is a very potent mutagen and its 
active metabolite reacts with guanine in DNA leading to mutations. In geographical areas of 
aflatoxin B1 dietary exposure, such as China and Africa, there is a strong association between 
mutations in P53 (at codon 249) and exposure to this agent (Hussain 2007). Prolonged 
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exposure to chemicals or hereditary and metabolic disorders causes chronic inflammation 
which results in the release of free radicals, chemokines and cytokines. These reactive oxygen 
and nitrogen oxide free radicles (RNOS) along with their reaction products causes DNA 
damage. Further RNOS enhances the enzymatic activity of cyclooxygenase-2 which results in 
activation of the WNT pathway contributing to HCC carcinogenesis (Grisham 2002). 
 
Genetic aberrations and signalling pathways in liver carcinogenesis: Several genes and 
cytogenetic aberrations have been described in HCC. The most frequently deleted chromosome 
arms are 17p, 8p, 16q, 16p, 4q,9p, 13q, 1p and 6q, whereas the most frequent chromosomal 
gains are located on 1q, 7q, 8q and 17q. Mutations in p53 gene are noted in 30% and telomere 
length is altered in more than 80% of human HCCs.  
 
Abnormal activation of cell signalling pathways results in a neoplasm. The critical signalling 
cascades that perpetuate liver cancer are; 1) WNT-β-catenin signalling pathway which is the 
most commonly disrupted pathway in HCC. Abnormal regulation of transcription factor β-
catenin results in expression of gene products involved in cell proliferation angiogenesis, anti-
apoptosis and the formation of extracellular matrix (Avila 2006). 2) The phosphoinositide 3-
kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling pathway plays an 
important role in HCC tumour growth and survival and it is activated in 30–50% of HCCs. 
mTOR pathway can be dysregulated via abnormal activation of receptor tyrosine kinases such 
as epidermal growth factor receptor (EGFR), insulin-like growth factor 1 (IGF1R), 
mesenchymal–epithelial transition factor (MET), vascular endothelial growth factor receptor 
(VEGFR) or platelet-derived growth factor receptor (PDGFR). 3) The ERK/MAPK pathway 
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regulates cellular proliferation, differentiation, angiogenesis and survival (Gollob 2006). This 
pathway can be activated through mutations in RAS oncogene or overexpression of growth 
factors, activated pathway contributes to HCC progression and metastasis (Whittaker 2010). 
 
HCC is regarded as a heterogeneous disease and the cellular origin still remains uncertain. 
Animal experiments highlighted four groups of cells in the hepatic lineage which may respond 
to different carcinogenic regimens: (1) the mature hepatocyte in diethylnitrosamine (DEN) 
hepatocarcinogenesis model (2) The bile duct progenitor cells when furan model was used. (3) 
The ductular ‘bipolar’ progenitor cell in N-2-acetylaminofluorene (N-2-AAF) based regimens 
and (4) the periductular stem cell, which is the cell of origin of HCC in choline deficiency 
models (Sell 2002). 
 
HCC is an aggressive malignancy and the mode of metastasis includes local invasion, 
lymphatic and haematogenous spread. The common sites of distant spread are lungs, adrenals 
and bone (Tamura 2001). Unfortunately when HCC presents with clinical symptoms, the 
tumour is usually advanced. The available effective treatments are only applicable to a 
relatively small proportion of patients diagnosed at an early stage except with surveillance. 
 
1.2. Diagnosis: The diagnosis is based on a combination of clinical, laboratory, radiological and 
pathology examinations. Diagnostic conﬁrmation and tumour staging is essential for the 
management of HCC. Unfortunately it is a silent disease with non-specific clinical symptoms 




Imaging plays an important role in the diagnosis of HCC. Recent advances in radiology allows 
better characterisation of hepatic lesions, however accurate identification of sub-centimetre 
lesions in a cirrhotic background continues to be a challenge. 
Serum α-fetoprotein (AFP): A diagnosis of HCC based on serum AFP alone is challenging as 
up to 20% of HCC do not secrete AFP irrespective of the size of tumour. In AFP producing 
tumours, the levels usually correlate with tumour size and volume at the time of diagnosis. 
Serum AFP level greater than 200ng/ml is highly specific for HCC in high-risk patients with 
suspicious lesions on imaging. 
Ultrasound (USS):  CT and MRI imaging has largely replaced USS due to its low sensitivity 
and positive predictive value. In current practise the role of USS is largely limited to a 
screening tool. 
 
Multi-phasic Computerised tomography (CT): CT evaluation of suspected HCC is done by the 
use of 4-phase scanning that captures images before injection of contrast, during arterial, 
venous and delayed phases of intravenous contrast. Vascular supply to the lesion is the key 
pathologic factor in the differential diagnosis. The presence of arterial enhancement followed 
by delayed hypo-intensity of the tumour in the portal venous and delayed phases of CT scan is 
pathognomic of HCC. 
 
Magnetic resonance imaging (MRI): Triple-phase dynamic contrast enhanced MRI uses similar 
concepts applied to CT in the diagnosis of HCC. The sensitivity and specificity are similar to 
multi-phasic CT scan. 
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Angiography: Only used selectively to define vascular anatomy prior to surgical resection or 
transarterial chemoembolization. 
 
Positron emission tomography combined with computed tomography (PET-CT): PET-CT has 
limited application in the diagnosis of primary HCC. High levels of glucose-6-phosphatase in 




F-FDG) resulting in only 30-
50% uptake. The use of dual PET-CT protocol using 
11
 C-acetate in combination with 
18
F-FDG 
has improved the sensitivity in detecting HCC metastases but its role in primary HCC is still 
limited (Ho 2007).  
 
Diagnostic laparoscopy with contrast enhanced intraoperative ultrasonography is reported to 
have greater sensitivity for detection of both liver lesions and extrahepatic metastases than 
conventional imaging but its role in routine practice has not gained support (Montorsi 2007). A 
chest CT and bone scintigraphy (optional) are performed to exclude metastatic disease prior to 
surgery, but these tests lack sensitivity for detection of small lesions and fail to identify 
micrometastases. A routine pre-operative biopsy is not performed in HCC due to the perceived 
risk of needle tract seeding of HCC cells (Durand 2001). This precludes the identification of 
potentially important prognostic variables, particularly microscopic vascular invasion and 
tumour differentiation that can be used to develop better risk stratification during pre-operative 
staging.  
 
Screening for HCC: Unless diagnosed early HCC carries a dismal prognosis. The median 
survival of patients presenting with advanced HCC is less than 6 months (Llovet 2005). 
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Routine surveillance of high-risk cirrhotic patients increased the diagnostic rate of HCC, 
identified tumours at an early stage and reduced mortality (Zhang 2004, Chen 2003). A six 
monthly serum AFP combined with USS examination is recommended in screening high-risk 
patients for HCC (Thompson Coon 2007).  
 
Tumour staging:  Cancer staging is crucial to select an optimal treatment for individual 
patients, estimate the prognosis and evaluate the results. Patients with HCC constitute a special 
group where the applicability and efficacy of the treatments is also determined by the 
underlying liver cirrhosis. The conventional tumour node metastases (TNM) system used for 
oncological staging is therefore not applicable for HCC and may result in inaccurate prediction 
of survival. 
 
The prognostic models for HCC should include: assessment of tumour burden, impairment of 
liver function, clinical performance status and choice of treatment (Briux 2005). Pre-operative 
tumour extent can be evaluated using contrast-enhanced MRI or helical CT of the abdomen, 
chest CT and an optional bone scan in advanced disease. Liver function is assessed using 
Child-Pugh scoring system and Model for End-stage Liver Disease score (MELD) and portal 
hypertension is graded by measuring hepatic-venous pressure gradient.  
 
Several staging systems were developed incorporating some or all of the above mentioned 





The advantages and limitations in clinical application of these systems are discussed: 
1) Okuda stage (Okuda 1985): It was the first staging system incorporating both tumour and 
liver function parameters and has been widely used in the last decade.  The drawback was 
use of a broad classification for assessment of tumour burden (more or less than 50% of 
liver involvement). In the current era of early tumour diagnosis this classification is not 
adequate to stratify patients prior to treatment or subgroup according to tumour size. 
2) French classification (Chevret 1999): This classification was developed using a 
prospective study including 761 patients. Five tumour and liver function variables were 
identified to stratify patients into 3 risk groups A, B and C. The major limitation was poor 
patient selection reflected by worse survival outcomes for best stages (Cillo 2004). In 
comparison with other staging systems it has limited prognostic capacity for early 
tumours. 
3) Cancer of the Liver Italian Program (CLIP) score (Farinati 2000): This system was 
developed using a retrospective study. The score is calculated by adding four biochemical 
and tumour parameters and patients are divided into seven prognostic stages. It has been 
compared with Okuda and TNM stages and has better discriminatory power. The 
limitations were, like Okuda system, it cannot distinguish between apparently disparate 
tumour types and the survival figures from the external validation studies were variable. 
4) The Chinese University Prognostic Index (CUPI) score (Leung 2002):  This was 
developed in Hong Kong based on a study analysing the outcomes of 926 patients, the 
majority of whom were HBV positive. The issues were similar to that of the French 
classification, where the original and validation studies reported poor survival in patients 
with early stage disease. 
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5) The Japan Integrated Staging (JIS) (Liver cancer study group of Japan 2000): Includes 
both TNM and Child-Pugh classifications but lacks validation in Western countries. 
6) The Barcelona- Clinic Liver Cancer (BCLC) staging (Llovet 1999):  This was developed 
using variables related to tumour stage, liver function status, physical status and cancer 
related symptoms by the Barcelona group. It is the only system that incorporates all the 
EASL variables and considers type of treatment as prognostic variable (Bruix 2001). 
Many prognostic models (CLIP, French, Okuda, CUPI) only included advanced or small 
groups of radically treated cases leaving behind the cohort of patients with early disease 
amenable for radical treatments. BCLC addressed the issue by dividing the cases into 
early, intermediate, advanced and end-stage linked with a treatment algorithm. BCLC has 
been validated to be the best prognostic model when applied to patients treated with 
potentially radical treatments (Cillo 2004). 
 
The heterogeneous methodology and populations included has resulted in staging systems 
with no universal acceptance. Three of the systems (BCLC, CLIP, and JIS) have been 
validated in different patient cohorts. The Cancer of the Liver Italian Program (CLIP) score 
has shown to be of particular value in advanced cases in a French population (Collette S, 
2008). The pTNM system is based on the pathology report and may be relevant to stratify 
patients for studies of adjuvant treatments. Although there is no single ideal staging system 
for HCC, the Barcelona-Clinic Liver Cancer (BCLC) group 5 stage system has been adopted 
by many centres as it is combines the most practical evaluation of liver function with tumour 
staging to provide an algorithm of treatment. The system identifies those patients with early 
HCC who may benefit form curative therapies (stage 0 and A) and those at intermediate 
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(stage B or C) or advanced stage who may benefit from palliative treatments, and finally 
those with a very poor life expectancy (stage D).  
 
1.3 Management of HCC: Assessment of both the tumour and the underlying liver is 
undertaken by a multidisciplinary team. The aim of treatment is to remove the neoplasm while 
preserving liver function. The factors dictating the therapeutic approach are severity of 
underlying cirrhosis, portal hypertension and the overall tumour burden. Available options 
include surgical resection, orthotopic liver transplantation (OLT), loco-regional therapies, 
chemotherapy and biological therapies. 
 
Surgical resection:  Surgical treatment is offered to patients with no underlying cirrhosis or 
those with Child class A or B liver functional status. Adequate estimation of pre-operative liver 
function and planning the extent of hepatectomy improves outcomes of surgical resection. Portal 
hypertension is an independent predictor of survival and if significantly elevated is considered a 
contraindication for hepatectomy (Bruix 2005). Hepatectomy is the treatment of choice in 
patients who are not suitable candidates for transplantation due to large tumour size, 
macrovascular invasion, advanced age or associated co-morbidities (Poon 2004). Although it 
offers good long term outcomes in patients with good hepatic reserve, this group of patients 
accounts for less than 5% of HCC in the Western population. 
  
Advanced surgical and anaesthetic techniques have significantly reduced the post-operative 
mortality and morbidity, although disease recurrence is a major concern. Cirrhosis is known to 
increase the risk of recurrence after resection of HCC and the 5-year recurrence rate exceeds 
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50% in patients with underlying cirrhosis (Poon 2000). It has been shown that intra-hepatic 
tumour recurrence is the most common form (60% to 70%), although systemic metastases occur 
in the lungs (37%), pleura (26%) and bone (11%) (Shirabe 1996).  
 
Many authors have attempted to correlate the patterns of intrahepatic metastasis with the time 
interval between recurrence and liver resection. It has been demonstrated that early recurrence 
within the first 2 years after resection of HCC is associated with tumour related factors such as 
high tumour grade, microvascular invasion and microsatellite lesions, whereas late recurrence is 
more likely to represent multicentric hepatocarcinogenesis in a cirrhotic liver (Portolani 2006).  
 
A variety of factors have been shown to have prognostic significance by predicting tumour 
recurrence. High alpha-fetoprotein level (>400ng/ml), poorly differentiated tumour and 
microvascular invasion on histo-pathological examination are associated with early recurrence. 
Male gender, older age, high transaminase levels, multiple primary tumours, and high alpha-
fetoprotein level have all been linked with late recurrence (Imamura 2003, Poon 2000).  Of all 
these identified risk factors from retrospective studies only tumour size and vascular invasion 
have been shown consistently to influence prognosis (Poon 2000; Tsai 2000). A preoperative 
histological or molecular examination of tumour and adjacent non-tumour tissue is needed in 
combination with radiological staging to accurately predict tumour recurrence (Villaneuva 
2011). At present the associated risk of needle track recurrence with a preoperative biopsy 
precludes its routine use in clinical practice (Llovet 2001). Early detection and effective 
treatment of HCC recurrence can prolong patient survival. Aggressive management of 
intrahepatic recurrence with re-resection or loco regional therapies such as transarterial 
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chemoembolization (TACE), radio-frequency ablation (RFA) and percutaneous ethanol injection 
(PEI) or salvage liver transplantation may improve outcomes after surgical resection (Poon 
2007). Unfortunately the majority of patients with intrahepatic recurrence are not candidates for 
re-resection because of multiple recurrences or inadequate liver functional reserve. Data to 
support a role for transarterial chemo-embolization either preoperatively or postoperatively, to 
prevent or treat recurrent HCC is unconvincing (Chua 2009 Schwartz 2005; Tanaka 1999). 
Currently there is no established effective adjuvant therapy in preventing recurrence after 
resection of HCC. Approaches such as transarterial iodine-131, interferon and adoptive 
immunotherapy require further evaluation by more randomized trials (Sun 2003).  Although the 
risk factor analysis provides a rough guide to assess the risk of recurrence, it cannot specifically 
predict in an individual patient. The biological behaviour of HCC remains largely unpredictable 
and the risk of recurrence due to an occult microscopic disease persists, an understanding  of 
micrometastases to develop possible targeted treatments is essential to prevent early tumour 
recurrence.  
 
Liver transplantation (LT): LT has changed the treatment strategy for patients with small 
volume disease and no extra-hepatic involvement. It treats both the tumour and underlying 
cirrhosis providing the best therapeutic option with a reasonable long-term survival benefit 
(Mazzaferro 1996). The early experience with OLT in the late 1980s was associated with a high 
early recurrence rate and 5-year survival rates ranging between 18%-40%. Mazzaferro et al, 
established the Milan selection criteria for LT, which identified a subgroup of patients with 
radiologic evidence of a single tumour ≤5 cm in diameter, or two to three tumours ≤3cm in 
diameter had 5-year recurrence-free survival rates of 75 and 83%, respectively. United Network 
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for Organ Sharing (UNOS) staging system for allocating organs for OLT in the United States 
adopted the Milan criteria to allocate organs for LT. More recently it has been considered that 
the Milan criteria may be too restrictive of access to LT and the extended University of 
California, San Francisco criteria (UCSF) i.e. single lesion less than 6.5 cm or up to three lesions 
with the largest lesion less than 4.5 cm with a total tumour diameter less than 8 cm has been 
introduced (Yao 2004). Although OLT offers the theoretical advantage of complete removal of 
the tumour as well as the underlying disease, tumour recurrence is a limitation even in patients 
meeting Milan criteria (Schlitt 1999).  Post-transplant tumour recurrence is reported as 15%-25% 
and is a significant cause of death following LT. The most common sites of tumour recurrence 
are liver followed by lung and bone (Zimmerman 2008). 
 
Predicting tumour recurrence using clinco-pathological variables can help in better allocation of 
the limited supply of donor livers and also initiate adjuvant treatments for the at-risk groups. 
Several studies attempted to develop scoring systems aimed at predicting post-transplant 
recurrence. Size of the tumour and micro-vascular invasion noted in the explant specimen were 
found to be the strong predictors of recurrence. In the absence of extra-hepatic disease, micro-
vascular invasion is the most powerful predictor of HCC recurrence (Ramos 2005, Pawlik 2006, 
Parfitt 2007). Poor tumour differentiation is associated with microscopic vascular invasion 
(Esnaola 2002, Zavaglia 2005). Size of the tumour ≥ 5cm is an independent predictor of 
recurrence and a surrogate marker for vascular invasion (Ramos 2005, Pawlik 2006, Parfitt 
2007). There is increasing evidence indicating that maximum diameter of the largest nodule is 
superior to the number of nodules in predicting post-OLT tumour recurrence. However there is 
discrepancy in defining a cutoff value for the maximum diameter among these studies. Marelli et 
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al. and Zimmerman et al. used a cutoff of 35 mm for the main nodule size while Esnaola et al. 
showed that tumour size > 4 cm in the explant liver was an independent predictor of micro-
vascular invasion. Shetty et al. found that explant tumour diameter >3 cm was significantly 
associated with recurrence. The Metro ticket data, presented at the International Liver Cancer 
Association (Barcelona 2007), also suggested that maximum diameter of tumour nodule(s) is 
more predictive of tumour recurrence than the number of nodules. Unfortunately, the tumour 
characteristics needed to accurately predict recurrence can only be assessed conclusively at 
explant histopathological examination. A pre OLT biopsy may not effectively demonstrate 
micro-vascular invasion or assess tumour grade accurately because of the known histological 
heterogeneity in large tumours (A 2001, Pawlik 2007). In addition percutaneous biopsy is 
associated with a risk of tumour seeding (Stigliano 2007).  
 
In patients who meet the strict selection criteria, post-operative tumour recurrence must reflect 
the presence of undetected microscopic extra hepatic disease (micrometastases) at the time of 
transplantation. Detecting micrometastases preoperatively may help to identify a subgroup of 
patients who are at a higher risk of tumour recurrence (Sutcliffe 2005). These disseminated cells 
often show different properties to those of the primary tumour.  Isolating, characterising and 
understanding the behaviour of these disseminated cells may potentially lead to the development 
of targeted therapies for these high risk patients. 
 
Loco-regional therapies: 
Transarterial chemoembolization (TACE): TACE offers palliative benefits for patients with 
large volume disease (Chok 2006). Chemo-embolization delivers chemotherapy directly to the 
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tumour via the arterial supply thus avoiding systemic toxicity. Doxorubicin, mitomycin and 
cisplatin are the most commonly used chemotherapy agents. Embolizing agents usually gelatin 
or microspheres that are administered along with chemotherapy cause ischaemic injury to tumour 
cells rendering them more sensitive to cytotoxic agents. TACE causes a significant delay in 
tumour progression and vascular invasion, a partial response is achieved in 15-55% of patients 
(Llovet 2002). Other available modalities of embolization includes arterial chemoembolization 
with degradable starch microspheres and continuous arterial Infusion of 5-Fluorouracil, selective 
internal radiation therapy using yttrium-90 microspheres (SIRT). 
  
Evidence from randomized controlled trials showed high rates of tumour response and a survival 
benefit with TACE and RFA when applied as primary treatment (Cho 2009, Cabibbo 2010). Use 
of such modalities in patients awaiting LT has been considered to improve post-LT survival, 
down-stage advanced HCC to within Milan criteria and prevents waiting list drop-out (Frangakis 
2010, Schwartz 2007). 
Although there are no randomised controlled trials to support the role of pre-transplant 
treatments, most centres have accepted the available indirect evidence as a basis for their routine 
application. 
 
Ablative modalities: Several percutaneous ablative treatments were developed for patients who 
are not suitable for surgical resection or transplantation. Percutaneous ethanol injection (PEI) & 
radiofrequency ablation (RFA) are the most common modalities used in clinical practice. Other 
alternative treatments include percutaneous acetic acid injection (PAI), microwave coagulation 
therapy (MCT), laser interstitial thermal ablation therapy and cryoablation therapy. The response 
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to ablative therapy is dependent on baseline liver function and the size of the tumour. In patients 
with Child-Pugh grade A, a response rate of 80% can be achieved with tumours less than 3 cm in 
diameter. PEI and RFA can provide 5-yr survival rates of 40–70% in well selected patients 
(Lencioni 2005, Sala 2004, Omata 2004).  
PEI technique involves slow injection of absolute or 95% alcohol into the lesion thus causing 
tumour necrosis. It is safe and highly effective for tumours less than 3cm in size. Radiofrequency 
ablation causes tumour necrosis by placement of a probe that generates heat by high frequency 
ultrasound directly into the lesion (Morris 2000; Ohmoto 2000). It can be used to effectively 
ablate a tissue of as much as 3 cm or more in diameter. RFA can be applied percutaneously, 
laparoscopically or during laparotomy. RFA is reported to achieve slightly better response rates 
with a significantly fewer number of sessions when compared to PEI. A five-year survival of 40-
70% has been reported and the response to ablative therapy depends on the tumour size and 
Child-Pugh grade (Germani 2010). 
 
Molecular therapies:  Molecular therapies targeting signalling pathways are currently under 
investigation. These agents either block the pathways related to cell proliferation and survival or 
signals related to dissemination of the disease. Sorafenib, an oral multikinase inhibitor targets 
cell proliferation and angiogenesis, both pathways that are the involved in hepatocarcinogenesis.  
Sorafenib, an oral multikinase inhibitor targets cell proliferation and angiogenesis, both 
pathways that are the involved in hepatocarcinogenesis. SHARP study demonstrated that 
Sorafenib improved median survival from 7.9 months to 10.7 months and slowed time to 
progression from 2.8 to 5.5 months (Llovet 2008). Based on these results, it is regarded as the 
standard therapy for metastatic disease and for HCC progressing despite optimal locoregional 
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therapy. A number of ongoing studies are establishing Sorafenib's adjuvant role in resection, 
local ablation and TACE. Early results from a recent study showed that concurrent Sorafenib and 
TACE treatment resulted in an overall median survival rate of 18.5 months (16.1-20.9 months) 
with acceptable side effect profile (Cabrera 2011). The results from studies targeting Ras/MAPK, 
Akt/mTOR pathways as well as monoclonal antibodies against vascular endothelial growth 
factors (VEGF) are pending (Llovet et al 2008).  
 
2. Micrometastases/ Disseminated tumour cells (DTC):  
Intra-hepatic tumour recurrence following curative surgical procedures suggests that microscopic 
tumour metastases are present prior to surgery. Microscopic disseminated tumour cells that have 
the potential to develop into clinical metastases have been labelled as ‘micrometastases’ (Sloane 
et al, 1980). Although a formal definition does not exist, micrometastasis is defined as 
microscopic deposits of malignant cells (smaller than 2mm) that are segregated from primary 
tumour and depend on neovascular formation for propagation. They are thought to originate from 
single tumour cells and are readily missed by routine pre-operative staging investigations. The 
fundamental biological characteristic which distinguishes them from macroscopic metastases is 
the absence of a specific blood supply. Micrometastatic cells depend on passive diffusion for 
oxygen and nutrition and this limits their growth to 2-3mm in size. They may remain in a 
dormant state for prolonged periods with no net growth (Pantel 1999). Disseminated cells may 
also persist in a viable state in the peripheral circulation and/or distant organs, such as lung and 
bone. They are detectable by very sensitive methods even in the absence of clinical metastases 




Micrometastases can be isolated in patients with epithelial malignancies and has prognostic 
significance. There is growing evidence of DTC in the peripheral blood, lymph nodes and bone 
marrow (BM) in a variety of solid organ cancers including breast, colorectal, oesophageal and 
pancreatic cancers. Knowledge regarding the presence of DTC in patients with HCC is limited. 
Several techniques have been developed to identify these cells and the two common methods are 
immunocytochemical staining and/or PCR analysis. 
 
2.1 Micrometastases and Hepatocellular Carcinoma 
Recurrence of HCC following potentially curative treatments in carefully selected patients 
indicates that DTC are dispersed from the primary tumour prior to surgery and persist in a viable 
state in the liver, peripheral circulation and/or distant organs. DTC in patients with HCC appear 
to have a predilection for the allograft or the liver remnant following surgical resection which 
remains the most common site (80%) of tumour recurrence (Otto 1998, Philosophe 1998, 
Weimann 1999, Yao 2001, De Carlis 2001, Klintmalm 1998, Schlitt 1999, Tamura 2001). There 
is considerably less evidence in support of a role for micrometastases in HCC recurrence when 
compared to other epithelial malignancies. 
 
The phenomenon of micrometastases is well studied in breast cancer. It has been shown that the 
presence of disseminated cells in bone marrow or peripheral blood is associated with a poor 
prognosis (Riethdorf 2008). Detection of micrometastases using laboratory-based techniques has 
some potential advantages. First, they may be isolated from samples of bone marrow or 
peripheral blood, which can be obtained safely for assessment of tumour staging. Second, 
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micrometastases status may be evaluated preoperatively and at intervals postoperatively to assess 
the therapeutic response in patients receiving adjuvant treatment.  
 
In HCC, several studies have focused on the use of reverse transcriptase polymerase chain 
reaction (RT-PCR), to detect either albumin mRNA or Alpha feto-protein (AFP) mRNA in blood 
and bone marrow samples (Kienle 2000, Aselmann 2001, Ijichi 2002). These have been used as 
markers of circulating disseminated HCC cells (Jeng 2004, Marubashi 2007). RT-PCR is highly 
sensitive for detecting albumin and can identify one disseminated HCC cell in a sample of 10 
million peripheral blood cells, however, is associated with a high false positive rate (Kubota 
2002). RT-PCR for AFP is of less value as a marker for micrometastases in patients with HCC as 
it is non-specific and can be detected even in patients without HCC as well as AFP-negative 
HCC (Sutcliffe 2005). Immunocytochemical detection assays use monoclonal antibodies that 
bind specifically to tumour associated proteins expressed by tumour cells. These assays are 
capable of detecting a single metastatic cell amongst millions of normal cells. Sutcliffe et al 
demonstrated that immunocytochemistry (ICC) using a monoclonal antibody against hepatocyte 
specific antigen (Hep Par-1) is a promising technique for detection of HCC micrometastases in 
the bone marrow. It was also shown that ICC is sensitive and superior to RT-PCR in terms of 
specificity and clinical relevance. Although these studies demonstrated techniques to detect DTC 
the clinical significance of their occurrence is still unclear. The biological properties of 
disseminated cells are poorly understood and the molecular mechanisms that regulate their cell 
growth, survival, and immune evasion are unknown. There is indirect and conflicting evidence 
suggesting that these cells may be cleared by the host immune system, may remain dormant for 
prolonged periods before developing into clinical metastases, or may not have potential to 
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develop into clinical metastases (O’Sullivan 1997, Braun 1999). Studies involving breast, 
colorectal and oesophageal cancers reported that tumour recurrence is not seen in every patient 
with detectable micrometastases. In our previous study cohort of 18 HCC patients undergoing 
transplantation, 7 out of 12 patients with Hep Par-1 positive micrometastases were alive and 
disease free at a median follow-up of 37 months (Range 1-81 months) (Sutcliffe 2005). 
 
To evaluate the clinical relevance and assess the malignant potential of DTC it is essential to 
isolate and study them using an in vitro culture model. Pantel et al. (1995) described a novel 
approach to isolate and immortalize micrometastatic cells in breast cancer, however, there is very 
little available literature on in vitro culture techniques using non-immortalised cells. Preoperative 
detection of micrometastases in patients with HCC and the study of the mechanisms that favour 
tumour recurrence are key areas for research that may have clinical and therapeutic implications. 
 
3. Stem cells and carcinogenesis: 
Stem cells are defined as cells that have the ability to perpetuate themselves through self-renewal 
and generate mature cells of a particular tissue through differentiation. The cellular origin of 
tumours remains an important question. Recent evidence suggests that stem cells are implicated 
in tumour development as well as metastases (Reya 2001). They possess unique cellular 
mechanisms to account for the therapeutic resistance and recurrence of the tumours. Stem cells 
are the only cells that have the ability to persist in the tissue for a sufficient length of time to 
acquire the necessary genetic changes for neoplastic transformation and have enough plasticity to 




Stem cells are generally defined by an ability to differentiate into multiple cell lineages and self-
renewal and contribute to not only organogenesis but also to regeneration in response to tissue 
and organ injury. Recent advances in stem cell biology have allowed the identification and 
characterization of stem cells in a variety of tissues and organs. In the setting of chronic 
inflammation, progenitor or stem cells within the peripheral tissue are forced to undergo multiple 
rounds of cell division causing DNA damage, accumulation of mutations and the emergence of 
malignant cells. (ZHAO and New hope for cancer) The stem cell origin of cancer was suggested 
by the pathologists Recamier and Virchow over 100 years ago and was based on the finding of 
histological similarities between a developing embryo and teratomas (Sell 2004). 
Teratocarcinomas are derived from embryonic germ cells which can differentiate into almost all 
cell lineages. These cancer cells can divide rapidly and are immortal, the properties which are 
similar to embryonic stem cells.  
 
The isolation of stem cells from epithelial tumours, such as breast (Al-Hajj 2003), prostate 
(Collins 2005), ovary (Szotek 2006), pancreas (Li 2007) and colon (Ricci-Vitiani 2007), have 
supported their involvement in carcinogenesis. 
 
Currently there are two models for the cellular origin of cancer. The stochastic model indicates 
that every cell in a tumour cell population has the ability to act as a cancer stem cell, but only 
those with a capacity for self-renewal would have the ability to sustain neoplastic growth. The 
alternative hypothesis, namely, the hierarchical model describes that only a biologically distinct 
subset of the total malignant cell population called the cancer stem cells (CSC) are capable of 
initiating a tumour. Although both models share a common idea that only a limited number of 
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cells within a tumour will initiate cancer, their biological principles and ultimately the clinical 
implications are very different. According to the stochastic theory, the cells within a tumour are 
relatively homogeneous and cytogenetic changes that lead to neoplasia are operative in all cells. 
Thus, research should be focussed on the entire tumour cell population to understand 
carcinogenesis pathways and develop new therapies. The stem cell model, however, assumes that 
the tumour cell population is heterogeneous and the sub-group of tumour-initiating cells are 
biologically and functionally distinct. The clinical implication from this model is that the 
elimination of all CSCs will terminate the growth of the tumour, and that failure to do so could 
result in tumour recurrence. 
 
Recent studies of human breast and neurological malignancies have isolated a minor 
phenotypically distinct tumour cell population that have self-renewal capacity and are able to 
generate tumour (Al Hajj 2003, Singh 2004). There is growing evidence supporting the origin of 
cancer as a hierarchical disease whose growth is sustained by a biologically distinct group of 
CSCs (Wang 2005). 
 
3.1 Stem cells in liver regeneration and carcinogenesis 
Human hepatocytes have a life span of over a year and seldom proliferate under normal 
physiological conditions. Alterations to liver mass brought on by surgical resection or by viral or 
chemical injury cause the quiescent hepatocytes to proliferative and restore functional liver 
substance. The degree of inflammation and cell loss dictates the type of cells involved in 
replenishing the cell mass. Replication of hepatocytes is sufficient to restore the liver mass 
following a surgical hepatectomy, however severe degrees of inflammation can result in 
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expansion of bipotential progenitor cells which can differentiate into hepatocytes and biliary 
cells. These cells have been described as “intermediate hepatobiliary cells” and “hepatic 
progenitor cells” or the human equivalent of rodent “oval cells” originating from the terminal 
branches of the intralobular biliary tree- the canals of Hering. The degree of stem cell and 
intermediate hepatocyte activation correlates with the degree of inflammation and fibrosis 
(Lowes 1999, Roskams 2003).This progenitor cell compartment is a potential target for 
carcinogenesis in the presence of chronic liver inflammation and growth factors. 
 
There has been a growing interest in the role of stem cells in liver cancer (Alison 2005, Libbrecht 
2006, Sell 2008). Current evidence from animal models of hepatocarcinogenesis suggests that 
only a minority of HCC are derived from mature hepatocytes. The Solt–Farber model 
demonstrated that ductular ‘bipolar’ progenitor cells give rise to HCC in an N-2-
acetylaminofluorene (N-2-AAF) based regimen while the choline deficiency model proposed 
that the peri-ductular oval stem cell gives rise to HCC. The evidence from chemical 
hepatocarcinogenesis animal models, the presence of bipotential hepatocyte and cholangiocyte 
cells in 28% to 50% of HCC tumour specimens, the relative resistance to chemo-radiotherapy 
and tumour transplantability suggests a role for stem cells in the origin and metastases of human 
HCC.  
 
3.2 Role of bone marrow in liver regeneration and hepatocarcinogenesis: 
There is growing evidence to support the presence of an extra hepatic source of progenitor cells 
which participate in liver generation. It is hypothesised that the type and degree of liver injury 
determines the recruitment and mobilisation of such cells, however, the exact underlying 
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pathways are still unclear. Evidence from studies demonstrating the expression of 
haematopoietic stem cell markers such as Thy1, CD34 and c-kit by hepatic progenitor cells 
(HPC) (Petersen 1998 Omori 1997 Baumann 1999) and differentiation of haematopoietic stem 
cells into hepatic progenitor cells (HPC) in animal models (Peterson 1999) suggests a possible 
bone marrow origin of HPC. 
Over recent years bone marrow (BM) stem cells have generated interest with the discovery of 
two properties namely transdifferentiation; the capacity to generate different types of tissue cells 
and differentiation plasticity, the ability to choose multiple differentiation pathways. Korbling et 
al. showed that stem cells from the peripheral blood of patients who underwent allogenic 
peripheral-blood stem cell transplant could differentiate into cells of liver, gastrointestinal tract 
and skin. Several in vivo and in vitro models have demonstrated the ability of bone marrow stem 
cells to differentiate into hepatocytes (Theise ND 2000, Schwartz RE 2002 Lagasse E 2002). 
There are conflicting views on whether the hepatocytes are a result of cell fusion or 
transdifferentiation of BM stem cells. 
 
The role of bone marrow stromal cells in normal hepatic maintenance or the pathways that could 
result in their mobilisation in response to chronic injury or malignancy in humans has not been 
addressed clearly to date. The most successful model in terms of the re-population and 
functionality of bone marrow-derived hepatocytes is the FAH (-/-) mouse, an animal model of 
tyrosinemia type I in which intravenous injection of BM cells rescued the mouse restoring its 
liver function (Lagasse 2000). A similar phenomenon was noted in sex mismatch liver transplant 
recipients where BM derived hepatocytes were identified in liver biopsy specimens in patients 
with severe liver injury (recurrent Hepatitis C) (Newsome 2003). 
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It was hypothesised that persistent liver injury initiates recruitment of mesenchymal/haemopoetic 
stem cells from the bone marrow (Lagasse 2000, Korbling 2002). Inflammatory mediators, 
growth factors and SDF-1 /CXCR4 signalling pathways are implicated in the homing of these 
cells to the liver to aid in liver regeneration (Kallis 2007). Furthermore, there is evidence 
implicating BM derived cells in the liver fibrogenic response. Sex mismatch bone marrow 
transplant mice models exposed to chronic carbon tetrachloride (CCl4) poisoning and a model of 
cholestatic liver disease in bile duct ligated mouse demonstrated that myofibroblasts associated 
with septal scars were BM derived. Paradoxically some studies showed therapeutic benefit of 
BM derived cells in ameliorating liver fibrosis in animal models (Sakaida 2004). Gaia et al. 
demonstrated that bone marrow derived stem cells can be mobilised in patients with end stage 
liver disease with the administration of granulocyte colony-stimulating factor (G-CSF) and this 
correlated with an improvement in clinical their condition. 
 
It is now widely accepted that cancer is a disease of stem cells and several experimental models 
were developed to study the role of stem cells in epithelial malignancies. The source of these 
cancer stem cells (CSCs) is thought to be either peripheral stem cells located in the neoplastic 
organ or BM derived cells (BMDC). BMDC are thought to act as a second line of defence in 
circumstances where the peripheral stem cells are subjected to atrophy and cell loss as a result of 
ongoing chronic injury and inflammation. BMDC share similar cell surface markers and follow 
the same chemotaxis and metastatic pathways used by CSCs, they can engraft into the stem cell 
niche and assume tissue stem cell function in the event of their atrophy. BMDC are inherently 
mutagenic and the presence of on-going inflammation and injury transforms them into cancer 
stem cells.  
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The involvement of BM cells in carcinogenesis was demonstrated beyond just theory by 
Houghton et al (2005). In their gastric carcinoma H. felis/C57BL/6 mouse model it was shown 
that chronic infection of mice with Helicobacter, a known carcinogen, resulted in repopulation of 
the stomach with BM derived cells. These cells subsequently progressed through metaplasia and 
dysplasia to intraepithelial cancer. Avital et al (2003) highlighted the contribution of bone 
marrow stem cells in the development of epithelial malignancies in 4 sex mismatch bone marrow 
transplant recipients.  
 
Whether HCC derives exclusively from epithelial cells within the liver, or has a bone marrow 
derived stem cell contribution, is unanswered. Furthermore, whether such cells affect tumour 
phenotype (e.g. metastatic potential or treatment responsiveness) is unclear. 
 
4 Clinical applications of isolating disseminated tumour cells (DTC): 
The best evidence from breast cancer research suggests that DTC are associated with poor 
outcomes, however, information regarding their biological and molecular properties is very 
limited. The DTC population is very heterogeneous and only a small subset of these cells might 
develop into overt clinical metastases. The expression of stem cell phenotypes and their 
association with cancer stem cells in breast cancer is still unclear. 
   
To increase the diagnostic accuracy or monitor the effectiveness of systemic adjuvant treatments 
more studies are needed at a cellular level (Pantel 2009). Isolation and in vitro culture of DTC 
will provide an opportunity to characterize their biological properties and molecular profile and 
thus may further lead to development of targeted therapies. (Pantel 1995, O’Sullivan 1999).  
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An in depth knowledge on DTC in patients with HCC will help improve our current staging 
systems, may help predict survival, assess the therapeutic response to down staging and the use 
of adjuvant treatments. It will also assist the development of targeted therapies to reduce the 
likelihood of tumour recurrence.  
 
Hypothesis:   
The aim of treatment in HCC is to prolong survival and improve the quality of life by eradicating 
the tumour while preserving liver function. Surgical resection or transplantation are potentially 
curative treatments in well selected patients, however, the risk of tumour recurrence still remains 
a major limitation. It is essential that these candidates are more accurately stratified according to 
risk of postoperative recurrence for effective use of available treatments. The current predictors 
of recurrence are mainly based on histological and molecular examination of the tumour tissue 
but this information is not routinely available prior to radical surgical treatments. Intrahepatic 
tumour recurrence especially following LT that offers treatment for both the tumour and 
underlying cirrhosis raises the possibility of microscopic disseminated disease. The presence of 
micrometastases has been associated with disease recurrence but their biological behaviour 
remains speculative. To-date there is no effective adjuvant treatment to reduce the risk of tumour 
recurrence and the poor response to systemic chemotherapy may be explained by the low 
proliferative state or the presence of effective cell repair mechanisms. An understanding of these 
micrometastatic cells is essential to develop targeted biological therapies that may offer more 






a) Establish a protocol for In vitro culture of disseminated hepatocellular carcinoma cells from 
peripheral blood  
b) Understand their biology as well as establish their origin by immunocytochemistry and 
molecular techniques.  
c) Assess the malignant potential of disseminated hepatocellular carcinoma cells using a 
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2.1 Alphabetical List of Reagents 
See appendix  
 
2.2 Ethical Approval: 
Ethical approval for this study was granted by King’s College Hospital Research Ethics 
Committee on 12
th
 June 2001. An amendment to permit collection of additional samples from 
patients without hepatocellular carcinoma was approved on 1
st
 February 2002. 
 
2.3 Patient Recruitment: 
Potential subjects were identified from the King’s College Hospital Liver Transplant Waiting 
List, wards and outpatient clinics. Detailed information on the purpose of the study and the 
associated risks with sample collection were provided to all who were invited to take part in our 
study. Those willing to participate in the study after reading the information and asking relevant 
questions were recruited. A written consent was obtained in all cases in accordance with the local 
ethical committee regulations. The subjects were permitted to withdraw from the study at any 
stage with no bearing on their clinical treatment. 
 
For the purpose of the study the recruited cohort was divided into 3 groups; Group 1- Patients 
with a clinical diagnosis of HCC, Group 2- Patients with end stage liver disease but with no 






2.4 Data Collection 
Demographic and essential data including preoperative investigations, radiological staging, 
adjuvant treatment modalities and postoperative histology were collected and stored on a 
password protected excel database. The details are presented in Table 1. 
 











Underlying liver disease 
Hepatitis status 
Serum AFP levels at presentation 






Size of the tumour 
Number of nodules 
Vascular 
invasion(Micro/Macro) 








2.5 Acquisition and processing of peripheral blood samples: 
Peripheral venous blood samples were obtained from the anterior cubital fossa of patients with 
HCC and control groups (20ml). The samples were collected under aseptic precautions in EDTA 
vacutainer bottles and were processed immediately. 
 
2.5.1 Density centrifugation: 
The peripheral blood was carefully layered onto Histopaque-1077 at a ratio of approximately 2 
volumes of histopaque for each volume of blood. The mixture was centrifuged at 1200 RPM and 
4
◦
C for 20 minutes. The buffy coat with mononuclear cell fraction was aspirated and washed 
twice with PBS at 1500 RPM for 5 min each. The supernatant was discarded and the cell pellet 
was resuspended in the prepared culture medium. The cells were counted using a 
haematocytometer (Merck, UK) and the viability was checked with tryphan blue. 10
3 
cells were 
cytospun on labelled polyprep glass slides (Sigma, UK) using cytocentrifugation (Hettich, 
Germany) at 3500 RPM for 6min. The pre-culture slides were air dried for 1hour and stored at -
80◦C for future analysis. 
 
2.5.2 In vitro cell culture: 
The cell suspension obtained from density centrifugation was resuspended in 10ml of Alpha 
MEM culture medium that was enriched with 20% fetal calf serum, 1% L-glutamine and 1% 
antibiotic and antifungal reagents. The mixture was transferred into a T75 culture flask and 
incubated at 37
◦
C and 5% CO2.  Culture medium was replaced after 12 hours. To minimise the 
loss of any disseminated cells the old medium was centrifuged at 1500 RPM for 5min and the 
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resultant cell pellet was resuspended and added to the flask. Human recombinant hepatocyte 
growth factor (HGF) was added at 10ng/ml on day 1, 2 and weekly thereafter.  
 
2.5.3 Cell detachment: 
Cell detachment using trypsin EDTA: The old culture medium was removed and the flasks 
were washed twice with PBS. 3ml of freshly thawed ice-cold trypsin EDTA was added to a T75 
flask and incubated at 37◦C for 3 minutes. The reaction was terminated by addition of culture 
medium with fetal calf serum. The loosely adherent cells were detached from the surface with 
rigorous shaking. The procedure was repeated 3 times to recover the maximum number of cells. 
 
Cell detachment using accutase:  The old culture medium was removed and the flasks were 
washed twice with PBS. 10 ml of ice-cold accutase (Sigma, UK) was added to a T75 flask and 
incubated at 37
◦
C for 5-10minutes. The procedure was repeated up to 4 times, it was noted that 
accutase could be used up to 45 minutes with no adverse effects on cell viability.  
 
2.5.4 Storage of cultured cells:  
The detached cells were centrifuged at 1500 RPM for 5 minutes. The supernatant was discarded 
and the cell pellet was resuspended in culture medium to make a volume equivalent to 1ml. After 
assessing the cell count and viability a part of the cell suspension was used to make cytospin 
slides as described in 3.4. 1000 cells were included in each slide and the slides were air dried for 
1 hour and stored at -80
◦




Cryopreservation: A freezing medium was made using one part dimethylsulphoxide in one part 
fetal calf serum and 2 parts culture medium. The cell suspension and ice-cold freezing medium 
were added to labelled sterile cryovial tubes at equal volumes to make a resultant volume of 1ml. 
The cryovials were stored in a cryopreservation canister containing 70% isopropanol at -80
◦
C for 
24-48 hours to allow the reduction of temperature by approximately 1
◦
C per minute, 
subsequently the samples were stored in a liquid nitrogen tank. 
 
2.6 Preparation of positive control cells: 
Type of cells: 
Primary human hepatoma cells 
Human hepatoma cell line 
Liver endothelial cells 
Primary human hepatocytes 
Bone marrow stem cells 
Human colon cancer cell line [CaCo-2]. 
 
2.6.1 Culture of human hepatoma cells 
Tumour tissue was obtained from fresh hepatectomy specimens, those who underwent pre-
operative TACE or any ablative procedures were excluded. Macroscopically viable tumour was 
sliced with a sterile scalpel avoiding the central areas of the tumour. The tissue was collected in 
Alpha MEM medium and transferred to the laboratory over ice. The specimen was chopped into 
1 mm
3 
size pieces and washed twice at 1400 RPM for 10 minutes. The pieces were immersed in 
Type 4 collagenase (0.8 mg/ml) and incubated at 37◦C for 2 hours with gentle agitation every 30 
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minutes. Following incubation partly digested pieces of the tissue were mashed with a 2ml 
syringe plunger; the resultant mixture was filtered through a 0.7µm sieve. The filtrate was 
centrifuged at 1400 RPM for 10 minutes and the cell pellet was washed twice. Three million 
cells with 40% viability were isolated from 10 g of tumour tissue, the cells were transferred into 
T75 flasks for further culture using the medium as described in 3.5.3. The flasks were incubated 
at 37 
◦
C and 5% CO2 for 5 days and the medium was renewed on alternate days. The cells were 
detached at confluence using trypsin EDTA. A proportion of cells were used for preparation of 
the cytology slides and the rest were cryopreserved. 
 
2.6.2 Culture of human hepatoma cell lines: 
Hep G2 cell lines were purchased commercially from the European collection of cell cultures 
(ECACC). The cryopreserved samples were quickly thawed at 37
◦
C, after cell count and viability 
check, 10
6 
cells were introduced into a T75 culture flask. The cell lines were maintained in the 
culture medium as described in Appendix VI. The flasks were incubated at 37
◦
C in 5% CO2 and 
culture medium was renewed every 2 days. At 80% confluence the cells were detached using 3 
ml of trypsin EDTA and incubated at 37 ◦C for 3 minutes. The detached cells were washed twice 
with culture medium containing fetal calf serum. The cell pellet was resuspended in an 
appropriate amount of culture medium for cryopreservation and preparation of positive control 







2.6.3 Liver endothelial cell culture:  
20 g of liver was obtained from donor organs that were deemed not suitable for transplantation 
due to the degree of steatosis.  The liver tissue was sliced into 1mm
3
 size pieces and washed 
twice at 1400 RPM for 10 minutes. The pieces were then immersed in collagenase type 1a (0.8 
mg/ml) and incubated at 37
◦
C for 1 hour with gentle agitation every 15 minutes. Following 
incubation the resultant digested mixture was filtered through a 0.7 µm sieve. The filtrate was 
centrifuged at 50g for 5 minutes to exclude hepatocytes. The supernatant was transferred into a 
50ml falcon tube with Minimal Essential Medium (MEM) and centrifuged at 1400 RPM for 10 
minutes, the cell pellet was resuspended in a freshly prepared culture medium favouring 
endothelial cell growth (Appendix VI). The cell mixture was transferred into collagen coated 
nine well plates and incubated at 37
◦
C in 5% CO2. The medium was changed every 2-3 days and 
the endothelial cell growth was monitored using cell morphology. At 80% confluence the cells 
were detached using 1ml of accutase per well and incubation at 37 
◦
C for 10 minutes. The 
detached cells were washed with culture medium, the resultant cell pellet was resuspended in an 
appropriate amount of culture medium for sub-culture. The culture conditions used selected for 
endothelial cell growth in preference to other cell types (e.g. Fibroblasts, Kupffer cells, smooth 





 passage were used to prepare control slides for immunocytochemistry using our 







2.6.4 Primary human hepatocytes: 
The normal human hepatocytes were a donation from the hepatocyte transplantation group 
(Institute of Liver Studies, King’s College Hospital). Hepatocytes were isolated from cadaveric 
donor livers that were deemed not suitable for transplantation due to steatosis or unused 
segments of the liver obtained from split or reduced grafts. A whole organ perfusion technique 
was employed to isolate hepatocytes (Mitry et al 2003) and the cells were maintained in an 
enriched William’s E medium as described in section 2.2. The median cell viability of 
hepatocytes obtained from split/reduced grafts was 70% and of those derived from rejected livers 
was 35%. Human hepatocytes were used as controls for our in vivo and in vitro experiments. 
 
2.6.5 Human colon cancer cell line [CaCo-2]: 
Growing cultures of CaCo-2 cell lines were purchased from European Collection of Cell 
Cultures (ECACC, UK) and maintained in a DMEM medium supplemented with additives as 
described in Appendix 1.  The cells were transferred into a T 75 flask and incubated at 37 
◦
C and 
5% CO2. Culture medium was replaced every 3-4 days and flasks were subcultured at 90-95% 
confluence. Sub-culturing involved removal of culture medium from the flask by aspiration, 
followed by addition of an appropriate volume of trypsin/EDTA (3ml for a 75ml flask) and 
incubation at 37 
◦
C for 3-5 min until cells detached from the flask. Loosely adherent cells were 
detached by gentle agitation of the flask. The cell suspension was washed twice with culture 
medium to remove trypsin and finally resuspended in an appropriate volume of culture medium 
for further culture or preparation of cytospin slides for immunocytochemistry. Cryopreservation 




2.7 Collagen coating of culture flasks: 
Protocol: 
Bornstein and Traub Type I calf skin collagen was purchased from Sigma-Aldrich (Sigma 
C3511) to coat the culture flasks 
 
Stock solution: 
1) 0.1M acetic acid is made by dissolving 0.575ml of acetic acid in 99.425ml sterile dH2O to 
make a total volume of 100ml. 
2) Dissolve collagen in 0.1M acetic acid at 1mg/ml  
3) Allow to dissolve over several hours, sterile filter and store in a glass bottle at 4
◦
 C  
 
At the time of coating dilute the stock solution at 1 in 20 dilution with distilled water to get a 
final concentration of 50mcg/ml of collagen. 
 
Coating the flasks: 
1) Spread 4ml of diluted collagen solution carefully at the bottom of the flask. Allow the protein 
to dry in a laminar flow hood for several hours at room temperature 
2) Remove the excess fluid from the coated surface and store the flasks at 4
◦
 C for future use 








2.8 Morphological, biological and functional assessment of cultured cells: 
Cytospin preparation and storage 
Detached cells from growing cultures or cryopreserved culture cells that were thawed were 
washed, and cell counts estimated using a haematocytometer (Merck, UK).  The cell pellets were 
finally resuspended in PBS at a concentration of 10
4
cells/ml. After loading cell suspensions onto 
labelled polyprep glass slides (100µl per spot), cytospin slides were prepared using 
cytocentrifugation  (Hettich, Germany) at 3500 RPM for 6 min. Slides were air dried for 1 hour, 
and stored in storage boxes at -80
o
C until use. Pre-prepared cytospin slides with culture cells, 
Hep-G2, primary HCC or hepatocytes were allowed to thaw at room temperature. The cell spots 
were circumscribed with a hydrophobic marker pen and the slides were dried for 1hour. 
 
2.8.1 Haematoxylin and Eosin (H&E) staining:  
The staining was performed in the following order: 
1) Fix section in 10% formaldehyde for 10 minutes 
2) Wash in distilled water 
3) Stain with Shandon Instant haematoxylin for one minute (The solution was filtered 
directly onto the slide) 
4) Wash in tap water 
5) Differentiate nuclei in 1% acid alcohol for 15seconds 
6) Wash in tap water until nuclei were blue 
7) Counterstain with 1% Eosin for 30 seconds 
8) Wash in water and dehydrate the section in absolute alcohol and xylene 





All primary antibodies were diluted in 1% PBS; the optimal concentration was determined by 
serial dilution. Immunocytochemistry was performed using antibodies CAM5.2, Hep Par-1, 
Polyclonal CEA, Anti human albumin, CD133, CD34, CD90, ATP7b ,CD68 and anti-smooth 
muscle actin according to the protocols described below 
 
Enzyme Method using Vectastain Streptavidine/Peroxidise kit: 
The slides were incubated as follows: 
1. 5% formalin for 20 minutes to fix the cells 
2. 3% hydrogen peroxide to block the peroxide for 5 minutes (Stock H202 solution = 30% 
therefore 1:10 dilution = 50µl + 450µl PBS) 
3. 10% normal horse serum as blocking serum (100µl normal horse serum+ 900µl PBS) for 
30 minutes 
4. Primary antibody at 4°C overnight 
5. Wash slides with PBS 
6. Biotinylated 2° antibody at room temperature for 10 minutes: 
(500µl blocking solution + 2.5µl of universal secondary antibody) 
7. Wash slides with PBS 
8. Streptavidine/Peroxidase complex for 5 minutes (50 µl of Streptavidine/Peroxidise 
complex stock solution is added to 2ml of PBS without K+ ) 




10. When the desired colour is achieved the enzyme reaction is stopped by adding PBS 
11. Sections were counterstained with haematoxylin for 1min 
12. Slides were mounted with 20% aqueous glycerol 
 
Fluorescent method using Vecta fluorescent kit: 
1. Slides were incubated with primary antibody overnight following steps 1 and 3 as 
described in section 3.7.1 (avoid incubation with H2O2) 
2. Add anti-mouse/ anti-rabbit fluorescent antibody (25µl of secondary antibody to 1ml of 
HEPES solution) and incubate at room temperature for 1hour 
3. Wash slides with PBS and then with water for 20 seconds 
4. Mount the section with propidium iodide containing mounting medium and nuclei 
counterstaining as red fluorescence 
All the incubations were performed in a humidified chamber and were terminated by washing 
with PBS. The washing procedure was repeated for 3 cycles of 2 min each. 
 
Periodic Acid Schiff (PAS) Staining to detect glycogen:  
The staining was performed on the cytospin cell spots as follows: 
1. Fix the cells with Carnoy's fixative ( 100% alcohol 60 ml, chloroform 30 ml and glacial 
acetic acid 10 ml) for 10 minutes  
2.    Oxidize in 0.5% periodic acid solution for 5 minutes.  
3.    Rinse in distilled water.  
4.    Stain with Schiff reagent for 15 minutes  
5.    Wash in lukewarm tap water for 5 minutes  
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6.    Counterstain in Mayer's hematoxylin for 1 minute.  
7.    Wash in tap water for 5 minutes.  
8.    Dehydrate and mount with DPX  
 
2.9 Animal model to assess biology of cultured cells 
Experimental animal: Adult 6 week old SCID mice (20–25 g, C.B-17/Icr), purchased from 
Charles River UK Ltd, were selected as recipients for the cultured disseminated cells. These 
severely immunodeficient mice have been successfully used as hosts in several tumour 
implantation experiments. The mice were maintained in filter-cages in the Comparative Biology 
Centre at King’s College London. All animal housing, handling, and experimental procedures 
were carried out in accordance with the Home Office guidelines for Animal Scientific 
Procedures UK. 
 
Type of cells: 
In vitro cultures from patients with HCC 
In vitro cultures from patients with cirrhosis 
Human hepatoma cell lines (Hep G2) 
Primary healthy human hepatocytes 
 
2.9.1 Cell sample preparation:  
Thawing and recovery of cryopreserved cells: The cryo-vials were transferred from liquid 
nitrogen storage and placed immediately in a 37° C water bath. The nearly thawed cells were 
diluted 10 times in ice cold culture medium with gentle shaking and cells were purified using a 
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24% isotonic percoll gradient medium. Following addition of Percoll, the 50ml falcon tube was 
topped up with culture medium and centrifuged at 250g and 4° C for 20minutes. The supernatant 
with non-viable cells was discarded and the cell pellet was washed twice with culture medium at 
50g for 5minutes. 
 
The thawed and purified experimental and control cell samples were resuspended in culture 
medium and then transferred into a T25 flask for overnight incubation at 37°C. On the day of 
transplantation the adherent cells were detached using the cell detachment protocol described in 
section 2.5.3. Following count and viability check the cells were resuspended in culture medium 
at a concentration of 2x10
4
cells/ml.  One millilitre of this cell suspension was transferred into a 
sterile eppendoft and micro centrifuged to obtain the final transplantation volume of 50µl. 
 
2.9.2 Cell transplantation:  
Anaesthetic technique: 100 µl of hypnorm and 100 µl of midazolam was diluted twice with 
distilled water, 60 µl of this diluted mixture was injected into the intraperitoneal cavity of each 
mice. 
 
Liver injections: The anaesthetised mice were placed on a warm operating surface and the 
ventral surface was shaved and sterilised using 100% ethanol. The abdominal cavity was 
accessed by a 1.5 cm midline incision, small bowel was retracted using a cotton swab and the 
liver was exposed. The prepared 50µl cell suspension with 20000 cells was injected directly into 
left lobe of the liver using a Hamilton micro syringe and the incision was closed with interrupted 
vicryl sutures.  
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Kidney injections: The abdominal cavity of the anaesthetised mice was opened by a 1 cm 
incision below the left costal margin. The lower pole of the kidney was clearly visualised after 
retracting the small bowel. The prepared cell volume was injected into the middle of the lower 
pole margin and the abdomen was closed with interrupted vicryl sutures. 
 
Following injections the mice were labelled by a punch excision of the anterior or posterior 
surface of the right or left ear lobe and were transferred into their cages. 
 
2.9.3 Retrieval of transplanted cells: 
Retrieving the transplanted liver:  Mice were sacrificed six weeks after transplantation by 
dislocating the cervical vertebrae. The liver was retrieved in total and the cell transplant segment 
was excised separate from the whole organ. The individual portions were transported to the 
laboratory in ice cold UW solution and stored in labelled cryo-vials at -80°C following snap 
freezing. 
 
Retrieving transplanted kidney:  The mice were sacrificed two weeks following cell 
transplantation. Both the kidneys were retrieved in total and the left kidney was divided 
transversely to obtain separate upper and lower poles. The two halves of the left kidney and the 
whole right kidney were snap frozen and stored in separate cryo-vials at -80°C further analysis. 
 
2.9.4 Tissue sections for analysis:  
The samples were either processed and embedded in paraffin wax or the frozen tissue was 
directly sliced into 10 µm cryosections. 
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The paraffin sections were dewaxed by immersion in xylene followed by absolute alcohol. H&E 
staining was performed on the frozen and deparaffinized tissue slides using the protocol 
described in section 2.8.1. 
 
Immunohistochemistry on paraffin sections: 
Following dewaxing the slides were rinsed in distilled water and phosphate buffered saline. 
Antigen retrieval was performed by immersing the slides in a 0.1M citrate buffer at pH 6.0 and 
heating in a microwave at 700 watts for 25 minutes. After leaving to cool for 20 minutes at 4°C 
the slides were washed in PBS and sections were circumscribed with a hydrophobic marker pen. 
 
The Novacastra ready-to-use peroxidase detection system was used in the following order for 
enzyme staining. All steps were performed in a humidified chamber at room temperature and the 
incubations were terminated by PBS wash (3 cycles of 2 minutes each). 
 
1. Neutralize endogenous peroxidase using peroxidase block for 5 minutes 
2. Incubate with protein block for 5 minutes 
3. Incubate with optimally diluted primary antibody for 60 minutes 
4.  Incubate with biotinylated secondary antibody for 30 minutes 
5. Incubate with streptavidin-HRP polymerase for 30 minutes 
6.  Develop peroxidase activity with a freshly prepared DAB working solution (50µl of 
DAB Chromogen to 1ml of DAB substrate buffer) for 5 minutes 
7. Counterstain with Hematoxylin 
8. Mount sections with glycerine 
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The techniques described in section 2.7.2 were used for frozen sections 
 
Positive and negative controls: All of the immunocyto/immunohistochemical analysis 
experiments were performed using positive and negative controls. Two types of negative 
controls were used: one was by performing all the steps in the protocol but omitting the primary 
antibody and the other was staining a known negative sample. 
The tissue sections were analysed using cytokeratin 8 and 18, MHC class 1, Ki 67 and CD34 
antibodies in optimal dilutions. To further support the presence of transplanted human cells, the 
tissue specimen was analysed for the presence of human genomic DNA.  
 
2.9.5 Molecular techniques:  
Total RA extraction: Total RNA was extracted using Trizol reagent (Invitrogen). Briefly, 
cells were lysed by pipetting Trizol in a 1.5ml sterile eppendoft tube (approximately 800µl per 
10
4
 cells) and incubated for 5 min at room temperature. Chilled chloroform was then added 
(0.2ml per 1ml Trizol) and after shaking vigorously for 15 seconds the tube was incubated for 3 
min at room temperature (RT). After centrifuging at 12000 x g for 15 min and 4°C, the aqueous 
phase supernatant containing total RNA was transferred to a sterile eppendoft tube containing an 
equal volume of isopropanol and incubated for 10 min at RT. RNA was precipitated by 
centrifugation (12000g, 4
o
C, 10 min) and washed carefully with 75% ethanol (1ml of ethanol for 
1ml of trizol reagent at 7500g, 4
o
C, 5min). The RNA pellet was allowed to dry and dissolved in 
5-30µl of RNase-free water and stored at -80
o
C. The purity of RNA samples was assessed by 
measuring the OD260/OD280 ratios on a NanoDrop ND-1000 spectrometer (NanoDrop, 
Wilmington, DE), resulting in a ratio of 2.00 - 2.08 in all cases. 
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DA isolation:  After complete removal of the aqueous phase containing RNA, the interphase 
and organic phase were incubated with 100% ethanol (0.3ml of ethanol per 1ml of Trizol) for 2 
min at RT and DNA was precipitated by centrifugation at 2000g for 5minutes and 4
o
C. The 
DNA pellet was washed twice in a solution containing 0.1 M sodium citrate in 10% ethanol (1ml 
of solution per 1ml of Trizol at 2000g, 4
o
C, 5min), resuspended in 75% ethanol for 20 minutes at 




C, 5minutes. The DNA pellet was allowed to dry and dissolved 
in a pH adjusted 8mM NaOH solution for long term storage at 4
o
C. 
DA isolation from paraffin blocks: A total nucleic acid isolation kit for paraffin embedded 
tissues (Invitrogen) was used as per the company protocol.  After deparaffinization and 
rehydration with 100% ethanol the tissues were incubated with digestion buffer (100µl of buffer 
for ≤ 40µm and 200 µl for 40-80 µm of tissue) at 50
o
C for 16 hours. Following addition of an 
appropriate amount of isolation additive and ethanol (for 100 µl of digestive buffer -120 µl of 
isolation additive and 275 µl of 100% ethanol) the mixture was passed through a filter cartridge 
and washed with 700 µl of wash 1 and 500 µl of wash 2. 60 µl of RNase mix (10 µl of RNase 
and 50 µl of nuclease free water) was added to the filter cartridge and incubated for 30min at RT. 
After washing and centrifugation at 10000g for 30 seconds the filter cartridges are transferred 




Sample processing for Human Gene 1.0 ST arrays 
Total RNA was extracted using Trizol reagent (Invitrogen) and quality/integrity was assessed 
using ribosomal RNA band analysis on a 2100 Bioanalyser and RNA 6000 Nano LabChips 
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(Agilent). 75ng of total RNA was reverse transcribed and amplified into cDNA using NuGEN’s 
Pico WT–Ovation labelling kit following the manufacturer’s protocols (NuGEN Inc.). The Exon 
conversion module from NuGEN was used to synthesise, the sense orientation copy from 
amplified cDNA and the Biotin module for biotin-labelling. We followed NuGEN’s 
recommendations for Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Santa Clara) and 
subsequent processing using standard hybridisation, washing and staining reagents 
(Hybridisation Wash Stain (HWS) kit). Scanned array images (DAT and CEL files) were 
generated using Affymetrix’s AGCC software and analysed using their Expression Console 
package which generates normalised and background-corrected probeset-summarised signals for 
each gene on the array. The standard gene-level RMA workflow was used to achieve this data 
output. Control probeset data was removed from the main dataset prior to data analysis proper. 
To do this we deleted the rows which contained information for various ‘normgene’ probesets 
(as shown in the ‘category’ annotation column of the whole data table). This resulted in removal 
of 4201 probesets from the original summarised dataset (33,297 probesets) leaving 29,096 
probesets for further analyses. 
 
Data analysis: 
The filtered data table was formatted as a ‘.gedata’ tab-delimited text file and imported into 
Qlucore’s Omics Explorer 2.1 software for analysis. The software, which utilises a visual, 
Principal Components Analysis (PCA) approach to display the relationships between samples 
and genes allowed the selection of differentially expressed genes using standard statistical 
techniques. We employed a simple 1-way ANOVA to filter genes which were differentially 
regulated across the different sample groups (bone marrow CD34+cells, HCC cells, HepG2 cells 
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and primary hepatocytes), and used the p-value slide bar to create the various statistical cut-off 
gene lists for the different comparisons of interest. Gene lists (containing all regulated genes) 
were displayed as heat maps to show gene expression patterns within the list, and sub-lists of 
interest were selected on the basis of specific expression patterns.  
 
Real time RT-qPCR: 
We used a single-step real-time PCR with the 7900HT Fast Real-Time PCR System (Applied 
Biosystems Inc, CA, USA). RNA was reverse transcribed using TaqMan® Gold RT-PCR Kit 
one step reaction mix.  qPCR was performed in 20-µl reaction mixtures using TaqMan  gene 
expression master Mix (Applied Biosystems) in 96 well plates. The mix was optimized for real-
time PCR quantitative analysis and contained AmpliTaq Gold® DNA Polymerase UP (Ultra 
Pure), Uracil-DNA Glycosylase, dTNPs with dUTP, Passive Reference 1 and optimized mix 
components of 6 primers (Glypican, Lyve1, Survivin). The thermal cycling conditions comprised 
an initial 2-minute, 50 °C step for optimal UDG enzyme activity and a 10-minute, 95 °C to 
activate the AmpliTaq Gold UP enzyme followed by 40 cycles of 95°C for 15 seconds(denature), 
and 65°C for 1 minute(anneal/extend). An external standard template containing human GAPDH 




The PCR selection kit (Invitrogen) was used according to the company protocol to amplify the 
relevant DNA samples. The reaction mix consisted of PCR buffer, dNTP mixture, MgSO4, 
Primer mix, Template DNA, Platinum® Taq and autoclaved distilled water to make a final 
concentration of 50µl. The tubes were incubated in a thermal cycler at 94°C for 2 minute to 
completely denature the template and activate the enzyme. 40 cycles of amplification was 
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performed at 94°C for 15–30 seconds (denature), 55°C for 15–30 seconds (anneal) and 68°C for 
1 minute (extend). 
 
2.10 Slide interpretation 
The stained slides were visualised under confocal or fluorescent microscopy as necessary. The 
experimental slides were examined after positive and negative control slides to ensure successful 
staining. The morphology of cells and pattern of staining was critically examined in the 
experimental samples before deeming them positive. All results were confirmed by an expert 





















3.1 Introduction: Hepatocellular carcinoma (HCC) is emerging as a major health issue in the 
Western world. It is currently the leading cause of death among patients with chronic liver 
disease (Llovet 2005). Surgical resection and transplantation can achieve best outcomes in well-
selected patients (5-year survival of 60%–80%) and are offered as the first line curative 
procedures. Tumour recurrence is a major obstacle following surgical resection and also 
complicates liver transplantation despite the use of strict selection criteria. The outcomes of 
patients with recurrence are poor and currently it is a significant cause of late death (Fong 2004). 
Recurrence can be explained by three different mechanisms; inadequate tumour resection, 
intrahepatic haematogenous or lymphatic tumour cell spread, and de novo (multicentric) tumor 
development in a cirrhotic liver (Schlitt 1999).  However tumour recurrence in patients following 
radical total hepatectomy and liver transplantation has raised the possibilities of disseminated 
microscopic tumour cells (DTC) or an extrahepatic origin of HCC. 
 
Tumour size and number are currently the only surrogate markers available to select patients and 
unfortunately these are not reliable determinants of tumour biology (Chen 2009). Additional 
markers that could improve the current staging systems need to be explored. The correlation 
between the presence of DTC and tumour recurrence has led to the development of techniques to 
identify these cells in several epithelial cancers but still knowledge on their biological behaviour 
is unknown. Pre-operative detection of these DTCs may help to identify patients in need of 
additional systemic therapies after curative resection of primary tumour. 
 
Several studies have described immunocytochemical and molecular assays to detect DTC in 
regional lymph nodes, peripheral blood and bone marrow of patients with epithelial tumours 
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including HCC. The current understanding of DTC and their relationship to tumour recurrence is 
largely derived from studies on breast cancer. Experience from breast cancer suggests that the 
mere presence of DTC does not predict the risk of metastases and additional molecular 
characterization is required to assess their biological potential. It has been shown that DTC in 
breast cancer can remain dormant for prolonged periods, are resistant to chemotherapy and have 
a cancer stem-cell phenotype(CD44+CD24–/low,cytokeratin19+muC1–,epCam+) suggesting a 
role for cancer stem cells in the propagation of DTC (Pantel 2009).   
 
The primary aim of this chapter was to develop a protocol to isolate and perform in vitro 
expansion of disseminated tumour cells in patients with HCC. The secondary aim was to assess 
the morphological and functional characteristics and expression of stem cell like phenotype of 
the cultured cells using immunocytochemistry. 
 
3.2 Patients and methods:  
During the study period a total of 45 patients with hepatocellular carcinoma provided written 
consent to participate. One patient subsequently withdrew and therefore peripheral blood 
samples were collected from 44 patients (Group 1). The median age was 61 years (Range 26-82 
years) and 84% of the patients were male. The aetiology of underlying liver disease was either 
alcohol induced or hepatitis viral infection in the majority. The median tumour size was 3.4 cm 
(Range 1.3-17cm). Macrovascular invasion was noted on the pre-operative staging investigations 




The control group consisted of 50 patients with chronic liver disease, but without hepatocellular 
carcinoma (Group 2- liver disease controls).  The median age was 52 years (Range 19-67 years) 
and 30% of this group were of female sex. The aetiology of liver disease was alcohol related in 
45% and the rest comprised of a mixture of hepatitis infection, cholestatic liver diseases and 
cryptogenic cirrhosis. The median MELD score at presentation was 14 (Range 7-34). The 
aetiology of liver disease in the patient and control groups is summarised in Table 1. 
 





Aetiology of liver disease Patients with HCC 
(n=44) 
Patients with cirrhosis but 
without HCC (n=50) 
Alcohol related chronic liver disease 20 22 
Viral (HBV and HBC) 20 10 
Auto-immune 1 5 
Cholestatic liver disease(PBC&PSC) 2 6 
Cryptogenic 1 3 
Metabolic (enzyme deficiencies, NASH) - 4 
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Twenty normal subjects with neither chronic liver disease nor hepatocellular carcinoma were 
also included in the study (Group 3- healthy controls). The median age was 32years (Range 21- 
45 years) and majority were of female sex (73%). 
 
Establishing an in vitro culture protocol: 
There is no published evidence regarding successful culture of DTC from HCC. The experience 
with primary in vitro expansion of DTC from other epithelial cancers is very limited. Initial 
experiments with breast cancer micrometastases revealed that these cells have a time-limited 
proliferative potential and therefore expansion of cell number is difficult. With this experience 
Pantel et al focused on the development of an immortalized micrometastatic cell line with a 
process that leads to the selection of only those cell clones which adapt best to the culture 
conditions (Pantel 1999). 
  
The high-glucose Dulbecco's modified eagle medium (D-MEM) with 15% fetal bovine serum 
(FBS) described by Loo et al (2005) for primary culture of DTC was used initially with our 
patient samples. Unfortunately this medium did not support the growth of DTC from HCC 
patients.  
 
The isolation and expansion of cells is strongly associated with the culture conditions. 
Modifications to the culture medium, cell density or culture flasks can make significant changes 
to cell growth. In an attempt to establish a culture protocol for the cells of interest, changes were 
made to the type of medium (DMEM vs. Alpha MEM), cell density (T25cm2 vs. T75cm2 culture 
flasks) and culture flasks (collagen coated vs. non-coated flasks). 
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Growth factors regulate cell replication by providing both stimulatory and inhibitory signals for 
proliferation. Their use has been described in several in vitro experiments at optimal levels to 
enhance cell proliferation. A variety of growth factors have potent mitogenic effects on 
Recombinant hepatocyte growth factor (HGF), a potent mitogen first purified from rat platelet 
and human and rabbit plasma (Nakamura 1986, 1987, 1989) has been studied extensively with 
respect to DNA synthesis and proliferation in vitro (Richman 1976; McGowan 1981). HGF 
stimulates hepatocyte DNA synthesis and proliferation within 3 to 4 hours of its addition to the 
culture flask (Kimura 1997). The role of using HGF to differentiate bone marrow progenitor 
cells into functional hepatocytes has been described by Jiang et al (2002). 
 
 Alpha- minimum essential medium (MEM) was described to be not only the optimum medium 
but also superior to DMEM for the expansion of hematopoietic cell lineage (Sotiropoulou 2006, 
Chen 2009). An enriched Alpha-MEM with 20% FBS and recombinant hepatocyte growth factor 
to favour the growth of possible hepatocyte like cells was therefore selected as the medium for 
expansion of our cells. 
 
The mononuclear cell layer (Buffy coat) from the blood specimen was isolated by density 
centrifugation and the potential DTC were cultured using the protocol described in Chapter 2. 
The medium was replaced on alternate days and culture flasks were monitored every day for cell 
attachment, viability and growth. The culture was carried on for a minimum of two weeks to 
allow growth of disseminated cells. The established cell colonies were detached and cytospin 




Antibodies to assess the morphology of cultured cells: 
 Cytokeratin 8 and 18(Cam 5.2):  The cytokeratins form a cytoplasmic intermediate filament 
network in many epithelial cells.  There are approximately 20 different polypeptides, whose 
expression patterns differ among different epithelial tissues. Normal adult human hepatocytes 
express cytokeratin 8 and 18. These filaments form a pericanalicular sheath that envelopes the 
whole hepatocyte resulting in a membranous immunocytochemical staining (Su 1998). 
 
Hepatocyte paraffin -1 (Hep Par-1): Hepatocyte specific antigen (HSA) is expressed by the 
majority of HCC’s and normal hepatocytes and not by biliary or non-parenchymal liver tissue. 
HSA binds specifically to a mouse monoclonal antibody, Hepatocyte Paraffin-1 (Hep Par-1) 
which is used to differentiate primary hepatocellular tumours from tumours of biliary or 
metastatic origin in cases of diagnostic uncertainty (Wennerberg 1993, Leong 1998, Siddidui 
2001, Zimmerman 2001). The exact location of the HSA antigen is unclear but it is thought that 
the epitope is located in hepatocellular mitochondria which results in a granular cytoplasmic 
immunocytochemical staining. Hep Par-1 has been established as a reasonably sensitive marker 
for HCC (Lau 2002). 
 
Polyclonal Carcinoembryonic antigen (PCEA): CEA is an oncofetal glycoprotein that is 
present in small amounts in normal adult gastrointestinal, pancreatic, and biliary tract cells.  A 
characteristic biliary canalicular pattern of PCEA expression is observed in majority of HCC 
lesions. This pattern of PCEA immunoreactivity is a result of cross-reactivity with biliary 
glycoprotein 1 that is expressed by normal bile ducts and bile canaliculi.  The reported sensitivity 
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of PCEA staining for HCC ranges from 60-95% (Borscheri 2001). Normal liver also exhibits a 
canalicular staining pattern with this antibody (Porcell 2000).  
  
ATP 7b: Is a transporting P-type ATPase that plays a key role in copper metabolism. Wilson’s 
disease gene (ATP 7b) that codes for this protein is primarily expressed in the liver and kidney. 
The protein is localized to the plasma membrane of both hepatocytes and biliary epithelial cells 
and helps transport copper into bile and serum as ceruloplasmin. Mutation of ATP 7b gene is the 
cause of Wilson’s disease that results in excessive deposition of copper mainly in the liver and 
brain. ATP 7b antibody was used in our study to assess the expression of hepatocyte like 
phenotypes by the cultured cells. 
 
CD68: Cluster of differentiation 68 is a 110-Kd transmembrane glycoprotein of unknown 
function highly expressed by human monocytes and tissue macrophages. 
 
Anti SMA: Smooth Muscle Actin (SMA) is found in the cytoplasm of smooth muscle cells. The 
anti-SMA antibody stains Kupffer cells in the liver, smooth muscle cells of blood vessels, and 
gastrointestinal tract. 
 







Antibodies to assess the expression of stem cell like phenotype:  
CD34: CD 34 is an adhesion molecule with a putative role in early haematopoiesis by mediating 
the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. 
It is highly expressed on haematopoietic progenitors, as well as on endothelial cells, brain, and 
testis. 
CD133: This was originally known as AC133 and is a member of pentaspan transmembrane 
glycoprotein family. CD133 antigen is a cell surface marker mainly expressed by haematopoietic 
stem cells but its function is currently unknown. It is also expressed by neural and endothelial 
stem cells, foetal liver and some malignant tumours. 
CD90:  It is a cell membrane bound glycoprotein also known as Thy-1 antigen.  CD90 is 
expressed by a variety of progenitor cells such as, haematopoietic stem cells, mesenchymal stem 
cells, hepatic stem cells and keratinocyte stem cells. The function of CD 90 is yet not fully 
elucidated, however it is thought to have roles in apoptosis, cell adhesion, cell migration and 
tumour metastases (Abeysinghe 2003). 
 
The expression of hepatocyte specific characteristics by the in vitro cultured cells was further 
assessed using the following functional markers: 
 
Human albumin: Albumin is the most common protein in the serum and is produced by the 





Glycogen: Also known as animal starch serves as long-term energy storage in the body. It is 
primarily synthesized and stored in hepatocytes and muscle cells. The presence of glycogen in 
the cultured cells was assessed by using PAS stain. 
 
The immunocytochemical analysis for the relevant antigens and PAS stain to assess the presence 
of glycogen was performed as per the protocols described in chapter 2. 
 
3.3 Results:  
In vitro Culture: 
Peripheral blood was cultured from subjects in group 1 (Patients with HCC), group 2 (chronic 
liver disease controls) and group 3 (healthy human volunteers) under identical conditions. 
Robust colony growth, as evidenced by cell counts in excess of 3x10
4 
was noted in 6 patients 
from group 1. The cell colonies were widely separated and consisted of closely arranged groups 
of oval/round cells with a prominent centrally located nucleus as shown in Figure 1. Small 
colonies of large cells ranging from 5000 to 10000 in number were noted in 15 patients from 
group 1 and 5 patients from group 2 (Figure 2). No cell growth was noted in controls from group 
3 at the end of a two-week culture (Figure 3). The cells were slow growing and no significant 
difference was noted in the external morphology between cells cultured from group 1 and group 
2 when reviewed by an expert liver histopathologist (Figure 4). Collagen coating of the culture 






Figure 1: Robust cell growth - cell colonies of oval/round cells with prominent central nucleus 
(Day 10 In vitro culture) 
 
 













Cells from patients with cirrhosis but no HCC            Cells from patients with cirrhosis and HCC 







The cell colonies were detached washed and analysed using immunocytochemistry.  
 
Cell morphology: Detached cultured cells from groups 1 and 2 stained were first stained with 
H&E to study the external morphology. This revealed large hexagonal cells with a peripherally 
placed nucleus resembling the appearance of hepatocytes as shown in Figure 5. 
 
Negative staining with CD 68 and Anti SMA antibodies excluded the possibility of these large 
cells being macrophages or Kupffer cells (Figure 6&7). 
 
Further analysis of the morphology of cultured cells using Cam 5.2, Hep Par-1, Polyclonal CEA 
and ATP 7b showed features similar to human hepatocytes. The relevant pictures along with the 
corresponding positive and negative controls are shown below in Figures 8,9,10 and 11. 
 
Functional phenotype: Cultured cells from both HCC and cirrhotic controls expressed albumin 
and glycogen which are characteristic markers of hepatocellular function (Figures 12 and 13). 
 
Stem cell phenotype: A significant proportion of cultured cells from group 1 and 2 expressed 
CD34, however, the expression of CD133 and CD90 was sparse and confined only to cultured 





Figure 5a) Human hepatocytes 
demonstrating a population of uni or bi nucleate hexagonal cells.
 
Figure 5b) Cultured cells from patients with cirrhosis and HCC: H&E staining showing 
hexagonal cells with peripherally placed nucleus
 
 
isolated for hepatocyte transplantation: H&E staining 
 
 






Figure 5c) Cultured cells from patients with cirrhosis but no HCC: H&E staining showing 















 Figure 6a) Negative staining with CD 68 antibody excluding the possibility of 
cells being macrophages or Kupffer cells 
 






 (Positive control): Human small bowel 
 
86 
in vitro cultured 
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Figure 7a: Immunocytochemistry using anti SMA antibody: Negative staining excluding the 
possibility of in vitro cultured cells being macrophages or Kupffer cells  
 
 
Figure 7b: Immunocytochemistry using anti SMA antibody (positive control): Human intestinal 







Figure 8: Immunocytochemistry using antibody against cytokeratin 8&18 (Cam 5.2):  
8 a) Cultured cells from patients with cirrhosis and HCC: The cells demonstrate a diffusely 
positive cytoplasmic staining with cam 5.2 antibody 
 
 
8 b) Cultured cells from patients with cirrhosis but without HCC: These cells also expressed 






8 c) Positive control- Human hepatoma cell line (HepG2) 
 
 








Figure 9: Immunocytochemistry with antibody against hepatocyte specific antigen (HSA) - 
Hep Par-1: 
 
9 a) Cultured cells from patients with cirrhosis and HCC: Staining is characteristically 
cytoplasmic, the nuclei were counterstained with haematoxylin. 
 
 
9 b) In vitro culture cells from patients with cirrhosis but no HCC: Positive cytoplasmic staining 





9 c) Positive control- Normal human hepatocytes 
 
 









Figure 10: Immunocytochemistry with antibody against Polyclonal CEA:  
 
10 a) Cultured cells from patients with cirrhosis and HCC: A characteristic biliary canalicular 
pattern of immunocytochemical staining (arrow) was noted with this antibody 
 
 
10 b) Cells cultured from patients with cirrhosis and without HCC: These cells also expressed 






10 c) Positive control- Normal human hepatocytes 
 
 









Figure 11: Immunocytochemistry with anti ATP 7b antibody:  
11 a) Cultured cells from patients with cirrhosis and HCC: A typical membrane staining was 
noted as shown by the marker. 
 
 
11 b) In vitro culture cells from patients with cirrhosis but no HCC: Membrane staining was 




 11 c) Positive control- Healthy human hepatocytes.
 









 Figure 12: Hepatocyte functional markers
human albumin: 
 
12 a) Cultured cells from patients with 
this antibody 
 
12 b) Cells from patients with cirrhosis and without HCC: Diffuse staining of the cytoplasm 
 
- Immunocytochemistry with 






 12 c) Positive control- Human hepatocytes
 












Figure 13: Hepatocyte functional marker- PAS staining for glycogen: 
 
13 a) In vitro culture cells from patients with cirrhosis and HCC: characteristic diffuse 
cytoplasmic staining of the glycogen reserves 
 
 
13 b) Cultured cells from patients with cirrhosis but without HCC: cytoplasmic staining was 






13 c) Positive control- Fine needle aspiration cytology of intestinal smooth muscle cells  
 
 








Figure 14: Immunocytochemistry using stem cell marker CD34: 
 








 14 c) Positive control- Liver endothelial cells (nuclei counterstained with Propidium iodide
stain) 
 












Figure 15: Immunocytochemistry using stem cell marker CD133: 
 
15 a) In vitro culture cells from patients with cirrhosis and HCC: limited membrane staining 
(arrow) was noted with CD133. The nuclei were counterstained with Propidium iodide (red). 
 
 






















 Figure 16: Immunocytochemistry with
 
16 a) In vitro culture cells from patients with cirrhosis and
in a very small population of cells
 
16 b) Positive control- Bone marrow stem cells
 
 
 stem cell marker CD90: 


























3.4 Discussion:   
Curative treatments can only be offered to a minority of HCC patients who present early but 
tumour recurrence still remains a considerable risk. Unlike LT procedures, there are no strict 
criteria in the selection of patients for a surgical resection The Milan criteria is widely accepted 
to allocate cadaveric livers for patients with HCC. A 5 year survival in excess of 70% has been 
achieved internationally using this selection criteria. However studies aimed at validation of the 
Milan criteria also identified excellent outcomes in patients outside this strict criteria that lead to 
the introduction of an extended UCSF criteria. 
 
The pre-operative tumour data such as size and number have been the only basis for all of these 
selection criteria. The analysis of outcomes using these tumour parameters by different groups 
produced variable results, also a major drawback was the inclusion tumour variables from post-
operative histology (Toso 2008, 2009, Mazzaferro 2009). 
 
The strong predictors of tumour recurrence such as vascular invasion or tumour differentiation 
are not routinely available pre-operatively. Tumour size has been shown to be as a surrogate 
marker for vascular invasion, it is the only available variable from radiological imaging to stage 
HCC. Radiological estimation of tumour morphology is very subjective even with the use of 
modern imaging modalities. A retrospective study comparing pre-operative radiological staging 
and post-operative pathological staging in 789 liver transplant recipients concluded that the 




There is a clinical need to develop methods that could the assess tumour biology with the help of 
simple and minimally invasive diagnostic modalities. The inclusion of such potential markers 
will further improve our selection criteria and improve the treatment outcomes. 
 
Disseminated tumour cells have been isolated from simple peripheral blood sample specimens in 
several epithelial cancers. They were linked with early tumour recurrence and poor prognosis. If 
DTC represent cells detached from primary tumours, their isolation and analysis could shed light 
on the biological behaviour of cancers.   
 
Studies on patterns of tumour recurrence suggested that the commonest site of recurrence for 
HCC is the remnant after resection or transplanted liver graft (Ou 2005). The patterns of tumour 
recurrence were divided into early and late; tumour biology is associated with early recurrence  
while a de novo carcinogenic process is noted in late recurrence. Nearly 90% of early recurrence 
is intra-hepatic and such a pattern especially after LT suggests that circulating tumour cells with 
a potential to migrate and engraft in the liver are undetected during staging investigations. 
Clinical correlation suggests that the presence of micrometastases in HCC patients is associated 
with tumour recurrence (Ijichi 2002, Marubashi 2007). It has been possible to detect 
disseminated tumour cells at a single cell level in bone marrow (BM) and peripheral blood using 
immunocytochemical and molecular assays. The detection rate of cells using these techniques is 
in the order of 1-2 cells per million of bone marrow cells. However, the baseline assumption that 
circulating mRNA is equivalent to circulating cells, the lack of reliability of mRNA detection 




There is some evidence to suggest micrometastases can remain dormant for a prolonged period 
of time and may or may not develop into clinical metastases (Braun & Pantel 1999). It has been 
hypothesised that the tumour cells detected in patients who develop recurrence may be 
phenotypically different from those detected in patients who do not develop tumour recurrence. 
Sutcliffe et al (2005) demonstrated that despite the presence of DTC, not all patients with HCC 
developed recurrence (Sutcliffe 2005). 
 
The ability to consistently identify micrometastases and understand their biology at a molecular 
level (by developing an in vitro culture protocol to increase the number of these rare cells) would 
advance our understanding of HCC and may have an impact on clinical outcome. Experiences 
from in vitro culture of micrometastatic cells from oesophageal cancer (O’Sullivan 1999) suggest 
that isolation of DTC from foregut cancers is feasible. 
 
The results of our study show that in vitro culture of DTC from patients with HCC is possible 
and that these cells possess characteristic morphological, phonotypic and functional features of 
hepatocytes.  
 
Of note, however small colonies of hepatocyte-like cells were also isolated in 5 out of 50 patients 
with cirrhosis (group 2) who did not have HCC, but not from healthy volunteers. The presence of 
these cells could be explained by the cellular mechanisms behind liver regeneration. It is now 
well accepted that two physiological forms of liver regeneration occur in response to the type of 
liver injury. Hepatocytes are the first line cells that help in liver regeneration while the liver 
progenitor cells serve as second line of defence when hepatocytes can no longer regenerate. 
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Swanson et al. with the use of genetically modified mice (hereditary tyrosinemia type I) showed 
that when hepatocytes are not capable of dividing rapidly enough to restore damaged liver, liver 
progenitor cells and possibly, extra hepatic progenitor cells including those in the bone marrow 
are recruited to help in the regeneration process. 
  
The cellular response to regeneration is purely determined by the nature of liver injury. Repeated 
chronic injury as seen in viral hepatitis or steatohepatitis could potentially activate progenitor 
cells from an extra-hepatic source to differentiate into hepatocytes. The proportion of bone 
marrow (BM)-derived hepatocytes in human liver have ranged from non-existent in some studies 
to over 40% and this variation is probably due to differences in the severity of liver parenchymal 
damage (Alison 2005). The contribution of haematopoietic stem cell (HSC) to liver regeneration 
in animal experiments and humans remains controversial with data both supporting and 
challenging the findings. Rodent experiments using a fumarylacetoacetate hydrolase (FAH)-
deficient mouse model (fatal hereditary tyrosinemia type I) demonstrated that HSC can 
differentiate into functional hepatocytes (Lagasse). However, attempts to define their role in 
restoring a functional liver in human beings are still at an experimental stage (Houlihan 2008).  
 
The detection of circulating hepatocyte-like cells in small group of patients with end-stage liver 
disease in our study supports a possible extra-hepatic source that helps in liver regeneration. The 
positive staining with CD34 antibodies suggests a haematopoietic origin of these cells. It was 
also observed that 60% of patients in this small sub-group had alcohol induced liver injury and a 
high MELD score, which could indicate a possible relationship between degree of hepatocyte 
damage and circulating hepatocytes. 
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The molecular pathways involved in migration of HSC have been investigated in murine and 
human subjects. It was shown that the chemokine stromal cell-derived factor-1 (SDF-1) and its 
receptor, CXCR4, interactions participate in the mobilization and migration of human HSCs to 
the liver during injury (Dalakas 2005). Factors regulating long-term engraftment and 
differentiation of HSCs into hepatocytes are yet to be defined. 
 
The positive immunocytochemistry using stem cell markers (CD34, CD133 and CD90) raises the 
possibility of the presence of cancer stem cells within cultures derived from our experimental 
samples (group 1- HCC patients). There is substantial evidence supporting the presence of cancer 
stem cells (CSC) in many solid organ malignancies, these cells exhibit properties of both normal 
stem cells and cancer cells and are associated with aggressive cancer behaviour (Visvader 2008).  
 
 According to CSC hypothesis, tumours are organized into a hierarchy of heterogeneous cell 
populations, and only a small subset of cells, termed CSCs or tumour-initiating cells, have the 
ability to drive and sustain tumour growth. The cancer stem cell hypothesis provides a new 
insight into hepatocarcinogenesis. Evidence from animal experiments demonstrated that only a 
minority of HCC are derived from mature hepatocytes. The hypothesis that a human HCC could 
have a stem cell origin is based on the following indirect evidence ; 1) in a rodent 
hepatocarcinogenesis model hepatic progenitor cell (HPC)/oval cells have been shown to be the 
cells of origin of HCC, 2) a considerable proportion of HCCs express hepatocyte progenitor 
markers that are not generally expressed by mature hepatocytes and 3) many tumours contain a 




The role of CSCs in the origin and propagation of HCC is less clear as their expression is not 
ubiquitous. Several HCC stem cell markers were highlighted in the published studies but their 
exact roles are still under investigation (Tong 2011). The first recognised and commonly used 
marker to identify CSC in HCC is CD133, this marker is only confined to a small sub-population 
of tumour tissue and absent in normal liver. Studies using human HCC cell lines demonstrated 
that CD133 +ve sub-population of cells had an enhanced clonogenicity in vitro and 
tumorigenicity in vivo. They also were noted to have properties of stem cells such as ability to 
self-renew and differentiate into non-hepatocyte lineages (Chan 2007, Song 2008, Tang 2010).  
The second widely used CD surface protein for the identification of liver CSCs is CD90. Yang 
and colleagues found a significant positive correlation of CD90 expression with tumorigenicity 
and metastatic potential in the panel of liver cell lines tested. It was also reported in their study 
that CD 90+ve cells were present in peripheral blood samples of patients with aggressive HCC 
phenotype but not in normal controls or patients with cirrhosis (Yang 2008).  
In our study the expression of CD133 and CD90 by cells cultured from patients with HCC was 
the only discriminating feature compared to those isolated from patients with cirrhosis and no 
HCC. These markers are only expressed by very small sub-population of HCC and the very low 
expression by our experimental cells also indicates that the CSC phenotype was probably not 
retained by the majority of differentiated hepatocytes. This hypothesis was supported by 
evidence from a mouse model of intestinal cancer where despite all neoplastic cells arising from 
CD133+ stem cells, only a small fraction of the tumour cells retained CD133 expression 
(Visuvader 2011)  
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The origin of CSCs in HCC is controversial with some studies supporting a bone marrow origin 
while others suggest a liver stem cell origin (Sell 2008). The immunocytochemistry results in 
this chapter suggests that circulating cells isolated from patients with HCC, express markers 
(CD34,CD133,CD90) that could associate them with a hematopoietic or stem cell origin.  
The immunocytochemistry analysis has shown that the cultured cells had acquired features of 
hepatocytes. Apart from the low expression of CSC markers there were no features that 
distinguished cells derived from patients with HCC from those cultured from cirrhosis controls. 
The malignant potential of DTC cannot be determined accurately by immunocytochemistry 
alone, and further work is required to confirm whether they originate within bone marrow or 
represent circulating liver-derived cells.  
3.5 Conclusion: The results obtained showed that circulating hepatocyte like cells are present in 
patients with HCC and chronic liver disease. The true biological behaviour of these cells is not 
clear.  
The aim of the next chapter is to evaluate the malignant nature and the origin of cells cultured 









CHAPTER 4: BIOLOGICAL BEHAVIOUR AD ORIGI OF 
DISSEMIATED TUMOUR CELLS I HCC 
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4.1 Introduction: Disseminated tumour cells have been detected in the bone marrow or 
peripheral blood of patients with epithelial cancers using immunocytochemistry or molecular 
assays. However there is only a limited knowledge about the genetic, phenotypic and biological 
characteristics of these cells. Pantel et al extensively investigated the clinical relevance of the 
detection of DTC in breast cancer. The largest multicentric study including 4703 breast cancer 
patients showed that micrometastasis could be detected in 30% of patients and their presence is 
an independent risk factor for poor overall survival. The results also concluded that despite the 
associated adverse prognosis, nearly half of the patients identified with DTC did not develop 
clinical metastases after 10 year follow-up (Pantel 2009).   
 
In our previous study that aimed at identifying an effective diagnostic tool to detect 
micrometastases in HCC, we analysed bone marrow aspirates from 32 subjects (18-HCC; 9- 
patients with cirrhosis and 5- healthy volunteers without liver disease). Seventeen (94%) patients 
with HCC were within the Milan criteria pre-operatively. Explant histology reported 
microvascular invasion in 8(44%) and poor differentiation in 4(22%). At a median follow-up of 
43months it was observed that nearly half of the patients with detectable micrometastases did not 
develop tumour recurrence (Sutcliffe 2005).  
 
The phenomenon of dormancy has been observed in DTC isolated from patients with breast 
cancer. Meng et al demonstrated that DTC can be detected in patients with no evidence of 
clinical metastases up to 22 years after curative mastectomy. The underlying molecular 
mechanisms that can maintain DTC dormancy or activate them to form clinical metastases have 
yet to be identified. It is important to further characterise DTC and to understand the homeostatic 
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mechanisms such as anti-tumour immune response or angiogenesis suppression to develop 
potential therapeutic agents. 
 
Our previous experiment demonstrated that DTC can be isolated in patients with HCC and that 
they have morphological features and a functional phenotype similar to hepatocytes 
(Immunocytochemistry analysis using relevant antibodies- Chapter 3).  Interestingly similar cells 
were also detected in a small proportion of patients with chronic liver disease but with no clinical 
evidence of HCC. The H&E staining and immunocytochemistry assessment could not 
demonstrate any strong differences between these two groups of cells, particularly the malignant 
potential of cultured cells from patients with HCC. 
 
Liver cirrhosis is the strongest risk factor for HCC, distinguishing pre-neoplastic lesions from 
HCC is still a challenge even for expert histopathologist. Pathological examination is considered 
as gold standard to discriminate HCC from cirrhotic nodules. Although immunostaining plays a 
very important role in the clinical diagnosis of HCC, it has diagnostic limitations. (Saad 2004, 
Llovet 2006). Genomic-wide cDNA microarrays and quantitative real-time reverse transcription-
polymerase assay studies have been attempted to develop a molecular index which is efficient at 
categorizing liver tissue samples as normal or cirrhotic liver or HCC, however, none of them 
were able to produce a signature that is clinically acceptable (Paradis 2003, Okabe 2001, Xiao 
2001, Shirota 2001) 
 
Llovet et al have developed a 3-gene set that allows a reliable diagnosis of HCC and can also 
discriminate between HCC and dysplasia or cirrhosis. This 3 gene signature consisting of 
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LYVE1, glypican-3 and survivin is shown to have a sensitivity of 95%, specificity of 94% and 
an accuracy of 94% in discriminating HCC from dysplastic or cirrhotic nodules. The 3-gene set 
was also validated in 29 samples (Llovet 2006). We selected this 3 gene signature along with 
TGF-alpha and p53 to discriminate DTC from cells isolated from patients with cirrhosis (Yeh 
2007, Anzola 2004, Zhang 2004). The cells cultured from patients with HCC were further 
assessed for the expression of a wide range of malignant genes shown to be associated with poor 
prognosis in solid organ tumours and HCC. 
 
The results of our previous experiment also demonstrated the expression of bone marrow stem 
cell (BMSC) phenotype by the cultured cells from patients with HCC which raised the possible 
BM origin of DTC. Bone marrow is a rich source for pleuripotent stem cells and has been 
proposed as the source for cancer stem cells in several epithelial cancers. The Helicobacter pylori 
gastric cancer mouse model showed that BMSC are inherently mutagenic and can transform into 
malignant cells with an appropriate stimulus (Houghton 2005).  
 
The evidence for BM involvement in hepatocarcinogenesis is still controversial (Theise 2000, 
Lagasse 2000, Kubota 2008, Sell 2009). In-view of considerable evidence both supporting and 
disputing it, we attempted to investigate the association between BMSC and our cultured cells by 
comparing their gene expression profiles. 
 
The aim of this chapter is therefore: 1) to investigate the in vitro neoplastic behaviour of cultured 





4.2 Materials and methods:  
In an attempt to differentiate cells cultured from patients with cirrhosis and HCC and a control 
group with cirrhosis and no identifiable HCC, we used the 3 gene signature described by Llovet 
et al and the expression of TGF-alpha and p53. None of the cirrhosis control group has 
developed HCC at the latest follow up.  
 
The 3- gene expressions were evaluated by using qPCR. Single-step real-time qPCR was 
performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems Inc, CA, USA).  
qPCR was carried out
 
in 20-µl reaction mixtures using the TaqMan gene expression master mix 
(Applied Biosystems Inc, CA, USA) in 96 well plates using the protocol described in section 
2.9.5. Levels of glypican 3, LYVE1 and survivin were assessed and an external standard
 
template containing human GAPDH cDNA was included in each run to generate a standard 
curve. qPCR probes were purchased from Applied Biosystems Inc. 
 
TGF-alpha and p53 analysis was performed by RT-PCR using a PCR selection kit (Invitrogen, 
UK), following the company protocol. Primers were purchased from Eurofins MWG Operon 
































Description of selected genes: 
Glypican 3 (GPC3): Is a member of the glypican family of cell-surface heparan sulfate 
proteoglycans and serves as a co-receptor for heparin-binding growth factors. It is reported that 
GPC3 messenger RNA (mRNA) levels are over expressed in 75% of HCCs but not in focal 
nodular hyperplasia or cirrhosis (Zhu 2001). Hsu et al demonstrated that GPC3 mRNA was 
detectable in 74.8% of primary and recurrent HCCs but only 3.2% of normal livers. Cappuro et 
al suggested that GPC3 promotes the growth of HCC by stimulating the canonical Wnt pathway 
(Cappuro 2005). Although GPC3 mRNA expression was noted in foetal livers and placenta 
suggesting its expression by regenerating hepatocytes, Nakatsura et al showed no such 
correlation in their study (Nakatsura 2003). 
 
Survivin: Is an oncofoetal protein that belongs to the inhibitor of apoptosis proteins family. It is 
undetectable in terminally differentiated adult tissues but widely expressed by foetal tissue and a 
variety of cancer cells. Survivin inhibits the activation of caspases leading to negative regulation 
of apoptosis. It has been implicated in the carcinogenesis of neuroblastoma, colorectal, non–
small-cell lung and gastric cancer. Survivin expression was increased (3.3- fold) in early and (24-
fold) in advanced HCC, compared with normal tissue (Llovet 2006, Montorsi 2007). Studies 
investigating the expression and function of survivin using human HCC cell lines observed that 
its expression correlates with cell proliferation and tumour progression (Ito 2000). 
 
Lymphatic vessel endothelial hyaluronan receptor (LYVE)-1: Is a transmembrane 
glycoprotein that is expressed by normal lymphatic endothelium and sinusoidal cells in the liver. 
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Although the physiological role of this receptor is not clearly defined, it has been associated with 
tumour metastases and poor prognosis. LYVE-1 is reportedly down-regulated in solid tumours, 
such as breast, lung, and endometrial cancer suggesting destruction of the lymphatics by tumour 
invasion. LYVE-1 is also down regulated in HCC (Carreira 2001), Llovet et al observed a 1.6-
fold decreased in dysplastic nodules and a 20-fold decreased in early HCC. 
 
Transforming growth factor alpha (TGF-α): Growth factor signal pathways regulate cell 
proliferation, differentiation, and apoptosis and aberrant or over expression of these factors could 
lead to neoplasia. TGF-α is a mitogen synthesized as a transmembrane polypeptide and has been 
implicated in the molecular pathogenesis of HCC. Transgenic mouse models showed that over 
expression of TGF-α resulted in increased hepatocyte proliferation, dysplasia, adenoma and HCC 
(Jo 1999, Yeh 2007). Chug et al showed that TGF-alpha mRNA expression was significantly 
elevated in patients with HCC when compared with chronic viral hepatitis controls (Chung 
2000). 
 
Protein 53(p53): Is a nuclear phosphoprotein coded by a tumour suppressor gene p53. It 
functions as a transcriptional regulatory protein and has a critical role in the regulation of the cell 
cycle. Tumour suppressor genes are of great importance in human carcinogenesis and mutations 
in the p53 gene have been reported in a variety of human cancers including HCC. Studies 
investigating the incidence of mutations or over expression of p53 in different geographic HCC 
populations have yielded variable results. The incidence of p53 mutations in HCC throughout the 
world varies between 15% in Europe and 42% in China, with a worldwide frequency of 27% 
(Bressac 1990, Ozturk 1991, An 2001). A high level of cellular p53 protein due to 
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overexpression of p53 gene correlates with the degree of malignancy (Guan 2006). Abnormal 
expression of p53 in HCC is regarded as an indicator of the genetic instability and biological 
aggressiveness of the tumour (Anzola 2003). 
 
The expression of cancer-associated genes in cells cultured from patients with HCC was studied 
by microarray analysis. More than 300 microarray studies have investigated deregulated genes in 
HCC to-date, however, the challenge of identifying clinically relevant genes persists (Andrisani 
2011). Following an extensive literature search we considered those genes that have a potential 
role in the diagnosis, pathogenesis and predicting the prognosis of HCC as bench mark to 
analyse the cultured cells from patients with HCC. A list of genes that are expressed by HCC as 
well as those associated with poor prognosis both in HCC and other solid tumours are displayed 
in Tables 1, 2 and 3 along with appropriate references.  
 
As the cells isolated from patients with cirrhosis were limited by number it was not possible to 
include them in this analysis. The gene expression profiles of DTC were compared with controls 











Table 1: 10 genes previously described as diagnostic markers of HCC 
Ref Gene 
Symbol 
Gene ame Reference 
1 KRT19    Cytokeratin 19 Grabarević, Z. et al. Comparative analysis of 
hepatocellular carcinoma in men and dogs. Coll. Antropol. 
33, 811-814 (2009). 
2 TM4SF1      Transmembrane 4 L 
six family member 1 
Dong, H. et al. Gene expression profile analysis of human 
hepatocellular carcinoma using SAGE and LongSAGE. 
BMC Med. Genom. 2, 5 (2009). 
3 AFP                        Alpha fetoprotein Johnson, P.J. The role of serum alpha-fetoprotein 
estimation in the diagnosis and management of 
hepatocellular carcinoma. Clin. Liver Dis. 5, 145–59 
(2001). 
4 GPC3                         Glypican 3 Hsu, H.C., Cheng, W. & Lai, P.L. Cloning and expression 
of a developmentally regulated transcript MXR7 in 
hepatocellular carcinoma: biologic significance and 
temporospatial distribution. Cancer Res. 57, 5179–5184 
(1997). 
5 PEG10              Paternally expressed 
10 
Tsou, A.P. et al. Over expression of a novel imprinted 
gene, PEG10, in human hepatocellular carcinoma and in 
regenerating mouse livers. J. Biomed. Sci. 10, 625-635 
(2003). 
6 CPE                    Carboxypeptidase E Wang, W., Peng, J.X., Yang, J.Q., Yang, L.Y. 
Identification of Gene Expression Profiling in 
Hepatocellular Carcinoma Using cDNA Microarrays. Dig. 
Dis. Sci. 54, 2729–2735 (2009). 
7 DKK1                 Dickkopf homolog 1 Patil, M.A. et al. An integrated data analysis approach to 
characterize genes highly expressed in hepatocellular 
carcinoma. Oncogene 24, 3737-3747 (2005). 
8 NEDD4L            
 
Neural precursor cell 
expressed,    
developmentally 
down-regulated 4-like   
Lee, H.S. et al. Novel candidate targets of Wnt/β-catenin 
signalling in hepatoma cells. Life Sci. 80, 690–698 (2007). 
9 NEK3          
 
NIMA (never in 
mitosis gene a)-related  
kinase 3 
Hernández, M., Almeida, T.A. Is there any association 
between nek3 and cancers with frequent 13q14 deletion? 
Cancer Invest. 24, 682-688 (2006). 
10 FDPS                  Farnesyl diphosphate 
synthase 
Sung, Y.K. et al. Glypican-3 is over expressed in human 





Table 2: List of 18 genes previously described to be associated with poor prognosis in HCC 
Ref Gene 
symbol 
Gene ame Reference 
1.  IGF2BP3     
 
Insulin-like growth 
factor 2 mRNA                                 
binding protein 3 
Jeng, Y.M. et al. RNA-binding protein insulin-like growth 
factor II mRNA-binding protein 3 expression promotes 
tumour invasion and predicts early recurrence and poor 
prognosis in hepatocellular carcinoma. Hepatol. 48, 1118-
1127 (2008). 
2 RAB23            Member RAS 
oncogene family 
Liu, Y.J. et al. Rab23 is a potential biological target for 
treating hepatocellular carcinoma. World J. Gastroenterol. 
13, 1010-1017 (2007). 
3 NQO1          NAD(P)H 
dehydrogenase, 
quinone 1 
Chiu, M.M., Ko, Y.J., Tsou, A.P., Chau, G.Y., Chau, Y.P. 
Analysis of NQO1 polymorphisms and p53 protein 
expression in patients with hepatocellular carcinoma. Histol. 
Histopathol. 24, 1223-1232 (2009). 






Wong, C.C., Wong, C.M., Tung, E.K., Man, K., Ng, I.O. 
Rho-kinase 2 is frequently over expressed in hepatocellular 
carcinoma and involved in tumour invasion. Hepatol. 49, 
1583-1594 (2009). 
5 DLK1           Delta-like 1 
homolog 
(Drosophila) 
Jin, Z.H., Yang, R.J., Dong, B., Xing, B.C. Progenitor gene 
DLK1 might be an independent prognostic factor of liver 
cancer. Expert Opin. Biol. Ther. 8, 371-377 (2008). 
6 ZHX2             Zinc fingers and 
homeoboxes 2 
Hu, S. et al. Expression of zinc-fingers and homeoboxes 2 in 
hepatocellular carcinogenesis: a tissue microarray and 
clinicopathological analysis. Neoplasma 54, 207-211 (2007).
 
7 LIN28B           Lin-28 homolog B 
(C. elegans) 
Viswanathan, S.R. et al. Lin28 promotes transformation and 





KRT19             Cytokeratin 19 Yang, X.R. et al. Cytokeratin 10 and cytokeratin 19: 
predictive markers for poor prognosis in hepatocellular 
carcinoma patients after curative resection. Clin. Cancer Res. 
14, 3850-3859 (2008). 
9 DKK1             Dickkopf homolog 
1 
Yu, B. et al. Elevated expression of DKK1 is associated with 
cytoplasmic/nuclear beta-catenin accumulation and poor 





PEG10           Paternally 
expressed 10 
Ip, W.K. et al. Identification of PEG10 as a progression 
related biomarker for hepatocellular carcinoma. Cancer Lett. 
250, 284-291 (2007).
 
11 CCR6        Chemokine (C-C 
motif) receptor 6 
Uchida, H. et al. Chemokine receptor CCR6 as a prognostic 
factor after hepatic resection for hepatocellular carcinoma. J. 




12 BMP4             Bone 
morphogenetic 
protein 4 
Maegdefrau, U. et al. Bone morphogenetic protein 4 is 
induced in hepatocellular carcinoma by hypoxia and 
promotes tumour progression. J. Pathol. 218, 520-529(2009)
 




G                           
(WHITE), member 
2 
Shi, G.M. et al. Identification of side population cells in 
human hepatocellular carcinoma cell lines with stepwise 
metastatic potentials. J. Cancer Res. Clin. Oncol. 134, 1155-
1163 (2008).
 
14 SPP1                Secreted 
phosphoprotein 1 
Pan, H.W. et al. Over expression of osteopontin is associated 
with intrahepatic metastasis, early recurrence, and poorer 
prognosis of surgically resected hepatocellular carcinoma. 
Cancer 98, 119-127 (2003).
 
15 CCL20         Chemokine (C-C 
motif) ligand 20 
Yamauchi, K., Akbar, S.M., Horiike, N., Michitaka, K., Onji, 
M. Increased serum levels of macrophage inflammatory 
protein-3alpha in hepatocellular carcinoma: relationship with 
clinical factors and prognostic importance during therapy. 
Int. J. Mol. Med. 11, 601-605 (2003). 
16 GSTA4       Glutathione S-
transferase alpha 4 
McGlynn, K.A. et al. Susceptibility to aflatoxin B1-related 
primary hepatocellular carcinoma in mice and humans. 
Cancer Res. 63, 4594–4601 (2003).
 
17 ROBO1      
 
Roundabout, axon 
guidance receptor                                   
homolog 1 
Avci, M.E., Konu, O., Yagci, T. Quantification of SLIT-
ROBO transcripts in hepatocellular carcinoma reveals two 
groups of genes with coordinate expression. BMC Cancer 8, 
392 (2008). 
 
18 CTGF              Connective tissue 
growth factor 
Mazzocca, A. et al. Down-regulation of connective tissue 
growth factor by inhibition of transforming growth factor 
beta blocks the tumour-stroma  
cross-talk and tumour progression in hepatocellular 
















Table 3: List of 43 genes associated with poor outcome in non-HCC solid tumours 
Ref Gene Symbol           Gene name Reference 
1 S100P         S100 calcium binding 
protein P 
Dairkee, S.H. et al. Immutable functional attributes 
of histological grade revealed by context-
independent gene expression in primary breast 
cancer cells. Cancer Res. 69, 7826-7834 (2009). 
2 FBLN1                    Fibulin 1 Roger, P., Pujol, P., Lucas, A., Baldet, P., Rochefort, 
H. Increased immunostaining of fibulin-1, an 
estrogen-regulated protein in the stroma of human 
ovarian epithelial tumours. Am. J. Pathol. 153, 1579-
1588 (1998). 
3 CCL20      Chemokine (C-C motif) 
ligand 20 
Chang, K.P. et al. Macrophage inflammatory 
protein-3alpha is a novel serum marker for 
nasopharyngeal carcinoma detection and prediction 
of treatment outcomes. Clin. Cancer Res. 14, 6979-
6987 (2008). 
4 LAMB1                Laminin, beta 1 Bresalier, R.S. et al. The laminin alpha 1 chain Ile-
Lys-Val-Ala-Val (IKVAV)-containing peptide 
promotes liver colonization by human colon cancer 
cells. Cancer Res. 55, 2476-2480 (1995). 




protein-coupled receptor 5 
McClanahan, T. et al. Identification of over 
expression of orphan G protein-coupled receptor 
GPR49 in human colon and ovarian primary 
tumours. Cancer Biol. Ther. 5, 419-426 (2006). 
6 STC2                 Stanniocalcin 2 Meyer, H.A. et al. Identification of stanniocalcin 2 as 
prognostic marker in renal cell carcinoma. Eur. Urol. 
55, 669-678 (2009). 
7 MUC15        
 
Mucin 15, cell surface   
associated 
Huang, J. et al. Over expression of MUC15 activates 
extracellular signal-regulated kinase 1/2 and 
promotes the oncogenic potential of human colon 
cancer cells. Carcinogenesis 30, 1452-1458 (2009). 
8 IGF2BP1      
 
Insulin-like growth factor 2 
mRNA  binding protein 1 
Köbel, M. et al. Expression of the RNA-binding 
protein IMP1 correlates with poor prognosis in 
ovarian carcinoma. Oncogene 26, 7584-7589 (2007). 
9 ETV4                   Ets variant 4 Cheville, J.C. et al. Gene panel model predictive of 
outcome in men at high-risk of systemic progression 
and death from prostate cancer after radical 
retropubic prostatectomy. J. Clin. Oncol. 26, 3930-
3936 (2008). 
10 KIAA1199       KIAA1199 Matsuzaki, S. et al. Clinicopathologic significance of 
KIAA1199 over expression in human gastric cancer. 
Ann. Surg. Oncol. 16, 2042-2051 (2009). 
11 TYRO3      TYRO3 protein tyrosine Zhu, S. et al. A genomic screen identifies TYRO3 as 
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kinase a MITF regulator in melanoma. PNAS 106, 17025-
17030 (2009). 
12 BMP4         Bone morphogenetic protein 
3 
Montesano, R., Sarközi, R., Schramek, H. Bone 
morphogenetic protein-4 strongly potentiates growth 
factor-induced proliferation of mammary epithelial 
cells. Biochem. Biophys. Res. Commun. 374, 164-
168 (2008). 
13 JAG1                    Jagged 1 Reedijk, M. et al. High-level co expression of JAG1 
and NOTCH1 is observed in human breast cancer 
and is associated with poor overall survival. Cancer 
Res. 65, 8530-8537 (2005). 
14 EGLN3      Egl nine homolog 3 (C. 
elegans) 
Couvelard, A. et al. Over expression of the oxygen 
sensors PHD-1, PHD-2, PHD-3, and FIH Is 
associated with tumour aggressiveness in pancreatic 
endocrine tumours. Clin. Cancer Res. 14, 6634-6639 
(2008). 
15 ADORA2B      Adenosine A2b receptor Li, S., Huang, S., Peng, S.B. Over expression of G 
protein-coupled receptors in cancer cells: 
involvement in tumour progression. [Review] Int. J. 
Oncol. 27, 1329-1339 (2005). 





Berois, N. et al. ppGalNAc-T13: a new molecular 
marker of bone marrow involvement in 
neuroblastoma. Clin. Chem.52, 1701-1712 (2006). 
17 PGC            Progastricsin (pepsinogen 
C) 
Alvarez, M.L., González, L.O., Barbón, J.J., 
Astudillo, A., Vizoso, F.J. Expression and clinical 
significance of pepsinogen C in uveal melanomas. 
Int. J. Biol. Markers 19, 240-244 (2004). 
18 FDPS        Farnesyl diphosphate 
synthase 
Ettinger, S.L. et al. Dysregulation of sterol response 
element-binding proteins and downstream effectors 
in prostate cancer during progression to androgen 
independence. Cancer Res. 64, 2212-2221 (2004). 
19 PAGE1        Pantigen family, member 1 Chen, M.E., Lin, S.H., Chung, L.W., Sikes, R.A. 
Isolation and characterization of PAGE-1 and 
GAGE-7. New genes expressed in the LNCaP 
prostate cancer progression model that share 
homology with melanoma-associated antigens. J. 
Biol. Chem. 273, 17618-17625 (1998). 
20 S100A1     S100 calcium binding 
protein A1 
DeRycke, M.S. et al. S100A1 expression in ovarian 
and endometrial endometrioid carcinomas is a 
prognostic indicator of relapse-free survival. Am. J. 
Clin. Pathol. 132, 846-856 (2009). 
21 CA9              Carbonic anhydrase IX Korkeila, E. et al. Expression of carbonic anhydrase 
IX suggests poor outcome in rectal cancer. Br. J. 





22 ROCK2     
 
Rho-associated, coiled-coil  
containing protein kinase 2 
Fu, X.D. et al. Extra-nuclear signalling of 
progesterone receptor to breast cancer cell movement 
and invasion through the actin cytoskeleton. PLoS 
One. 3 e2790 (2008). 
23
 
MKKS     McKusick-Kaufman 
syndrome 
Kim, J.C. et al. Gene expression profiling: canonical 
molecular changes and clinicopathological features 
in sporadic colorectal cancers. World J. 
Gastroenterol. 14, 6662-6672 (2008). 
24
 
FAM162A     
 
Family with sequence 
similarity  
162, member A 
Cho, Y.E., Kim, J.Y., Kim, Y.W., Park, J.H., Lee, S. 
Expression and prognostic significance of human 
growth and transformation-dependent protein in 
gastric carcinoma and gastric adenoma. Human 
Pathol. 40, 975-981 (2009). 
25 AHCY          Adenosylhomocysteinase Scotto, L. et al. Identification of copy number gain 
and over expressed genes on chromosome arm 20q 
by an integrative genomic approach in cervical 
cancer: potential role in progression. Genes 
Chromosomes Cancer 47, 755-765 (2008). 
26 DLK1       Delta-like 1 homolog 
(Drosophila) 
Yin, D. et al. DLK1: increased expression in gliomas 
and associated with oncogenic activities. Oncogene 
25, 1852-1861 (2006). 
27
 
PTTG1IP   
 
Pituitary tumor-
transforming 1 interacting 
protein 
Stratford, A.L. et al. Pituitary tumour transforming 
gene binding factor: a novel transforming gene in 
thyroid tumorigenesis. J. Clin. Endocrinol. Metab. 
90, 4341-4349 (2005). 
28 S100A3     S100 calcium binding 
protein A3 
Liu, J. et al. In silico analysis and verification of 
S100 gene expression in gastric cancer. BMC Cancer 
8, 261 (2008). 
29 CKMT1A 
/CKMT1B                   
Creatine kinase, 
mitochondrial  1A/1B. 
Cimino, D. et al. Identification of new genes 
associated with breast cancer progression by gene 
expression analysis of predefined sets of neoplastic 
tissues. Int. J. Cancer 123, 1327-1338 (2008). 
30 ABCG2   
 
ATP-binding cassette, sub-
family G  
(WHITE), member 2 
Tsunoda, S. et al. ABCG2 expression is an 
independent unfavourable prognostic factor in 
oesophageal squamous cell carcinoma. Oncology 71, 
251-258 (2006). 
31 SPP1            Secreted phosphoprotein 1 Likui, W, Hong, W, Shuwen, Z. Clinical significance 
of the upregulated osteopontin mRNA expression in 
human colorectal cancer. J. Gastrointest. Surg. 14, 
74-81 (2010). 
32 FAM57A    
 
Family with sequence 
similarity 57, member A 
Pan, D., Wei, L., Yao, M., Wan, D., Gu, J. Down-
regulation of CT120A by RNA interference 
suppresses lung cancer cells growth and sensitizes to 





33 DSG2                   Desmoglein 2 Kurzen, H., Münzing, I., Hartschuh, W. Expression 
of desmosomal proteins in squamous cell carcinomas 
of the skin. J. Cutan. Pathol. 30, 621-630 (2003). 
34 ENO2           Enolase 2 (gamma, 
neuronal) 
Yeh, C.S. et al. Significance of the glycolytic 
pathway and glycolysis related-genes in 
tumorigenesis of human colorectal cancers. Oncol. 
Rep.19, 81-91 (2008). 
35 IGF2BP3       
 
Insulin-like growth factor 2  
mRNA binding protein 3 
Li, D. et al. IMP3 is a novel prognostic marker that 
correlates with colon cancer progression and 
pathogenesis. Ann. Surg. Oncol. 16, 3499-3506 
(2009). 




kinase kinase kinase 4 
Liang, J.J. et al. Expression of MAP4K4 is 
associated with worse prognosis in patients with 
stage II pancreatic ductal adenocarcinoma. Clin. 
Cancer Res. 14, 7043-7049 (2008). 
37 SQLE               Squalene epoxidase Helms, M.W. et al. Squalene epoxidase, located on 
chromosome 8q24.1, is upregulated in 8q+ breast 
cancer and indicates poor clinical outcome in stage I 
and II disease. Br. J. Cancer. 99, 774-780 (2008). 
38 ROBO1       
 
Roundabout, axon guidance  
receptor, homolog 1 
(Drosophila) 
Wang, B. et al. Induction of tumour angiogenesis by 
Slit-Robo signalling and inhibition of cancer growth 
by blocking Robo activity. Cancer Cell 4, 19-29 
(2003). 
39 ETV5                Ets variant gene 5 Chotteau-Lelièvre, A. et al. Prognostic value of 
ERM gene expression in human primary breast 
cancers. Clin. Cancer Res. 10, 7297-7303 (2004). 
40 S100A2   S100 calcium binding 
protein A2 
Ohuchida, K. et al. Over-expression of S100A2 in 
pancreatic cancer correlates with progression and 
poor prognosis. J. Pathol. 213, 275-282 (2007). 
41 CTGF       Connective tissue growth 
factor 
Pandey, D.P. et al. Estrogenic GPR30 signalling 
induces proliferation and migration of breast cancer 
cells through CTGF. EMBO J. 28, 523-532 (2009). 
42 SMYD2      
 
SET and MYND domain  
containing 2 
Komatsu, S. et al. Over expression of SMYD2 
relates to tumour cell proliferation and malignant 
outcome of oesophageal squamous cell carcinoma. 
Carcinogenesis 30, 1139-1146 (2009). 
43
 
RPS6KB1     
 
Ribosomal protein S6 
kinase, 70kDa, polypeptide 
1 
van der Hage, J.A. et al. Over expression of P70 S6 
kinase protein is associated with increased risk of 
locoregional recurrence in node-negative 
premenopausal early breast cancer patients. Br. J. 






We further investigated the origin of DTC and their relationship with the bone marrow derived 
stem cells using gene expression profiling. Evidence from a study by Staub et al (2009) reported 
that the site of origin of metastatic cancers from an unknown primary can be predicted by the 
gene expression signatures. They showed that gene expression patterns of normal tissues harbour 
phenotypic information that is retained in tumours and can be sufﬁcient to recover the type of 
primary tumour from expression patterns alone. This principle was applied in our study in an 
attempt to determine the origin of DTC.  
Microarray analysis was performed to assess the expression of normal liver genes by the cells 
cultured from patients with HCC and compared to the HepG2 cell line, human hepatocytes 
(donated by the hepatocyte transplantation research group) and purified CD34
+ve
 bone marrow 
cells. 
 
Quantitative RT-PCR and Microarray: Cultured cells from patients with HCC (n=3) and 
cirrhotic controls (n=1) were used for the experiment. Human hepatoma cell line (HepG-2), 
healthy human hepatocytes and purified CD34
+ve
 bone marrow cells were utilised as controls 
where appropriate. RT-PCR, qPCR and microarray experiments were performed according to the 
protocol described in section 2.9.5. 
 
4.3 Results: qPCR comparing the expression of the markers glypican 3, survivin and LYVE1 in 
circulating cells from patients with HCC; HepG2 cells; primary hepatocytes and circulating cells 
from patients with cirrhosis but no HCC produced results in accordance with previously 
published findings by Llovet et al (Llovet 2006). We observed a greater than 3 logarithmic 
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increase in the expression of glypican 3 and greater than 1 logarithmic increase in survivin 
expression in cells cultured from patients with HCC and in the HepG2 cell line, when compared 
to cells cultured from patients with cirrhosis, but not HCC and primary hepatocytes. In 
comparison with hepatocytes, a greater than 1 logarithmic reduction in expression of LYVE1 
was observed in cells derived from patients with HCC and the HepG2 cell line, which also 
confirmed the findings in the published literature.  The results are displayed in Figure 1. 
 
Figure 1: Selected 3 gene expression profile in cultured cells from patients with cirrhosis and 
HCC (n=3) compared with controls {cells from patients with cirrhosis and no HCC (n=1); 






Expression of TGFα and p53 examined by RT-PCR resulted in a consistently increased 
expression of these markers in cells cultured from patients with HCC (n=3) or the HepG2 cell 
line (n=1), when compared with primary hepatocytes (n=1) and cells derived from a patient with 
cirrhosis, but no HCC (n=1). Ethidium bromide stained PCR after gel electrophoresis are 
displayed in Figure 2 
 
Figure 2: Gel electrophoresis of PCR products p53 and TGFα expressed by cells cultured from 
patients with cirrhosis and HCC (n=3) compared with controls {cells from patient with cirrhosis 
but no HCC (n=1); human hepatocytes (n=1); HepG2 cells (n=1)} 
 
 
























4.3.1 Expression of cancer genes by DTC: Microarray analysis revealed an over-expression of 
18 genes that are known to be associated with poor prognosis in HCC (Table 2). The results also 
demonstrated the over-expression of 43 genes that have been associated with poor prognosis in 
other solid tumours (Table 3). Of these, 23 genes have not previously been described in gene 
expression signatures associated with HCC and 9 are associated with adverse prognostic 
outcomes in HCC as well as other solid tumours. This analysis further identified increased 
expression of 10 genes previously described as being characteristic of HCC (Table 1).  All p-
values for differential gene expression in this analysis exceeded 1x10-4. The results are presented 
in figures 3, 4, 5 and tables 4 and 5 respectively. 
 
Figure 3: Microarray analysis comparing gene expression in cultured cells from patients with 
cirrhosis and HCC (n=3) with bone marrow cells (n=4) and primary hepatocytes (n=3) identified 
overexpression of 18 genes known to be associated with poor survival in HCC 
 
 
*BM- bone marrow cells; 1y hepatocytes- primary human hepatocytes; HCC- cultured cells from 








Figure 4: Microarray analysis comparing gene expression in cultured cells from patients with 
cirrhosis and HCC (n=3) with bone marrow cells (n=4) and primary hepatocytes (n=3) identified 
overexpression of 43 genes associated with poor outcome in non-HCC solid tumours (23 genes 
of these are not previously described in HCC) 
Gene symbol Gene name                 P value 
S100P  S100 calcium binding protein P                                                                                                                                                                   
FBLN1  Fibulin 1  
CCL20  Chemokine (C-C motif) ligand 20  
LAMB1  Laminin, beta 1  
LGR5  Leucine-rich repeat containing G protein coupled receptor 5  
STC2  Stanniocalcin 2  
MUC15  Mucin 15, cell surface associated  
IGF2BP1 Insulin-like growth factor 2 mRNA binding protein 1  
ETV4  Ets variant 4  
KIAA1199 KIAA1199 
TYRO3  TYRO3 protein tyrosine kinase  
BMP4  Bone morphogenetic protein 4  
JAG1  Jagged 1  
EGLN3  EGL nine homolog 3  
ADORA2B Adenosine A2b receptor  
GALNT13 GalNAc-T13 
PGC  Progastricsin (pepsinogen C) 
FDPS  Farnesyl diphosphate synthase 
PAGE1  P antigen family, member 1  
S100A1  S100 calcium binding protein A1  
CA9  Carbonic Anhydrase IX  
ROCK2  Rho associated coiled coil containing protein kinase 2  
MKKS  McKusick-Kaufman syndrome  
FAM162A Family with sequence similarity 162, member A  
AHCY  Adenosylhomocysteinase  
DLK1  Delta-like homolog 1  
PTTG1IP Pituitary tumour-transforming 1 interacting protein  
S100A3  S100 calcium binding protein A3  
CKMT1A/1B Creatine kinase, mitochondrial 1A / 1B  
ABCG2  ATP binding cassette, sub family G member 2 
SPP1  Secreted phosphoprotein 1  
FAM57A Family with sequence similarity 57, member A  
DSG2  Desmoglein 2  
ENO2  Enolase 2  
IGF2BP3 Insulin-like growth factor 2 mRNA binding protein 3  
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4  
SQLE  Squalene Epoxidase  
ROBO1  Roundabout axon guidance receptor, homolog 1  
ETV5  Ets variant 5  
S100A2  S100 calcium binding protein A2  
CTGF  Connective tissue growth factor                                                                                               
SMYD2  SET and MYND domain containing 2                                                                1            2         3 
RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1  
 
 *1- bone marrow cells; 2- primary human hepatocytes; 3- cultured cells from patients with 
















































Figure 5: Gene expression analysis comparing cultured cells from patients with cirrhosis and 
HCC (n=3) with HepG2 cells (n=3), bone marrow cells (n=4) and primary hepatocytes (n=3) - 
The analysis identified expression of ten known diagnostic markers of HCC by the cells cultured 
from patients with cirrhosis and HCC. 
 
Gene symbol Gene name    P value  
KRT19  Keratin 19    58.2E-10  
TM4SF1 Transmembrane 4 L six, member 1  4.28E-11  
AFP  Alpha-fetoprotein    6.66E-12 
GPC3  Glypican 3     2.37E-11 
PEG10  Paternally Expressed 10    1.23E-10 
CPE  Carboxypeptidase E    8.74E-10 
DKK1  Dickkopf homolog 1    5.73E-10 
NEDD4L Neural precursor cell expressed 4-like  3.72E-09 
NEK3  NIMA-related kinase    3 1.67E-10                  1            2           3            4 
FDPS  Farnesyl diphosphate synthase   4.22E-04 
 
 
*1 –cultured cells from patients with cirrhosis and HCC; 2– HepG2 cell line; 3 - bone marrow 



























Table 4: Genes associated with poor prognosis in solid tumours but not previously been 
described in HCC. 
Gene symbol Gene name 
FBLN1 Fibulin 1  
LAMB1 Laminin, beta 1  
MUC15 Mucin 15, cell surface associated  
KIAA1199 KIAA1199 
TYRO3 TYRO3 protein tyrosine kinase   
EGLN3 EGL nine homolog 3  
GALNT13 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 (GalNAc-T13) 
PAGE1  P antigen family, member 1   
S100A1 S100 calcium binding protein A1  
CA9 Carbonic Anhydrase IX   
MKKS McKusick-Kaufman syndrome  
FAM162A Family with sequence similarity 162, member A  
AHCY Adenosylhomocysteinase  
PTTG1IP Pituitary tumour-transforming 1 interacting protein  
S100A3 S100 calcium binding protein A3  
CKMT1A / 
CKMT1B 
Creatine kinase, mitochondrial 1A / creatine kinase, 
mitochondrial 1B  
FAM57A Family with sequence similarity 57, member A  
DSG2 Desmoglein 2  
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4  
SQLE Squalene Epoxidase  
ETV5 Ets variant 5  
S100A2 S100 calcium binding protein A2  





Table 5: Genes previously described in other cancers that are known markers of adverse 













4.3.2 Source of DTC in patients with HCC: Microarray analysis of high gene expression in 
cells cultured from patients with HCC (n=3), the HCC cell line HepG2 (n=3) and primary human 
hepatocytes (n=3), compared with purified CD34
+ve
 bone marrow cells from patients with no 
liver disease (n=4), demonstrated an expression signature characteristic of hepatocellular lineage 
(Figure 6).   They expressed cardinal hepatocellular genes including alpha-2-macroglubulin, 
apolipoprotein A - C, albumin, transferrin, ceruloplasmin, fibrinogen and haptoglobin and all p-
values for differential gene expression exceeded 1x10
-9
(Table 6). These results suggest that the 
despite the phenotypic similarities with BM stem cell, the DTC in our patient group appear to be 




Gene symbol Gene name 
S100P S100 calcium binding protein P 
LGR5 Leucine-rich repeat containing G protein coupled receptor 5 
STC2 Stanniocalcin 2 
IGF2BP1 Insulin-like growth factor 2 mRNA binding protein 1 
ETV4 Ets variant 4 
JAG1 Jagged 1 
ADORA2B Adenosine A2b receptor 
PGC Progastricsin (pepsinogen C) 
ENO2 Enolase 2 – AKA neuron-specific enolase 
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Figure 6: Microarray analysis of gene expression in cells cultured from patients with cirrhosis 
and HCC (n=3), HepG2 (n=3) and primary human hepatocytes (n=3), compared with purified 
CD34+ve bone marrow cells (n=4), demonstrated an expression signature characteristic of 
hepatocellular lineage by the cells cultured from patients with cirrhosis and HCC 
 
Gene symbol Gene name 
AZGP1               Alpha-2-glycoprotein 1, zinc-binding 
F2                       Coagulation factor II (thrombin) 
FMO5                 Flavin containing monooxygenase 5 
FGB                     Fibrinogen beta chain 
SERPINC1          Serpin peptidase inhibitor, clade C (antithrombin), member 1 
HP                        Haptoglobin 
C6orf145              Chromosome 6 open reading frame 145 
C2 / CFB              Complement component 2 / Complement factor B 
C2 / CFB              Complement component 2 / Complement factor B 
SERPINA3  Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
SLC2A2  Solute carrier family 2 (facilitated glucose transporter), member 2 
ORM1  Orosomucoid 1 
FGG  Fibrinogen gamma chain 
CP  Ceruloplasmin (ferroxidase) 
FGA  Fibrinogen alpha chain 
RBP4  Retinol binding protein 4, plasma 
PPARGC1A  Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
CFI  Complement factor I 
TTR  Transthyretin 
ORM1 / ORM2  Orosomucoid 1 / Orosomucoid 2 
C4BPB  Complement component 4 binding protein, beta 
C3  Complement component 3 
CPB2  Carboxypeptidase B2 (plasma) 
F5 Coagulation factor V (proaccelerin, labile factor) 
APOC2 Apolipoprotein C-II 
CYP27A1 Cytochrome P450, family 27, subfamily A, polypeptide 1 
SULT2A1 Sulfotransferase family, cytosolic, 2A, DHEA-preferring, member 1 
SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
SAA4 Serum amyloid A4, constitutive 
A1CFAPOBEC1 Complementation factor 
PAH Phenylalanine hydroxylase 
FGL1 Fibrinogen-like 1 
ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide 
MYO1B Myosin IB 
SERPIND1 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 
MTTP Microsomal triglyceride transfer protein 
GPX3 Glutathione peroxidase 3 (plasma) 
ANG / RNASE4 Angiogenin, ribonuclease, RNase A family, 5 / Ribonuclease, RNase A family, 4 
GJB1 Gap junction protein, beta 1, 32kDa 
TCEA3 Transcription elongation factor A (SII), 3 
FABP1 / PRDM1 Fatty acid binding protein 1, liver / PR domain containing 10 
ADH6 Alcohol dehydrogenase 6 (class V) 
TF Transferrin 
SERPINA7 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 
APOA2  Apolipoprotein A-II 
   1         2       3      4 
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APOH Apolipoprotein H (beta-2-glycoprotein I) 
ALB Albumin 
AMBP Alpha-1-microglobulin/bikunin precursor 
EPB41L5 Erythrocyte membrane protein band 4.1 like 5 
SLC47A1 Solute carrier family 47, member 1 
APOA1 Apolipoprotein A-I 
UGT2B7UDP  Glucuronosyltransferase 2 family, polypeptide B7 
PVRL3 Poliovirus receptor-related 3 
APOB Apolipoprotein B (including Ag(x) antigen) 
A2M Alpha-2-macroglobulin 
FAM114A1 Family with sequence similarity 114, member A1 
HGD Homogentisate 1,2-dioxygenase (homogentisate oxidase) 
IGF2 / INS-IGF2 Insulin-like growth factor 2 (somatomedin A) / INS-IGF2 readthrough transcript 
KIF21A Kinesin family member 21A 
FN1 Fibronectin 1 
PARD3 Par-3 partitioning defective 3 homolog  
MLLT4 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog); translocated to, 4 
TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer factor) 
ENPP1 Ectonucleotide pyrophosphatase / phosphodiesterase 1 
AHSG Alpha-2-HS-glycoprotein 
DSP Desmoplakin 
SEP10 Septin 10 
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 
SDC2 Syndecan 2 
EMP2 Epithelial membrane protein 2 
SH3D19 SH3 domain containing 19 
PTPRK Protein tyrosine phosphatase, receptor type, K 
PPIC Peptidylprolyl isomerase C (cyclophilin C) 
SCML1 Sex comb on midleg-like 1  
PECR Peroxisomal trans-2-enoyl-CoA reductase 
RNF128 Ring finger protein 128 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein  
 
 
*1-bone marrow cells; 2- cells cultured from patients with cirrhosis and HCC; 3- human 










Table 5 : List of genes and P-values from a microarray analysis comparing gene expression in 
bone marrow (n=4) with circulating HCC cells (n=3); HepG2 cells (n=3) and primary 
hepatocytes (n=3).  
Gene 
symbol 
Gene name P-Value 
AZGP1 Alpha-2-glycoprotein 1, Zinc-binding 9.32E-12 
F2 Coagulation factor II (thrombin) 3.23E-12 
FMO5 Flavin containing monooxygenase 5 3.34E-09 
FGB Fibrinogen beta chain 7.19E-14 
SERPINC1 Serpin peptidase inhibitor, clade C (antithrombin), member 1 4.45E-11 
HP Haptoglobin 4.34E-12 
C6orf145 Chromosome 6 open reading frame 145 5.22E-10 
C2 / CFB Complement component 2 / Complement factor B 9.32E-10 
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
7.34E-12 
SLC2A2 Solute carrier family 2 (facilitated glucose transporter), 
member 2 
1.81E-09 
ORM1 Orosomucoid 1 6.70E-12 
FGG Fibrinogen gamma chain 2.92E-13 
CP Ceruloplasmin (ferroxidase) 1.03E-13 
FGA Fibrinogen alpha chain 1.30E-12 
RBP4 Retinol binding protein 4, plasma 7.76E-11 
PPARGC1A Peroxisome proliferator-activated receptor gamma, co 
activator 1 alpha 
8.88E-12 
CFI Complement factor I 6.45E-13 
TTR Transthyretin 5.83E-11 
ORM1/ 
ORM2 
Orosomucoid 1 / Orosomucoid 2 4.27E-11 
C4BPB Complement component 4 binding protein, beta 5.62E-10 
C3 Complement component 3 6.96E-12 
CPB2 Carboxypeptidase B2 (plasma) 1.07E-10 
F5 Coagulation factor V (proaccelerin, labile factor) 1.49E-09 
APOC2 Apolipoprotein C-II 5.71E-10 
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CYP27A1 Cytochrome P450, family 27, subfamily A, polypeptide 1 7.16E-10 
SULT2A1 Sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-preferring, member 1 
1.88E-10 
SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
1.80E-10 
SAA4 Serum amyloid A4, constitutive 1.56E-10 
A1CF APOBEC1 complementation factor 2.95E-10 
PAH Phenylalanine hydroxylase 4.31E-09 
FGL1 Fibrinogen-like 1 2.24E-11 
ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide 2.34E-10 
MYO1B Myosin IB 7.15E-10 
SERPIND1 Serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1 
4.46E-10 
MTTP Microsomal triglyceride transfer protein 1.13E-09 
GPX3 Glutathione peroxidase 3 (plasma) 4.24E-11 
ANG/ 
RNASE4 
Angiogenin, ribonuclease, RNase A family, 5 / Ribonuclease, 
RNase A family, 4 
3.16E-10 
GJB1 Gap junction protein, beta 1, 32kDa 3.40E-09 
TCEA3 Transcription elongation factor A (SII), 3 3.71E-09 
FABP1/ 
PRDM10 
Fatty acid binding protein 1, liver / PR domain containing 10 1.75E-13 
ADH6 Alcohol dehydrogenase 6 (class V) 2.26E-11 
TF Transferrin 1.04E-11 
SERPINA7 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 7 
4.93E-12 
APOA2 Apolipoprotein A-II 2.43E-10 
APOH Apolipoprotein H (beta-2-glycoprotein I) 1.60E-12 
ALB Albumin 4.28E-13 
AMBP Alpha-1-microglobulin / bikunin precursor 6.22E-10 
EPB41L5 Erythrocyte membrane protein band 4.1 like 5 9.23E-10 
SLC47A1 Solute carrier family 47, member 1 1.98E-09 
APOA1 Apolipoprotein A-I 1.45E-14 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 9.19E-10 
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PVRL3 Poliovirus receptor-related 3 9.81E-10 
APOB Apolipoprotein B (including Ag(x) antigen) 5.32E-13 
A2M Alpha-2-macroglobulin 1.78E-10 
FAM114A1 Family with sequence similarity 114, member A1 1.14E-10 
HGD Homogentisate 1,2-dioxygenase (homogentisate oxidase) 4.05E-12 
IGF2/INS-
IGF2 
Insulin-like growth factor 2 (somatomedin A) / INS-IGF2 
readthrough transcript 
1.66E-10 
KIF21A Kinesin family member 21A 3.75E-10 
FN1 Fibronectin 1 7.18E-11 
PARD3 Par-3 partitioning defective 3 homolog  3.60E-09 
MLLT4 Myeloid/lymphoid or mixed-lineage leukaemia; translocated 
to, 4 
2.65E-09 
TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer 
factor) 
3.05E-09 
ENPP1 Ectonucleotide pyrophosphatase / phosphodiesterase 1 3.60E-09 
AHSG Alpha-2-HS-glycoprotein 1.59E-09 
DSP Desmoplakin 2.42E-10 
SEP-10 Septin 10 9.51E-10 
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 6.51E-14 
SDC2 Syndecan 2 3.49E-09 
EMP2 Epithelial membrane protein 2 7.73E-10 
SH3D19 SH3 domain containing 19 2.55E-09 
PTPRK Protein tyrosine phosphatase, receptor type, K 1.01E-10 
PPIC Peptidylprolyl isomerase C (cyclophilin C) 3.51E-09 
SCML1 Sex comb on midleg-like 1 (Drosophila) 3.57E-10 
PECR Peroxisomal trans-2-enoyl-CoA reductase 2.03E-10 
RNF128 Ring finger protein 128 8.69E-10 








4.4 Discussion: Disseminated tumour cells have been identified in the blood and bone marrow of 
patients with breast, colorectal, oesophageal and prostate cancers. Their presence has been 
associated with tumour recurrence as well as poor long term survival. Several studies have 
suggested that DTC can be used as a surrogate marker of aggressive tumour biology, however, 
the true malignant nature of these cells has not been demonstrated. The isolation of DTC in 
peripheral blood samples of breast cancer patients 22 years after curative mastectomy highlights 
the need to study their biology and understand the molecular pathways associated DTC 
regulation.   
 
Understanding of the role of DTC in HCC is limited and their role in the development of tumour 
metastases is not clear. In the previous chapter we developed a protocol and successfully 
cultured DTC from patients with cirrhosis and HCC. The experiment also isolated similar cells 
from patients with liver cirrhosis and no HCC. Immunocytochemistry analysis showed that cells 
from both groups expressed morphological and functional markers similar to hepatocytes. This 
led to the work in this chapter using molecular assays to identify potential differences between 
the cultured cells from patients with cirrhosis and HCC and those with cirrhosis but no HCC.  
 
Accumulation of mutations and altered expression of various cell cycle regulatory genes result in 
carcinogenesis. A variety of tumour suppressor genes (P53, RB and IGF2R) and oncogenes (c-
myc, CCND1, CTNNB1, and c-Met) along with activation of the matrix metalloproteinase 
(MMP) family, angiopoietin, and vascular endothelial growth factor (VEGF) and inactivation of 
E-cadherin  have  been demonstrated to play pivotal roles in the development and progression of 
HCC. A comprehensive expression analysis of this complex process using microarray 
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technology has great potential for the discovery of new genes involved in carcinogenesis, cDNA 
microarray analysis for HCC was first reported by Lau et al (2000). Since this publication 
numerous microarray studies have been carried out in an effort to elucidate molecular 
mechanisms of hepatocarcinogenesis, metastasis and/or prognosis, however, reliable clinical 
markers for HCC have yet to be defined.  
 
Studies that focussed on identifying diagnostic biomarkers for HCC have produced varying 
results. Chuma et al(2003) suggested heat shock protein 70 (HSP70), Capurro and Nakatsura et 
al (2003) supported glypican-3 (GPC3) and telomerase reverse transcriptase (TERT) while 
Miura and Smith et al (2003) concluded serine/threonine kinase (STK6), and phospholipase A2 
(PLAG12B) were reliable markers of hepatocarcinogenesis. A molecular index using a 13-gene 
set (including TERT, TOP2A, and PDGFRA) (Paradis 2003) followed by a more recent 
microarray generated a signature of 120 genes which has been used to discriminate dysplastic 
nodules from HCC in hepatitis B patients with chronic liver disease (Nam 2005). Unfortunately 
none of these studies have produced markers that are sufficiently acceptable for a molecular 
diagnosis of HCC (Bruix 2005). 
 
Llovet et al (2006) in their study assessed the transcriptional proﬁles of 55 candidate genes in 
dysplastic nodules and HCC and identified a 3 gene signature (GPC3, LYVE1 and Survivin) that 
has a 94% accuracy in the diagnosis of HCC. The results from our qPCR experiment using this 
3-gene signature and the RT-PCR using TGFα and p53 demonstrated that only cultured cells 
from patients with cirrhosis and HCC have malignant characteristics comparable with human 
hepatoma cell line HepG2. The cultured cells from patients with HCC were further analysed for 
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the expression of neoplastic genes using microarray assays. Small number of cells from patients 
with cirrhosis but no HCC limited their inclusion in the analysis and use as controls. 
 
Weinberg et al proposed six characteristics of cancer that enable tumour growth and metastasis, 
that include: 1) sustaining proliferative signalling 2) evading growth supressors 3) activating 
invasion and metastasis 4) enabling replicative immortality 5) inducing angiogenesis and 6) 
resisting cell death. More than 300 studies have been published identifying dysregulated genes in 
HCC. The studies targeted one or more sub-groups of the carcinogenesis pathway described by 
Weinberg et al (2011). Although these studies identified a wide spectrum of adverse genes the 
results were, however, inconsistent. For the purpose of our study we have highlighted those 
genes with the best supporting evidence that have a role in the development and progression of 
HCC.  
Proliferation cluster genes are required for cell cycle progression. Studies investigating this 
group of genes in HCC identified that their enhanced expression is associated with aggressive 
tumours (vascular invasion) and poor prognosis (Chen 2002, Thorgeirsson 2004, Segal 2004, Yu 
2005). The common genes highlighted in these studies include CCNA2, CCNB2, CDC2, CKS2, 
E2F3, FOXMI, IGF2BP3, PCNA, PLK1, TOP2A.  
 
The second group of genes explored were the hepatic progenitor specific and EpCAM-positive 
gene signatures. Recent studies suggest that EpCAM positive cells are tumour initiating or 
cancer stem cells. Yamashida et al showed that EpCAM-positive cells isolated from human 
HCCs self-renewed, differentiated in vitro and formed large tumours in NOD/SCID mice 
(Yamashida 2009). The EpCAM positive gene signature is comprised of 70 genes and exhibits 
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increased expression of marker genes characterizing hepatic progenitors. These include 
cytokeratin 19 (CK19), C-kit and Wnt signalling-induced genes DKK1 and BAMBI. The 
common genes identified in the published literature are; CK19, CK8, CK18, EpCAM, CD133, 
AFP, MYC, DLK1, DKK1. (Lee 2006, Yamashita 2008). EpCAM expression is linked to poor 
prognosis in HCC. A recent review of gene signatures in HCC by Andrisani et al (2011) 
concluded that the proliferation cluster and hepatic cancer stem cell gene signatures are the only 
groups that have potential prognostic value in the clinical management of HCC.  The results of 
our analysis demonstrated over expression of such genes in cells cultured from patients with 
HCC. They also over expressed other genes involved in HCC progression and metastasis 
described in the literature. We also noted that our in vitro cultured cells from patients with HCC 
demonstrated abnormal expression of 43 genes that correlate with poor outcome in non-HCC 
solid tumours, and of note 23 of these genes that have not been described previously in HCC.  
 
Molecular analysis was performed to further characterise cells cultured from patients with HCC 
and those with cirrhosis, but without HCC. The results demonstrated that although the cells 
cultured from these two groups share some morphological and functional similarities they are 
inherently different. The 3 gene signature showed that only cells disseminated into the peripheral 
blood of patients with HCC expressed markers of HCC. These cells may represent primary 
tumour cells and therefore could be used to understand tumour biology and also develop new 
treatment strategies. Unfortunately due to poor in vitro expansion of cultured cells from patients 




The results from microarray analysis not only supported the neoplastic nature of DTC, but also 
provided further biological information about these cells. Sustaining proliferative signalling is 
the most important trait of cancer cells and this process is mediated by growth factors that 
regulate the cell cycle. Cell migration and invasion of tumour cells is further facilitated by a 
group of genes which are collectively known as EPCAM genes. The DTC in our experiment 
expressed both potentially important hallmarks of cancer and genes indicating biological 
aggressiveness. Several cancer pathways including the Wnt cell cycle pathway and genes 
involved in the epigenetic regulation with frequent genetic alterations have emerged as 
oncogenic drivers in HCC. Further understanding of the specific pathways associated with DTC 
will help understand the pathogenesis of HCC recurrence and may pave the way for the 
development of targeted treatments. 
 
4.4.1 Origin of DTC: There is conflicting evidence regarding the role of bone marrow derived 
stem cells in liver regeneration and hepatocarcinogenesis. The DTC in our experiment expressed 
markers similar to BM stem cells suggesting the possibility that these represented circulating BM 
derived stem cells. To investigate this we utilised the principle described by Staub et al. They 
demonstrated that tumours retain a significant part of their normal phenotype that is 
characteristic of their tissue origin and microarray-based tissue-type classifiers trained solely on 
normal tissues can predict their origin. The microarray analysis of cells cultured from HCC 
demonstrated the expression of genes that are characteristic of hepatocellular lineage, thereby 





4.5 Conclusion: From the results of this chapter we conclude that the cells cultured from patients 
with cirrhosis and HCC express a malignant phenotype. The circulating cells are hepatocellular 
in origin and may represent an aggressive HCC. 
 






















CHAPTER 5:  AIMAL MODEL TO STUDY THE I	 VIVO  




5.1 Introduction:  DTC have been detected in blood and bone marrow samples of patients with 
HCC using immunocytochemistry and molecular assays. The presence of DTC has been 
associated with tumour recurrence and poor prognosis (Kamiyama 2006, Marubashi 2007). 
However, variations in methodology and lack of knowledge about the true functional and 
biological behaviour of micrometastatic cells have prevented the transfer of these investigations 
into clinical practice. Studies focusing on the pattern of tumour recurrence in patients with 
detectable DTC have produced variable results and some including our previous study 
questioned the malignant potential of DTC (Sutcliffe 2005, Pantel 2009).  Our previous in vitro 
experiment demonstrated that DTC can be isolated from a small sub-group of patients with HCC 
and that these cells express a malignant phenotype. Although these results generated some useful 
information about the nature of DTC, translating these findings into clinical practice demands a 
suitable small animal model to study their in vivo biological behaviour. To date the in vivo 
malignant potential of the DTC in HCC has not been effectively demonstrated. The aim of this 
chapter was to develop an effective animal model and to study the in vivo behaviour of the 
cultured cells from both patients with and without HCC. 
5.2 Materials and methods:  
Development of a mouse model: Successful transplantation of human hepatocytes into an 
animal model requires it not to reject the graft and to provide a “supportive niche” that promotes 
expansion and engraftment of the transplanted cells (Meuleman 2005, Weber 2009). Recipient 
mice that have an inborn (genetic) or acquired (drug induced) immune deficiency have been 




For the purpose of our study the severe combined immunodeficiency (SCID) mouse was selected 
as our animal model. SCID is due to a rare recessive mutation on Chromosome 16 that results in 
failure of the development of cellular and humoral immune systems. SCID mice, therefore, have 
both T and B lymphocyte deficiency making them excellent recipients for cell transplantation. 
The SCID mouse model has been useful to study the potential use of hepatocyte cell 
transplantation as alternative to liver transplantation (Fisher 2006). Despite early success, 
improving and stabilizing engraftment and repopulation of transplanted human hepatocytes 
remains a signiﬁcant obstacle.  The success of hepatocyte repopulation in the host tissue is 
strongly dependent on the volume of cells used and the mode of infusion.  
 
The liver is an optimal site for transplantation of hepatocytes due to the presence of a 
physiological matrix that aids repopulation. The potential drawback with this mode of infusion is 
the difficulty in localizing the transplanted cells. Studies have shown that in the rodent hepatic 
remodeling takes place in 3-7 days making the engrafted cells histologically indistinguishable 
from the host cells (Allen, 2001). Extra hepatic sites such renal capsular space, peritoneal cavity, 
spleen and foot pad have been used as sites of infusion. Although they cannot offer a hepatic 
micro-environment, their use has the potential advantage of better localization of transplanted 
cells on a non-hepatic background.  
 
Studies with human hepatoma cell lines have used large number of cells (ranging from 1-5 
million) in both hepatic and extra-hepatic locations (Scatton 2006, 2007, Mischek 2009). The 
minimum cell number for the initiation of neoplastic transformation in the host organs has not 
been defined. The median cell mass obtained in a selected group of patients with cirrhosis and 
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To study the in vivo behaviour of cells when introduced in small number and to localize them in 
the host tissue accurately, we initially used human hepatoma cell line (HepG2). To facilitate 
localization, HepG2 cells were injected into the renal sub-capsule of SCID mice. 
 
5.2.1 Section 1: Development of a transplant model:  
Six week old male SCID mice were purchased from Charles River UK and handled in 
accordance with Home Office UK guidelines. The experiment was performed using the relevant 
protocols described in chapter 2. Briefly, frozen human hepatoma cells were thawed and cultured 






 Hep G2 cells 
were prepared for injection. Nine mice were anaesthetized and the described cell volumes were 
injected into the renal sub-capsular space of the left kidney. 
 
The mice from each group were sacrificed at 2, 4 and 6 weeks and the kidney specimens were 
collected for analysis. 10µm cryosections were prepared and the slides were analysed using H&E 
staining and immunohistochemistry. Cam 5.2 (CK8 and 18), MHC class-1 and Ki67 antibodies 
were used to localize the transplanted cells, initial test with these antibodies confirmed no cross-
reactivity with mouse tissue. The results are shown in Figures 1, 2, 3 and 4. 
 
Laser capture microdissection was attempted in selected samples. To facilitate the use of laser 
capture microdissection, cryosections were mounted on a special membrane slides and air dried 
overnight. The dissected tissue sections are shown in Figure 5. 
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 Results:   








 Figure 2a- Injected HepG2 cells 
against cytokeratin 8 and 18 (Cam 5.2) 
background negative staining of mouse kidney tissue
 
Figure 2b- Positive control –Human
 
 
localised using immunofluorescence staining with antibody 
- The HepG2 cells stained positive (thick arrow) on a 
 (thin arrow). 
 
 liver stained positive with Cam5.2. 
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 Figure 3a- Injected HepG2 cells localised using antibody against human MHC class
HepG2 cells stained positive (thick arrow) on a background ne
tissue (thin arrow). 
 
Figure 3b- Positive control- MHC class
 
 
gative staining of mouse kidney 
 
-1staining of human liver tissue 
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 Figure 4- Cryosections stained with cell proliferative marker Ki 67


















 A positive staining 
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Figure 5a: Use of laser microdissection- The tissue sections were mounted on a special 





























The results of the tissue analysis according to the cell volume and period of incubation are 
presented in a tabular format. 
 








Microscopy (H&E and Immunohistochemistry) 
H&E Cam 5.2 MHC class-1 Ki 67 
   10
4 
cells Normal Equivocal Positive Positive Negative 
10
5 
cells Normal Detectable HepG2 cells Positive Positive Equivocal 
10
6 
cells Normal Detectable HepG2 cells Positive Positive Equivocal 
 
 







Microscopy (H&E and Immunohistochemistry) 
H&E Cam 5.2 MHC class-1 Ki 67 
  10
4 
cells Normal Equivocal Positive Positive Negative 
10
5 
cells Normal Detectable HepG2 cells  Positive Positive Positive 
10
6 
















Microscopy (H&E and Immunohistochemistry) 
H&E Cam 5.2 MHC class-1 Ki 67 
   10
4 
cells Normal Equivocal Positive Positive Negative 
10
5 
cells Normal Detectable HepG2 cells Positive Positive Positive 




Discussion: Several studies were undertaken to identify an ideal mouse organ for hepatocyte 
transplantation. As the liver represents an ideal “home” for transplanted hepatocytes, the 
majority of the reported studies used either direct hepatic injection or splenic and portal venous 
routes for cell transplantation. The limitation with this mode of transplantation was the difficulty 
in localising the injected hepatocytes in the host liver background. This consequently led to 
exploration of ectopic sites such as kidney capsule, subcutaneous space and interscapular fat 
pads for hepatocyte transplantation. The results demonstrated that these sites can support short-
term hepatocyte survival despite the apparent lack of hepatotrophic factors. 
 
The second issue with cell transplantation was poor engraftment, the maximum percentage of 
engraftment that can be achieved is of the order of 2-5% even when large cell numbers are 
injected (>10
6 
cells). The results from studies using the liver for cell transplantation showed that 
more than 90% of transplanted hepatocytes are not detectable in the host liver following infusion 
(Allen 2001). There is also evidence to suggest that natural killer cell mediated lysis plays an 
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important role in eliminating allogenic cells in SCID mice even in the absence of T and B 
lymphocytes (Olszewski 1999, Kawahara 2010).  
 
The results from our experiment show that although micro and macroscopic neoplastic changes 
were detectable only from injected cell numbers >10
5
, HepG2 cells from smaller cell number 
injections (10
4 
cells) persisted in the host tissue after 2 and 4 weeks. The persistence of HepG2 
cells even from very small cell mass injections suggest that malignant hepatic cells have 
mechanisms to survive in ectopic tissue and to escape cell lysis by the host natural killer cells. 
The latter is an important property for tumour propagation. The successful localisation of small 
cell number injections led to the final experiment of injecting cultured cells into an animal model 
to study their in vivo behaviour. 
 
5.2.2 Section 2: SCID mouse model to study the In vivo properties of cultured cells. 
Materials and methods:  
In vitro cultures from patients with cirrhosis and HCC (n=6) 
In vitro cultures from patients with cirrhosis and without HCC (n=3) 
Primary healthy human hepatocytes (n=6) 
 
Cell sample preparation: The experimental cells were thawed, purified and prepared for 
transplantation following the protocol described in Chapter 2. 
 
Fifteen mice were randomly allocated into cell transplant experimental and control groups. In 
vitro cultures from patients with HCC (n=6), cirrhosis, but no HCC (n=3) and normal human 
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hepatocytes were used with the latter two as controls. The cultured cells from patients with 
cirrhosis and HCC were injected into the renal sub-capsule (n=3) and directly into the left lobe of 
the liver (n=3). 2x10
4
 cells from each group were injected into the liver or kidney of SCID mice 
using the protocols described in Chapter 2. Cells cultured from patients with cirrhosis, but no 
HCC were limited in number and therefore were used only in the renal sub-capsular space. 
 
Briefly, under anaesthesia, the abdominal cavity was accessed by a laparotomy and the organ of 
choice (liver or kidney) was exposed. The prepared cell number was injected directly into the left 
lobe of the liver or lower pole of the left kidney using a Hamilton syringe. Three aliquots of 
cultured cells from patients with cirrhosis and HCC were injected into the mouse liver using 
human primary hepatocytes as controls (n=4). For the kidney injections a total of eight SCID 
mice were used as follows; 3 with cells cultured from patients with cirrhosis and HCC, 3 with 
cells cultured from patients with liver cirrhosis and without HCC and 2 with normal primary 
human hepatocytes.  
 
Retrieving transplanted organs: The mice were sacrificed by dislocating the cervical vertebrae. 
SCID mice in which the liver was used as the site of injection were sacrificed after 4 weeks.  The 
liver was retrieved and the cell transplant lobe was excised from the whole organ. The mice with 
renal sub-capsular injections were sacrificed after 2 weeks, both kidneys were retrieved in total 
but the left kidney was then divided transversely to obtain separate upper and lower poles. The 
individual portions of tissue were transported to the laboratory in ice cold UW solution and 




The samples were either processed and embedded in paraffin wax or frozen tissue was directly 
sliced into 10 µm cryosections for further analysis. The host tissue sections were analysed for the 
presence of any neoplastic changes as well as persistence of injected cultured cells. 
Immunohistochemistry, H&E and genomic human DNA analysis were used as tools for the 
analysis. Antibodies specific to human cytokeratin (CK8&18 pre-diluted by the manufacturer), 
MHC class-1(1:250 dilution) and CD34 (1:250 dilution) were selected for 
immunohistochemistry. The primary antibodies were diluted in 1% PBS and the optimal 
concentration was determined by serial dilution.  
 
The paraffin or frozen tissue samples were processed using the protocols described in Chapter 2 




There were no noticeable gross macroscopic changes in the transplanted kidney or liver 
specimens following retrieval.  
 
Microscopic appearance: 
Analysis of liver sections: The H&E staining of liver sections obtained from mice that were 
injected with cells from patients with cirrhosis and HCC showed focal dysplastic changes and/or 
features of neoplasia with anisocytosis (cells of unequal size), poikilocytosis (abnormally shaped 
cells), hyperchromatism and lobular disarray The liver sections from relevant controls (primary 
human hepatocytes) demonstrated a normal liver architecture on H&E staining.  
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Figure 6a- H&E staining of SCID mouse liver injected with cells cultured from patients with 





Figure 6b: H&E staining of SCID mouse liver injected with primary human hepatocytes- Normal 




 The immunohistochemistry analysis was limited only to CD34 antibody due to cross reaction 
between the mouse background liver and human specific antibodies (MHC class
CK8&18). The CD34 antibody ana
the H&E sections were of human origin.
 
Figure 7a- Immunohistochemistry using antibody against CD34










lysis confirmed that the neoplastic cells that were evident on 
 







Figure 7b) Immunohistochemistry using CD34 antibody on a section of SCID mouse liver 
injected with cells cultured from patient with cirrhosis and HCC- Cluster of CD34 positive cells 




Figure 7c) Immunohistochemistry using CD34 antibody on a section of SCID mouse liver 
injected with primary human hepatocytes- No positive staining was noted 
 
 
 Molecular analysis of the tissue blocks with dyspl
source of these changes as human cells
The results of human genomic DNA analysis are show
 
Figure 8- Human genomic DNA analysis:
 
M:   1 Kb marker from NEB 
1: Positive control - Human liver tissue
2, 3, and 4: Mouse liver tissue injected
 
astic changes on H&E sections 
 (cultured cells from patients with cirrhosis and HCC). 
n in the figure 8. 
 
 




 cirrhosis and HCC  
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Analysis of Kidney sections: Injected cultured cells were only detectable from the kidney 
sections of mice that received cultured cells from patients with cirrhosis and HCC. These cells 
demonstrated hepatocyte morphology on H&E staining and expressed cytokeratin 8 and 18 and 
human MHC class 1 phenotype, but did not express markers of cell proliferation 
(immunocytochemistry using Ki67 was negative).  Following 2 weeks of in vivo culture in the 
renal sub-capsular space no culture cells were detectable in mice that received cells from patients 
with cirrhosis, but no HCC or primary human hepatocytes. The results are shown in figures 9, 10 
and 11. 
 
Figure 9- H&E cryosection of kidney injected with cells from patients with cirrhosis and HCC – 









Figure 10a: Immunohistochemistry using antibody against cytokeratin 8 and 18 (Cam 5.2) - 




Figure 10b: Immunohistochemistry using Cam 5.2 antibody on a kidney section injected with 
cells cultured from patient with cirrhosis and HCC- Positively stained cultured cells on a 





Figure 11a: Immunohistochemistry using antibody against human MHC class-1 antigen - 




Figure 11b: Immunohistochemistry using MHC class-1 antibody on a kidney section injected 
with cells cultured from patient with cirrhosis and HCC- Positively stained cultured cells on a 





5.3 Discussion: The in vivo biological behaviour of DTC is poorly understood and there are no 
studies to-date that address this. Experiments describing the methods of detecting DTC only help 
to identify a sub-group of patients with potentially more aggressive tumour biology. To develop 
novel cell targeted therapies it is essential to understand the cell pathways associated with 
survival and propagation of malignant cells. We made an initial attempt to study the in vivo 
behaviour of DTC in HCC and to investigate the potential differences between the cells isolated 
from patients with cirrhosis and with or without HCC using a murine immunodeficient adoptive 
transfer model.  
 
The major limitation to the study was the number of cells cultured. To try to overcome this we 
incorporated the potential advantages of easy localisation of injection of cells into a heterotopic 
cell transplantation model using a renal sub-capsular site and also provided an optimal 
physiological matrix using an orthotopic cell transplant model (direct liver injection) in the other. 
The results of this experiment indicate that the in vivo behaviour of the cultured cells from 
patients with cirrhosis and HCC is different those cultured from patients with cirrhosis and 
without HCC. Only cultured cells from patients with cirrhosis and HCC were viable following 2 
weeks of incubation in the kidney sub-capsular space. These cells were resistant and appeared to 
have survived despite the small volume injections in a heterotopic environment. Additionally, 
they may possess pathways that facilitate their escape from the cell mediated lysis induced by 
natural killer cells of the SCID mouse. Of note, these cells did not express markers of cell 
proliferation suggesting that they were dormant. Persistence, dormancy and escaping immune 
lysis are those properties of malignant cells that will result in propagation and recurrence of the 
tumour despite potentially curative treatments. 
171 
 
The cultured cells from HCC patients also demonstrated features of neoplasia when introduced 
into a hepatic micro-environment. These changes were confined only to this sub-group of liver 
injections. A further analysis confirmed the human origin of these neoplastic cells excluding the 
possibility of cell fusion or of nonspecific changes that could have resulted from cell injections. 
Although we were not able to demonstrate a macroscopic neoplastic transformation due to the 
limited cell number, the experiment provided preliminary data regarding the in vivo malignant 
behaviour of DTC from HCC. 
 
5.4 Conclusion: Results from this chapter suggest that the cells isolated from patients with 
cirrhosis and HCC express features suggestive of a malignant phenotype in vivo and thereby 
differ from those morphologically identical cells isolated from patients with liver cirrhosis and 























CHAPTER 6: CLIICAL SIGIFICACE OF 













6.1 Introduction: Hepatocellular carcinoma recurrence is an important cause of death after liver 
transplantation or liver resection. A pre-operative risk stratification would allow more 
appropriate allocation of limited cadaveric grafts to lower risk cases, or to identify patients who 
may benefit from adjuvant therapies. Several tumour related factors have been identified to 
stratify the risk of recurrence, but these tumour characteristics are not available at pre-operative 
staging at present. However, this may change as our understanding of tumour behavior increases.  
 
Few studies have focused on identifying surrogate markers of aggressive tumours in blood and 
bone marrow samples and their methodology has lacked specificity (Sutcliffe 2005). In the 
previous chapters we demonstrated that hepatocyte-like cells can be isolated from the blood 
samples of patients with cirrhosis and HCC and that these disseminated cells expressed 
malignant features both in vivo and in vitro. 
 
 The aim of this chapter was:  
1) To evaluate the clinical significance of these disseminated cells detected in patients with 
cirrhosis and hepatocellular carcinoma  
2) To identify any relevant patient or tumour related factors that could result in their 








6.2 Patients and methods: Participants recruited from clinics and wards following a written 
consent were allocated into three groups: patients with a clinical diagnosis of cirrhosis and HCC, 
patients with well compensated cirrhosis and without HCC and normal healthy volunteers. 
 
Venous blood was collected and processed according to the protocol described in chapter 2. The 
presence of DTC in patients with cirrhosis and HCC was confirmed by immunocytochemistry 
analysis (CK 8&18, Hep Par-1, PCEA, ATP 7b, human albumin, Glycogen, CD133, CD34 and 
CD90) of the isolated in vitro cell colonies. 
 
To facilitate statistical analysis, patients with cirrhosis and HCC were further divided into 3 sub-
groups: Group A: robust cell growth (n=6); Group B: unsustained cell growth (n=15); and Group 
C: no cell growth (n=23), Group B was either amalgamated with Group A or completely 
excluded.   
 
Data was analysed using SPSS version 17. Descriptive statistics were presented as percentages or 
median values. The occurrence of DTC was correlated with clinical, radiological and histological 
parameters. Nonparametric Mann–Whitney U test and χ2 test were used to analyse the 
differences between the study groups. The survival data was analysed by log rank test and results 
were plotted using Kaplan Meier survival curves. A p-value of <0.05 was considered significant 








One hundred and fourteen venous blood samples were obtained from 44 patients with cirrhosis 
and HCC, 50 patients with cirrhosis and without HCC and 20 healthy volunteers. The relevant 
clinical parameters of the recruited patients are shown in table below. 
 
Clinical data of patients with Hepatocellular carcinoma (n=44): 
19 patients received potentially curative treatments in the form of liver resection or orthotopic 
liver transplantation. The median tumour size on radiological staging was 3.3cm (Range 1.2-
9cm) and nine patients had multifocal disease. Twenty nine patients (59%) received trans-arterial 
chemoembolization (TACE) or radio-frequency ablation (RFA), and of these nine (18%) were 
palliative therapies. Twenty one (42%) had normal serum alpha-feto protein (AFP). 
 
 Patients with cirrhosis and 
HCC 
 (n=44) 
Patients with liver 




Age (years) Median 61 (Range 26-82 
years) 




Sex(M:F) 36:8 35:15 6:14 
Hepatitis B 7 3  
Hepatitis C 13 7  
Alcohol 20 22  
MELD 10 (Range 6-20) 14 (Range 7-34)  
Child-Pugh 6 (Range 5-10) 8 (Range 5-13)  
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Analysis of variables between sub-groups of patients with HCC: This analysis revealed no 
significant risk factors that could result in the dissemination of tumour cells into the blood 
stream. The results were shown in the following tables. 
Table 1: Comparative analysis: Group A (Robust cell growth-n=6) +Group B (unsustained cell 
growth-n=15) vs. Group C (no cell growth-n=23) 
Parameter P value 
Sex  0.8965 
Hepatitis viral infection 0.5156 
Tumour size > 5cm (radiology) 0.0719 
Number of nodules > 3(radiology) 0.5696 
Liver biopsy (prior to blood sampling) 0.1133 
 
TACE (prior to blood sampling) 0.6103 
RFA (prior to blood sampling) 0.4105 
Micro vascular invasion 0.6210 






Table 2: Comparative analysis: Group A (n=6) vs. Group C (n=23) 
Parameter P value 
Sex (Female) 0.79 
Hepatitis viral infection 0.61 
Tumour size > 5cm 0.09 
Number of nodules > 3(radiology) 0.62 
Liver biopsy (prior to blood sampling) 0.18 
TACE (prior to blood sampling) 0.74 
RFA (prior to blood sampling) 0.48 
 
Micro vascular invasion 0.82 
Degree of tumour differentiation 0.55 
 
Survival data: The clinical follow-up for the 3 sub-groups was last updated in December 2012. 
The analysis was limited by sample size, the median survivals for Group A, B and C were 13 
months (Range 5-34 months), 34 months (Range 2-66 months) and 49 months (Range - 1-79 
months) respectively. Kaplan-Meier survival curves showed a trend towards reduced survival in 
those with DTC, however, this was not statistically significant (P=0.09). The different sub-group 
analysis is shown in figures 1&2  
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Clinical outcome of patients with cirrhosis: Cell colonies isolated from 3 patients with liver 
cirrhosis expressed features similar to human hepatocytes, however, immunocytochemical and 
molecular analysis of these cells showed that they did not have a malignant phenotype. At the 
end of our clinical follow-up none of these patients developed clinical or radiological evidence of 
HCC. A trend towards high MELD score was noted in these 3 patients with cirrhosis, but no 
HCC in whom hepatocyte-like cells were isolated. The scores were 17, 26 and 34 respectively. 
 
6.3 Discussion: 
HCC is the sixth most common malignancy worldwide, and the third most common cause of 
cancer related deaths. At present, curative treatments are offered only to a selected group of 
patients based on radiological evaluation of tumour bulk and preserved liver function. The 
reported tumour recurrence rate of up to 25% despite the application of strict tumour criteria 
highlights the need to improve upon the current staging system.  
 
Current radiologic techniques understage a significant proportion of cases and fail to detect 
microscopic extrahepatic disease (Mazzaferro 2008). HCC is an aggressive malignancy, studies 
focussing on the evaluation of microscopic disseminated disease (DTC) and understanding their 
tumour biology may provide information about risk and patterns of recurrence and aid in 
development of targeted molecular treatments.  
 
There is growing evidence supporting the use of biological tumour parameters in combination 
with tumour morphology to improve staging and also develop new treatment modalities. 
Disseminated tumour cells represent the primary tumour and analysis of these cells can provide 
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in-depth biological and molecular information of the primary cancer. The inclusion of DTC 
status detected in the blood or bone marrow samples in the staging, risk stratification and 
therapeutic monitoring of breast cancer patients has been investigated by Pantel et al (Pantel 
2009). The 6th edition of the American Joint Committee on Cancer Staging Manual has amended 
the breast cancer staging by including isolated tumour cells. Microscopic tumour deposits (≤ 0.2 
mm) detected by immunocytochemical or molecular techniques are identified as pN0 (i+) where 
i+ indicates micrometastatic disease.  
 
In a pooled analysis evaluating 4,703 patients with breast cancer, Braun et al. have reported a 
significantly decreased overall survival in patients with detectable DTC. The presence of DTC 
was significantly associated with higher tumour stage and was an independent predictor of poor 
outcome in breast cancer (Braun 2005).  
 
The significance of DTC in HCC and their role in tumour recurrence is still under active 
investigation. Studies that were designed to detect DTC in blood or bone marrow samples failed 
to evaluate their molecular and biological properties due to the very limited cell numbers 
(Sutcliffe 2005; Kienle, 2000; Wong, 1997). The frequency of DTC is 1-2 cells per 1 million 
bone marrow mononuclear cells and to understand their properties it is essential to increase the 
cell number by developing a suitable in vitro culture protocol.  
 
This study represents the first attempt to develop an in vitro protocol to culture and characterize 
DTC in HCC and further study the in vivo behavior using an animal model. The results from 
chapter 3 show that DTC can be cultured using a hepatocyte favouring cell medium and these 
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cells are similar to human hepatocytes in morphology and function. Additionally they express a 
stem cell phenotype and aggressive cancer genes which are associated with poor outcomes. The 
in vivo experiment indicated that DTC have an ability to survive by escaping the host cell 
mediated immune response and induce microscopic features of neoplasia. The clinical data also 
showed that patients with detectable microscopic disease have a trend towards reduced survival. 
 
Our data indicates that a sub-group of patients with aggressive tumour biology have DTC that 
can be isolated from a simple venous blood sample (20ml). DTC occurrence is not always 
associated with tumour morphology and therefore routine radiological staging cannot accurately 
predict their presence. The detection of DTC could potentially identify patients at risk of 
recurrence and provide a rationale for adjuvant treatments following potentially curative surgical 
resections. 
  
There is no strong evidence to support survival benefit with the use of adjuvant chemotherapy in 
HCC (Samuel 2009). HCC tumours generally respond poorly to systemic chemotherapy agents, 
and drug resistance has been attributed to presence of effective molecular pathways which repair 
DNA damage induced by chemotherapy agents (Burroughs 2004). Cancer stem cells have also 
been implicated in HCC chemo-resistance due to their inherent capacity for self-renewal (Fan ST 
2009). Evidence from our study shows that DTC are slow growing and have features of cancer 
stem cells, these properties may confer chemo-resistance.  
 
To improve survival there is a need to develop effective adjuvant treatment modalities that can 
tackle microscopic disease. Studies to further understand the molecular and immunocytological 
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properties of DTC may help in the development of specific targeted therapies in future. 
Monitoring of DTC in blood samples could also be used as a tool to measure the effectiveness of 
systemic adjuvant therapies and potentially test resistance to therapeutic agents in vitro. 
 
Our study also showed that circulating hepatocyte-like cells are present in patients with end stage 
liver disease. The observation that these cells isolated from a small number of patients with high 
MELD score indicates that severity of liver injury may have an influence on their occurrence. 
The role of these hepatocyte-like cells in restoring liver mass and their possible contribution to 




The results from this chapter suggest that presence of DTC is associated with aggressive tumour 
phenotype and reduced median survival. Incorporation of tools to assess micrometastatic disease 
burden into the current staging may improve patient selection for potentially curative surgical 
treatments and also identify a subgroup of patients who may benefit from adjuvant treatment. 
However, firm conclusions cannot be made due to limited sample size. Larger studies are needed 
to confirm our findings and expand analyses of the molecular and biological properties of DTC 





























HCC is an aggressive malignancy and potentially curative surgical procedures can only be 
offered to a small group of carefully selected patients using strict staging criteria. Currently 
tumour morphology assessed by radiological imaging is the only variable used as a surrogate 
marker of tumour biology. It is estimated that 25% of HCC are under staged with the current 
radiological imaging. Microvascular invasion and grade of tumour differentiation are strong 
predictors of tumour recurrence, however, current practice does not seek this information 
routinely before implementing curative treatments. A recent study by Mazzaferro et al (2008) 
showed that 10% of tumours within Milan criteria have microvascular invasion and are poorly 
differentiated. The study highlighted that tumour morphology on its own is not an accurate 
predictor of tumour biology but it has been accepted in clinical practise due to lack of robust 
biological or molecular markers that can predict HCC behaviour. The treatment of HCC is 
further complicated by the fact that the prognosis of patients who develop tumour recurrence is 
dismal due to lack of effective systemic therapies. 
 
In an effort to refine the current staging and understand factors related to tumour recurrence 
some studies have focussed on biological or molecular surrogate markers such as microscopic 
disseminated disease, plasma albumin mRNA and serum alpha-fetoprotein. To date, however, 
none of these have been successfully translated into clinical practice. 
 
Disseminated tumour cells detected in the blood or bone marrow have been associated with 
metastasis, chemoresistance and poor prognosis in several epithelial malignancies. Our previous 
study developed an effective tool to detect these disseminated cells, however, due to their scarce 
occurrence it was not possible to study their molecular and biological properties. To understand 
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the role of DTC in progression of HCC or to develop specific targeted treatment modalities the 
initial step was to increase their cell numbers to facilitate molecular and immunochemical 
analysis. 
 
This study represents the first attempt to develop a protocol to culture the DTC in patients with 
chronic liver disease and HCC and study their biological properties. In Chapter 3, venous blood 
samples from patients with cirrhosis and HCC were cultured with the relevant controls using a 
hepatocyte favouring culture medium. This technique yielded encouraging results by supporting 
the development of robust cell colonies in 6 out of 44 patients with HCC, 3 out of 50 patients 
with liver cirrhosis and none out of 20 normal healthy volunteers. All of these cultured cells co-
expressed hepatocellular markers; cytokeratin 8/18 (Cam 5.2), hepatocyte specific antigen (Hep 
par 1) and polyclonal CEA along with albumin and glycogen and are characteristic of hepatocyte 
function. 
 
Cancer stem cells (CSC) have been associated with tumour propagation and poor prognosis in 
HCC. The hepatocyte like cell colonies isolated from our first experiment were further analysed 
for the presence of stem cell markers. CSC in HCC are also known to share a variety of markers 
with haematopoietic stem cells causing conflicting opinions regarding their origin, however, to-
date there are no clear conclusions. While some studies favour the bone marrow as their source, 
others support the hepatic origin of these cells. We studied the relationship between cancer stem 
cells and DTC isolated in our study using well described markers (CD34, CD133, and CD90) 




We observed that whilst CD34 was widely expressed, CD133 and CD 90 expression was only 
confined to a very few cells that were derived from patients with cirrhosis and HCC.  CD133 and 
CD90 are shown to be expressed by malignant hepatoma cells. Experience from histological 
analysis of primary human HCC as well as human hepatoma cell lines demonstrated a positive 
correlation between their expression and biological tumour aggressiveness. The low expression 
of cancer stem markers CD133 and CD90 by our cultured cells derived from patients with HCC 
is consistent with previously published data on primary HCC.  
 
The question regarding the origin of DTC was addressed using a microarray analysis of high 
gene expression in cells cultured from patients with HCC, the HCC cell line HepG2 and primary 
human hepatocytes, compared with purified CD34
+ve
 bone marrow cells. The analysis showed 
that DTC cultured from patients with cirrhosis and HCC expressed hepatocellular markers which 
excluded their being bone marrow stem cells. These results suggested that DTC express markers 
of cancer stem cells and their source of origin is the liver. 
 
In our study a very small sub-group of controls with liver cirrhosis (3/50) also had circulating 
cells. These cells expressed markers of hepatocellular lineage and CD 34, but not CD133 or 
CD90.  To investigate the differences between the circulating cells isolated from patients with 
cirrhosis and HCC and those without HCC we used the 3 gene expression profile that was 
described by Llovet et al to discriminate HCC from dysplastic or cirrhotic nodules. The qPCR 
analysis revealed an increased expression of glypican 3 and surviving, but a reduced expression 
of LYVE1 in the cells cultured from patients with HCC when compared with cells obtained from 
patients with cirrhosis, but no HCC. These results were consistent with those published by Llovet 
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et al (2006). We also noted that the expression of TGF-alpha and p53 was consistently increased 
in cells derived from patients with cirrhosis and HCC when compared with those cultured from 
patients with only cirrhosis. These data indicated that a malignant phenotype is expressed only 
by circulating cells cultured from patients with cirrhosis and HCC. 
 
A further microarray analysis of cancer gene expression by the DTC revealed an over expression 
of 18 genes that are associated with poor prognosis in HCC and 43 genes that are associated with 
poor outcomes in non-HCC solid organ tumours.   
 
The in vitro isolation and analysis of DTC from blood samples of patients with cirrhosis and 
HCC showed that a small sub-group of patients can shed microscopic cells that are potentially 
malignant.  
 
The in vivo malignant potential of cultured DTC was tested using a SCID mouse cell 
transplantation model. A small volume of cultured cells (2x104) was injected directly into renal 
sub-capsular space and liver. Following an incubation period of two weeks it was observed that 
only cells from patients with cirrhosis and HCC survived in the renal sub-capsule and were 
detectable on H&E as well as immunohistochemistry staining. Interestingly the histology of liver 
sections injected with cells from HCC showed features of neoplasia while the control liver 
sections had normal architecture. The expression of human CD34 and human genomic DNA by 




These results showed that cells cultured from patients with HCC express molecular and 
biological properties that are different when compared to those isolated more infrequently from 
cirrhotic controls, reflecting their cancer lineage. 
 
Taking into consideration the small sample size, the analysis of clinical data suggested that the 
presence of DTC is not influenced by morphological parameters of the tumour or any pre-
operative interventions. The patients with isolated DTC had a trend towards worse clinical 
outcomes although the results were not statistically significant. 
 
Large studies from breast cancer research groups have identified the presence of DTC as an 
independent predictor of poor survival. The association between the presence of DTC and 
metastatic relapse of breast cancer has also been shown by published studies (Braun 2005, Pantel 
2008). Breast cancer metastasis models demonstrated that microscopic metastatic cancer cells 
detach early from primary tumours and are released into blood and BM. These microscopic cells 
are not detected by routine pre-operative radiological staging investigations but peripheral blood 
analysis could provide valuable information on the tumour dissemination. A pooled analysis 
from 9 European centres including more than 4000 patients showed that 30% of women with 
primary breast cancer have DTCs.  A 10-year survival analysis of breast cancer patients with 
DTCs revealed significantly decreased overall survival when compared to those with no DTCs 
(Braun 2005).  
 
The success of HCC treatment depends on robust pre-operative staging to identify extra-hepatic 
disease and to plan down-staging or adjuvant chemotherapy. Early spread of microscopic tumour 
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cells is undetected even by high-resolution imaging technologies which prevents any early 
intervention to improve outcomes of potentially curative treatments. DTCs can escape the host 
immune system in a dormant state and have the potential to develop into overt metastases when 
activated by internal/external signals. 
 
Our study shows that occult disseminated tumour cells are detectable in peripheral blood of a 
sub-group of HCC patients with aggressive phenotype and their presence cannot be determined 
by the pre-operative staging investigations. Further, the biology of HCC cannot be assessed 
accurately with tumour morphology alone. The current selection criteria could be improved by 
inclusion of additional markers which predict the tumour biology. DTCs represent the parent 
tumour and their isolation and characterisation could shed light on subsequent tumour behaviour. 
We demonstrated that DTC in HCC could be isolated from simple peripheral venous blood 
samples and expanded by in vitro culture for further characterisation. The detection of 
microscopic disease may offer further insight into the HCC and improve the utilisation of current 
surgical procedures (especially liver transplantation) and clinical outcomes. An in-depth 
knowledge of the molecular and biological properties of DTC could lead to the development of 
specific targeted therapies that can potentially down stage a tumour or provide adjuvant 
treatments following surgery.  
 
Further studies to characterise circulating hepatocyte-like cells in patient with cirrhosis may help 
in understanding the underlying mechanisms of liver regeneration in chronic liver injury and the 




7. FUTURE WORK: 
Objective Methodology 
Develop an optimal medium to increase 
the cell number 
 
 
1) Supplement the current medium with more growth 
factors/insulin/dexamethasone 
2) Use of Kubota’s medium that favours growth of 
hepatoblasts/neonatal liver cells (Kubota et al Stem Cells. 
2007 Sep;25(9):2339-49) 
Or  Develop an immortalised cell line by microinjection 
with T antigen DNA( Pantel et al; Journal of the National 
Cancer Institute, Vol. 87, No. 15, August 2, 1995) 
Assess the validity of alternative 
markers of  micrometastases 
Immunocytochemical analysis using antibody markers 
e.g. pCEA, TTF-1, cystatin B 
Application of new methods of 
detecting microscopic tumour cells 
Use of multimarker RT-PCR with a panel of tumor 
specific mRNA markers, Enzyme linked immunospot  
technology (ELISPOT), Automated detection (e.g. 
Automated microscopy, laser scanning cytometer) 
Study the interactions between 
disseminated tumour cells and hepatic 
endothelium to understand the 
pathways of tumour recurrence in liver 
 
1. Compare the effects of serum on tumour cell 
adhesion using larger number of patients with and 
without post-transplant HCC recurrence 
2. Identify specific serum factors that modify tumour cell 
adhesion to endothelium 
Improve SCID mouse animal model 
 
1.Induce growth of injected cells by performing a 
hepatectomy 
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Classification of hepatocellular carcinoma 










Tumour size  
Ascites  
Serum albumin  
Bilirubin 
 












Okuda I: No positive factor; Okuda II: 1 or 2 positive factors; Okuda III: 3 or 4 positive factors 
 
b:French classification  
 
 0 1 2 3 
Karnofsky index (%)  
Bilirubin (µmol/l)  
Alkaline phosphatase (MNL)  
Alpha-1 fetoprotein (µg/l)  



















Karnofsky index >80% = complete patient autonomy; MNL = maximum normal limit; 
US = ultrasound. Group A (low risk): 0 point; group B (intermediate risk): 1-5 points; 






c: Chinese University Prognostic Index(CUPI) classification  
Variable Score 
TNM classification 
I and II 
III A and III B 
IV A and IV B 
Asymptomatic at diagnosis 
Ascites 


















Score ≤1: low risk; score 2-7: intermediate risk; score ≥8: high risk. Risk of death within 3 












































Uninodular and extension <50% 
Multinodular and extension ≤50% 























e: Barcelona Clinic Liver Cancer (BCLC) classification of Hepatocellular carcinoma 
 










Stage PST  Tumour stage Okuda Liver function  Remarks 
  






    
Stage A and B  














No CRPH + bil N 
CRPH + bil. N  
CRPH + bil.↑  
Child A- B  
Stage B: 
intermediate  HCC  
0  Multinodular  I-II  Child A-B  
Stage C: advanced 
HCC  




I-II  Child A-B  Stage C  
At least one criterion:  
PST 1-2 or vascular 
invasion/  
extra-hepatic spread  
Stage D: end-stage 
HCC  
3-4  Any  III  Child C  Stage D 
At least one criterion:  
PST 3-4 or Okuda 
III/Child C  
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Child-Pugh grade A B B  
TNM stage by LCSGJ I II III IV 
The JIS score is calculated by summing the scores for the Child-Pugh classification (C-P grade) 
and the TNM tumour stage according to the Liver Cancer Study Group of Japan criteria 
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Stage II  
Stage III  






Fulfilling three factors 
Fulfilling two factors 
Fulfilling one factor 
 Fulfilling 0 factors 
T1 N0 M0 
T2 N0 M0 
T3 N0 M0 
T4 N0 M0 or T1-
T4N+M0 












The Child- Pugh classification for severity of liver disease 












Score 1 2 3 
Bilirubin ( µmol/l) <34 34-50 >50 
Albumin (g/l) >35 28-35 <28 
PT INR <1.7 1.71-2.3 >2.3 
Encephalopathy none mild marked 































* Wee A; Diagnostic utility of Immunohistochemistry in hepatocellular carcinoma, its variants and   












Results of Immunostains (%) (overall, 
range) 
α-fetoprotein (AFP) 



























a: Information to HCC patients participating in micrometastases study 
This sheet contains information about what to expect if you are taking part in the study.  Your 
participation is entirely voluntary.  Please keep this sheet for future reference. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You’.  This leaflet gives more information about medical research and looks at the questions you 
may want to ask.  A copy may be obtained from CERES, PO Box 1365, London N16 0BW.  If 
you have any concerns or questions which are not covered here, please contact Mr Narendra 
Battula (Tel: 07743846045) for further information.   
 
What is this study? 
The aim of this study is to try to improve the treatment of patients with liver cancer.  by looking 
at peripheral blood samples, it may be possible to detect cancer cells earlier, before they are 
visible on scans, so that treatment can be improved. In addition to the special tests that you will 
have had already, we plan to perform another blood test. These samples will be analysed to see if 
there are any sign of liver cells. 
 
If I agree to enter the study, can I withdraw subsequently? 
Yes. If you consent to take part in the study, you are under no obligation to continue and you are 
free to withdraw at any time without giving a reason.  Your future care and treatment will not be 
affected if you decide to withdraw from the study. 
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Is the procedure painful? 
Blood samples will be collected at the time of your routine blood tests, it is safe and there are no 
long term side effects. 
 
Will the study affect my treatment? 
No.  The treatment you receive will be exactly the same whether you decide to enter the study or 
not.  The results of the study will not benefit you directly, but hopefully it will improve our 
understanding of liver cancer, and may help the treatment of others in the future. 
 
















b: Information to control patients participating in micrometastases study 
This sheet contains information about what to expect if you are taking part in the study.  Your 
participation is entirely voluntary.  Please keep this sheet for future reference. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You’.  This leaflet gives more information about medical research and looks at the questions you 
may want to ask.  A copy may be obtained from CERES, PO Box 1365, London N16 0BW.  If 
you have any concerns or questions which are not covered here, please contact Mr Narendra 
Battula (Tel: 07743846045) for further information.   
 
What is this study? 
The aim of this study is to try to improve the treatment of patients with liver cancer.  by looking 
at peripheral blood samples, it may be possible to detect cancer cells earlier, before they are 
visible on scans, so that treatment can be improved. We also need to analyse blood samples from 
patients without cancer such as you for comparison. In addition to the special tests that you will 
have had already, we plan to perform another blood test. These samples will be analysed to see if 
there are any sign of liver cells. 
 
If I agree to enter the study, can I withdraw subsequently? 
Yes. If you consent to take part in the study, you are under no obligation to continue and you are 
free to withdraw at any time without giving a reason.  Your future care and treatment will not be 




Is the procedure painful? 
Blood samples will be collected at the time of your routine blood tests, it is safe and there are no 
long term side effects. 
 
Will the study affect my treatment? 
No.  The treatment you receive will be exactly the same whether you decide to enter the study or 
not.  The results of the study will not benefit you directly, but hopefully it will improve our 
understanding of liver cancer, and may help the treatment of others in the future. 
 


















Department Institute of Liver Studies 
Title of Study                Micrometastases in hepatocellular carcinoma 
Investigator's Name      Mr arendra Battula 
 
To be completed by the subject/patient/parent/guardian (delete as necessary) 
1. Have you read the information sheet about this study?                             YES/NO                                        
2. Have you had an opportunity to ask questions and discuss this study?     YES/NO                
3. Have you received satisfactory answers to all your questions?                 YES/NO                            
4. Have you received enough information about this study?                         YES/NO  
5. Do you understand that you are free to withdraw from this study at  
any time without giving a reason for withdrawing without affecting 
your future relationship with the medical or nursing care                               YES/NO  
6. Do you agree to take part in this study?                                                     YES/NO 
 
 
Signed: _______________________________Date _____________________  
 
Name in Block letters   ___________________________________________ 
 




7. For persons under 18 years of age the consent of the parents or guardians must be obtained and 
the assent of the child/young person should be obtained to the degree possible dependent on the 
age of the child/young person. 
8. In some studies witnessed consent may be appropriate. 
9. One copy of the signed consent form will be given to the patient, one will be kept by the 
investigator and one will be kept for the notes. 
 
The consent form must be signed by the actual investigator concerned with the project after having 
spoken to the subject to explain the project and after having answered his or her questions about the 
project. 















Alphabetical list of Reagents 
a: Reagents 
Acetone Sigma, UK 
Acetic acid                                                                           Sigma, UK 
Accutase Sigma, UK 
Alpha-Minimum Essential Medium Invitrogen, UK 
Antibiotic & Antifungal Invitrogen, UK 
Anti-human albumin-FITC conjugated Dako, UK (working dilution 1:50) 
Anti-human albumin Sigma UK (unconjugated mouse monoclonal antibody; 
woking dilution 1:250) 
Anti-mouse fluorescent kit Vecta, UK 
ATP 7b (unconjugated mouse 
monoclonal) antibody 
Abcam, UK (working dilution 1:500) 
Human bone marrow stromal cells 
(hMSC) 
Donation by Tulane University, USA 
CD68 - unconjugated mouse monoclonal 
antibody            
Sigma UK (working dilution 1:500) 
CD34 - unconjugated mouse monoclonal 
antibody         
Abcam, UK (working dilution 1:250) 
CD133 - unconjugated mouse 
monoclonal  antibody           
Sigma, UK (working dilution 1:250) 
CD 90-  unconjugated mouse 
monoclonal        
Dako, UK (antibody working dilution 1:100) 
Collagen (Bornstein and Traub Type I 
calf skin) 
Sigma, UK (0.3mg/ml in 10mM acetic acid) 
Collagenase Sigma,UK (Type 4) 
Collagenase Sigma, UK (Type 1a) 
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Cam 5.2 (Cytokeratin 8 & 18) antibody Becton-Dickinson, UK (readymade to use) 
Dimethylsulphoxide Life Technologies, UK 
Dulbecco's Modified Eagle Medium 
(DMEM) 
Invitrogen, UK 
Endothelial cell growth medium MV2 Promo cell, UK 
Ethanol (75%) Commercial suppliers, King’s College Hospital 
Fetal Calf Serum (FCS) Invitrogen, UK 
Fluorescent secondary antibody Vecta Kit 
GeneChip Hybridization, Wash, and 
Stain Kit 
Affymetrix, USA 
Haematoxylin, Carazzi’s Sigma, UK 
Haematoxylin, Mayer’s 
(Lillie’s modification) 
Dako, UK [Contains haematoxylin (5 g/l), aluminum 
ammonium sulphate (45 g/l), glycerine (30%), sodium 
iodate (0.2 g/l), pH 2.4] 
Human hepatoma cell line (Hep G2) ECACC, UK 
Hep Par-1 (mouse anti-human 
hepatocyte monoclonal antibody clone 
OCH1E5) 
Dako, UK (working dilution 1:500) 
Heparin  CP Pharmaceuticals UK 
Histopaque-1077 Sigma, UK ( polysucrose, 5.7g/dl; sodium 
diatrizoate, 9.0g/dl) 
Human Hepatocytes Donation from hepatocyte transplantation 
unit, King’s College   Hospital, UK 
Human colon cancer cell line CaCo-2 ECAAC,UK 
Human gene 1.0 ST array Affymetrix, USA 
Hypnorm (0.315mg/ml Fentanyl citrate + 10 mg/ml Fluanisone) 
Hydrogen peroxide (H2O2) 3% in PBS 
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Isopropropanol Sigma, UK 
Ki-67 (unconjugated rabbit polyclonal) Abcam, UK (working dilution 1:500 
L-Glutamine Invitrogen, UK 
Liquid nitrogen Commercial suppliers, King’s College Hospital. 
Midazolam Commercial suppliers, King’s College Hospital 
MHC class-1 (unconjugated mouse 
monoclonal) 
Dako, UK (working dilution 1:250) 
 
Novacastra Ready-to-Use peroxidase 
detection systems 
Novacastra laboratories, UK 
NuGEN Pico WT- Ovation labelling kit NuGEN Inc, USA 
Percoll density gradient medium Sigma, UK 
Periodic acid Solution 0.5% (Periodic 
acid -0.5 g in 100ml of distilled water) 
Sigma, UK 
Phosphate-buffered saline (PBS) Dako, UK (Contains 20mM sodium phosphate, 
150mM sodium chloride,  pH 7.0) 
Propidium iodide (PI) Vecta, UK 
Polyclonal CEA (unconjugated rabbit 
polyclonal) 
Dako, UK (working dilution 1:250) 
Real time PCR system(7900 HT) Applied Biosystems Inc, USA  
SCID mice (6 week old, Male) Charles River UK Ltd 
Schiff Reagent Sigma, UK 
Anti-Smooth muscle actin Dako, UK (working dilution 1:250) 
TaqMan Gene expression master mix Applied Biosystems Inc, USA 
Trypsin EDTA Invitrogen, UK 
Vectastain Streptavidine/Peroxidise kit Vecta, UK 





All of the above prepared medium were stored at 4
◦






Tryphan blue Invitrogen, UK 
Xylene Sigma, UK 
Cell culture medium- Disseminated cells 500ml of Alpha minimum essential medium enriched 
with 20% fetal calf serum (Invitrogen, UK), 1% L-
Glutamine (Invitrogen) and 1% antibiotic and 
antifungal reagents (Invitrogen, UK).  
Cell culture medium- endothelial 500 ml of Endothelial cell growth medium MV2 
(promo cell) supplemented with 10% fetal calf serum, 
10% endothelial growth factor and 1% penicillin and 
streptomycin. 
Cell culture medium- hepatocytes 500 ml of William’s E medium (Sigma) enriched with 
1% penicillin and streptomycin, 10% fetal calf serum, 
10MmHepes and 1% L-Glutamine.  
Cell culture medium- colon cancer cell 
lines 
500 ml of  Dulbecco's Modified Eagle Medium 
(Invitrogen) supplemented with 10% FCS, 1% 





The research work undertaken for this Thesis was conducted entirely by the Author Narendra 
Battula after receiving appropriate training in laboratory techniques. Professor Nigel Heaton and 
Dr Varuna Aluvihare acted as Clinical Supervisors for the project. Postdoctoral scientists (Drs 
Guo cai Huang, Min Zhao, Helen Brereton and Siamak Salehi) provided training in laboratory 
methodology and were available on a day-to-day basis for support and advice. Ethical approval 
for this project was granted by King’s College Hospital Research and Ethics Committee on 12th 
June 2001, and all patients were fully informed of the nature of the research and provided written 
consent. The research work was carried out in the Institute of Liver Studies, King’s College 
Hospital, London, UK and in the Rayne Institute, Denmark Hill Campus, King’s College 
London, UK. 
 
 
 
 
 
 
 
 
 
 
 
 
